



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6:

C12N 15/31, 15/82, 15/10, 1/21, 5/10, A01H 5/00, C07K 14/24, A01N 63/02 **A2**

(11) International Publication Number:

WO 99/42589

(43) International Publication Date:

26 August 1999 (26.08.99)

(21) International Application Number:

PCT/EP99/01015

(22) International Filing Date:

18 February 1999 (18.02.99)

(30) Priority Data:

09/027,080 60/116,439

20 February 1998 (20.02.98) 20 January 1999 (20.01.99) US

(74) Agent: BECKER, Konrad; Novartis AG, Corporate Intellectual Property, Patent & Trademark Dept., CH-4002 Basel (CH).

302 Orchard Lane, Chapel Hill, NC 27514 (US).

Hillsborough, NC 27278 (US). CHEN, Jeng, Shong [-/US];

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT. RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

TIS AG [CH/CH]; Schwarzwaldallee 215, D-4058 Basel (CH). (71) Applicant (for AT only): NOVARTIS-ERFINDUNGEN VER-

(71) Applicant (for all designated States except AT US): NOVAR-

WALTUNGSGESELLSCHAFT MBH [AT/AT]; Brunner Strasse 59, A-1235 Vienna (AT).

(72) Inventors; and

(75) Inventors/Applicants (for US only): KRAMER, Vance, Cary [US/US]; 608 Dana Court, Hillsborough, NC 27278 (US). MORGAN, Michael, Kent [US/US]; 5805 Garrett Road, Durham, NC 27707 (US). ANDERSON, Ame, Robert [US/US]; 1005 Green-Pace Road, Zebulon, NC 27597 (US). HART, Hope, Prim [US/US]; 4106 Planters Glen Court, Fuquay-Varina, NC 26526 (US). Warren, Gregory, Wayne [US/US]; 324 Bond Lake Drive, Cary, NC 27513 (US). DUNN, Martha, M. [US/US]; 6201 Oakview Court,

Published

Without international search report and to be republished upon receipt of that report.

(54) Title: INSECTICIDAL TOXINS FROM PHOTORHABDUS

(57) Abstract

Novel nucleic acid sequences isolated from Photorhabdus luminescens, whose expression results in novel insecticidal toxins, are disclosed herein. The invention also discloses compositions and formulations containing the insecticidal toxins that are capable of controlling insect pests. The invention is further drawn to methods of making the toxins and to methods of using the nucleotide sequences, for example in microorganisms to control insect pests or in transgenic plants to confer insect resistance.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

					,		Transmis under the re
AL AM AT AU AZ BA BB BE BF BG BJ BR BY CA CF CG	Albania Armenia Austria Australia Azerbaijan Bosnia and Herzegovina Barbados Belgium Burkina Faso Bulgaria Benin Brazil Belarus Canada Central African Republic	ES FI FR GA GB GE GH GN GR HU IE IL IS IT JP	Spain Finland France Gabon United Kingdom Georgia Ghana Guinea Greece Hungary Ireland Israel Iceland Italy Japan	LS LT LU LV MC MD MG MK ML MN MR MN MR MW MX NE	Lesotho Lithuania Luxembourg Latvia Monaco Republic of Moldova Madagascar The former Yugoslav Republic of Macedonia Mali Mongolia Mauritania Malawi Mexico Niger	SI SK SN SZ TD TG TJ TM TR UA UG US US VN	Slovenia Slovakia Senegal Swaziland Chad Togo Tajikistan Turkmenistan Turkey Trinidad and Tobago Ukraine Uganda United States of America Uzbekistan
BJ BR BY CA	Benin Brazil Belarus Canada	IE IL IS IT	Hungary Ircland Israel Iccland Italy	MN MR MW MX	Mali Mongolia Mauritania Malawi Mexico	TT UA UG US UZ	Trinidad and Tobago Ukraine Uganda United States of America Uzbekistan

3

INSECTICIDAL TOXINS FROM PHOTORHABDUS

The invention relates to novel toxins from *Photorhabdus luminescens*, nucleic acid sequences whose expression results in said toxins, and methods of making and methods of using the toxins and corresponding nucleic acid sequences to control insects.

Insect pests are a major cause of crop losses. Solely in the US, about \$7.7 billion are lost every year due to infestation by various genera of insects. In addition to losses in field crops, insect pests are also a burden to vegetable and fruit growers, to producers of ornamental flowers, and they are a nuisance to gardeners and home owners.

Insect pests are mainly controlled by intensive applications of chemical insecticides, which are active through inhibition of insect growth, prevention of insect feeding or reproduction, or death of the insects. Good insect control can thus be reached, but these chemicals can sometimes also affect other, beneficial insects. Another problem resulting from the wide use of chemical pesticides is the appearance of resistant insect varieties. This has been partially alleviated by various resistance management strategies, but there is an increasing need for alternative pest control agents. Biological insect control agents, such as Bacillus thuringiensis strains expressing insecticidal toxins like d-endotoxins, have also been applied with satisfactory results, offering an alternative or a complement to chemical insecticides. Recently, the genes coding for some of these d-endotoxins have been isolated and their expression in heterologous hosts have been shown to provide another tool for the control of economically important insect pests. In particular, the expression of insecticidal toxins in transgenic plants, such as Bacillus thuringiensis dendotoxins, has provided efficient protection against selected insect pests, and transgenic plants expressing such toxins have been commercialized, allowing farmers to reduce applications of chemical insect control agents. Yet, even in this case, the development of resistance remains a possibility and only a few specific insect pests are controllable. Consequently, there remains a long-felt but unfulfilled need to discover new and effective insect control agents that provide an economic benefit to farmers and that are environmentally acceptable.

The present invention addresses the need for novel insect control agents. Particularly needed are control agents that are targeted to economically important insect pests and that efficiently control insect strains resistant to existing insect control agents.

Furthermore, agents whose application minimizes the burden on the environment are desirable.

In the search of novel insect control agents, certain classes of nematodes from the genera *Heterorhabdus* and *Steinernema* are of particular interest because of their insecticidal properties. They kill insect larvae and their offspring feed in the dead larvae. Indeed, the insecticidal activity is due to symbiotic bacteria living in the nematodes. These symbiotic bacteria are *Photorhabdus* in the case of *Heterorhabdus* and *Xenorhabdus* in the case of *Steinernema*.

The present invention is drawn to nucleic acid sequences isolated from *Photorhabdus luminescens*, and sequences substantially similar thereto, whose expression results in toxins that are highly toxic to economically important insect pests, particularly insect pests that infest plants. The invention is further drawn to the toxins resulting from the expression of the nucleic acid sequences, and to compositions and formulations containing the toxins, which are capable of inhibiting the ability of insect pests to survive, grow or reproduce, or of limiting insect-related damage or loss in crop plants. The invention is further drawn to a method of making the toxins and to methods of using the nucleic acid sequences, for example in microorganisms to control insects or in transgenic plants to confer insect resistance, and to a method of using the toxins, and compositions and formulations comprising the toxins, for example applying the toxins or compositions or formulations to insect-infested areas, or to prophylactically treat insect-susceptible areas or plants to confer protection or resistance to the insects.

The novel toxins are highly active against insects. For example, a number of economically important insect pests, such as the Lepidopterans *Plutella xylostella* (Diamondback Moth), *Trichoplusia ni* (Cabbage Looper), *Ostrinia nubilalis* (European Corn Borer), *Heliothis virescens* (Tobacco Budworm), *Helicoverpa zea* (Corn Earworm), *Manduca sexta* (Tobacco Hornworm), *Spodoptera exigua* (Beet Armyworm), and *Spodoptera frugiperda* (Fall Armyworm), as well as the Coleopterans *Diabrotica virgifera virgifera* (Western Corn Rootworm), *Diabrotica undecimpunctata howardi* (Southern Corn Rootworm), and *Leptinotarsa decimlineata* (Colorado Potato Beetle) can be controlled by one or more of the toxins. The toxins can be used in multiple insect control strategies, resulting in maximal efficiency with minimal impact on the environment.

According to one aspect, the present invention provides an isolated nucleic acid molecule comprising: (a) a nucleotide sequence substantially similar to a nucleotide

. . 4

sequence selected from the group consisting of: nucleotides 412-1665 of SEQ ID NO:1, nucleotides 1686-2447 of SEQ ID NO:1, nucleotides 2758-3318 of SEQ ID NO:1, nucleotides 3342-4118 of SEQ ID NO:1, nucleotides 4515-9269 of SEQ ID NO:1, nucleotides 15,171-18,035 of SEQ ID NO:11, and nucleotides 31,393-35,838 of SEQ ID NO:11; (b) a nucleotide sequence comprising nucleotides 23,768-31,336 of SEQ ID NO:11; or (c) a nucleotide sequence isocoding with the nucleotide sequence of (a) or (b); wherein expression of the nucleic acid molecule results in at least one toxin that is active against insects.

In one embodiment of this aspect, the nucleotide sequence is isocoding with a nucleotide sequence substantially similar to nucleotides 412-1665 of SEQ ID NO:1, nucleotides 1686-2447 of SEQ ID NO:1, nucleotides 2758-3318 of SEQ ID NO:1, nucleotides 3342-4118 of SEQ ID NO:1, or nucleotides 4515-9269 of SEQ ID NO:1. Preferably, the nucleotide sequence is substantially similar to nucleotides 412-1665 of SEQ ID NO:1, nucleotides 1686-2447 of SEQ ID NO:1, nucleotides 2758-3318 of SEQ ID NO:1, nucleotides 3342-4118 of SEQ ID NO:1, or nucleotides 4515-9269 of SEQ ID NO:1. More preferably, the nucleotide sequence encodes an amino acid sequence selected from the group consisting of SEQ ID NO:2-6. Most preferably, the nucleotide sequence comprises nucleotides 412-1665 of SEQ ID NO:1, nucleotides 1686-2447 of SEQ ID NO:1, nucleotides 2758-3318 of SEQ ID NO:1, nucleotides 3342-4118 of SEQ ID NO:1, nucleotides 4515-9269 of SEQ ID NO:1, nucleotides 3342-4118 of SEQ ID NO:1, or nucleotides 4515-9269 of SEQ ID NO:1, nucleotides 3342-4118 of SEQ ID NO:1, or nucleotides 4515-9269 of SEQ ID NO:1, nucleotides 3342-4118 of SEQ ID NO:1, or nucleotides 4515-9269 of SEQ ID NO:1.

In another embodiment of this aspect, the nucleotide sequence is isocoding with a nucleotide sequence substantially similar to nucleotides 15,171-18,035 of SEQ ID NO:11. Preferably, the nucleotide sequence is substantially similar to nucleotides 15,171-18,035 of SEQ ID NO:11. More preferably, the nucleotide sequence encodes the amino acid sequence set forth in SEQ ID NO:12. Most preferably, the nucleotide sequence comprises nucleotides 15,171-18,035 of SEQ ID NO:11.

In still another embodiment of this aspect, the nucleotide sequence is isocoding with a nucleotide sequence substantially similar to nucleotides 31,393-35,838 of SEQ ID NO:11. Preferably, the nucleotide sequence is substantially similar to nucleotides 31,393-35,838 of SEQ ID NO:11. More preferably, the nucleotide sequence encodes the amino acid sequence set forth in SEQ ID NO:14. Most preferably, the nucleotide sequence comprises nucleotides 31,393-35,838 of SEQ ID NO:11.

In yet another embodiment of this aspect, the nucleotide sequence encodes the amino acid sequence set forth in SEQ ID NO:13, and preferably comprises nucleotides 23,768-31,336 of SEQ ID NO:11.

In one embodiment, the nucleotide sequence of the invention comprises the approximately 9.7 kb DNA fragment harbored in *E. coli* strain DH5a, designated as NRRL accession number B-21835.

In another embodiment, the nucleotide sequence of the invention comprises the approximately 38 kb DNA fragment harbored in *E. coli* strain DH5a, designated as NRRL accession number B-30077.

In still another embodiment, the nucleotide sequence of the invention comprises the approximately 22.2 kb DNA fragment harbored in *E. coli* strain DH5a, designated as NRRL accession number B-30078.

According to one embodiment of the invention, the toxins resulting from expression of the nucleic acid molecules of the invention have activity against Lepidopteran insects. Preferably, according to this embodiment, the toxins have activity against *Plutella xylostella* (Diamondback Moth), *Trichoplusia ni* (Cabbage Looper), *Ostrinia nubilalis* (European Corn Borer), *Heliothis virescens* (Tobacco Budworm), *Helicoverpa zea* (Corn Earworm), *Spodoptera exigua* (Beet Armyworm), and *Spodoptera frugiperda* (Fall Armyworm).

According to another embodiment of the invention, the toxins resulting from expression of the nucleic acid molecule of the invention have activity against Lepidopteran and Coleopteran insects. Preferably, according to this embodiment, the toxins have insecticidal activity against *Plutella xylostella* (Diamondback Moth), *Ostrinia nubilalis* (European Corn Borer), and *Manduca sexta* (Tobacco Hornworm), *Diabrotica virgifera virgifera* (Western Corn Rootworm), *Diabrotica undecimpunctata howardi* (Southern Corn Rootworm), and *Leptinotarsa decimlineata* (Colorado Potato Beetle).

In another aspect, the present invention provides an isolated nucleic acid molecule comprising a 20 base pair nucleotide portion identical in sequence to a consecutive 20 base pair nucleotide portion of a nucleotide sequence selected from the group consisting of: nucleotides 412-1665 of SEQ ID NO:1, nucleotides 1686-2447 of SEQ ID NO:1, nucleotides 2758-3318 of SEQ ID NO:1, nucleotides 3342-4118 of SEQ ID NO:1, nucleotides 4515-9269 of SEQ ID NO:1, nucleotides 15,171-18,035 of SEQ ID NO:11, and nucleotides 31,393-35,838 of SEQ ID NO:11, wherein expression of the nucleic acid molecule results in at least one toxin that is active against insects.

4.

In one embodiment of this aspect, the isolated nucleic acid molecule of the invention comprises a 20 base pair nucleotide portion identical in sequence to a consecutive 20 base pair nucleotide portion of nucleotides 412-1665 of SEQ ID NO:1, nucleotides 1686-2447 of SEQ ID NO:1, nucleotides 2758-3318 of SEQ ID NO:1, nucleotides 3342-4118 of SEQ ID NO:1, or nucleotides 4515-9269 of SEQ ID NO:1.

In another embodiment of this aspect, the isolated nucleic acid molecule of the invention comprises a 20 base pair nucleotide portion identical in sequence to a consecutive 20 base pair nucleotide portion of nucleotides 15,171-18,035 of SEQ ID NO:11.

In still another embodiment of this aspect, the isolated nucleic acid molecule of the invention comprises a 20 base pair nucleotide portion identical in sequence to a consecutive 20 base pair nucleotide portion of nucleotides 31,393-35,838 of SEQ ID NO:11.

In a further aspect, the present invention provides an isolated nucleic acid molecule comprising a nucleotide sequence from *Photorhabdus luminescens* selected from the group consisting of: nucleotides 412-1665 of SEQ ID NO:1, nucleotides 1686-2447 of SEQ ID NO:1, nucleotides 2758-3318 of SEQ ID NO:1, nucleotides 3342-4118 of SEQ ID NO:1, nucleotides 4515-9269 of SEQ ID NO:1, nucleotides 66-1898 of SEQ ID NO:11, nucleotides 2416-9909 of SEQ ID NO:11, the complement of nucleotides 2817-3395 of SEQ ID NO:11, nucleotides 9966-14,633 of SEQ ID NO:11, nucleotides 14,699-15,007 of SEQ ID NO:11, nucleotides 15,171-18,035 of SEQ ID NO:11, the complement of nucleotides 17,072-17,398 of SEQ ID NO:11, the complement of nucleotides 18,235-19,167 of SEQ ID NO:11, the complement of nucleotides 20,217-20,963 of SEQ ID NO:11, the complement of nucleotides 22,172-23,086 of SEQ ID NO:11, nucleotides 23,768-31,336 of SEQ ID NO:11, nucleotides 31,393-35,838 of SEQ ID NO:11, the complement of nucleotides 35,383-35,709 of SEQ ID NO:11, the complement of nucleotides 36,032-36,661 of SEQ ID NO:11, and the complement of nucleotides 36,654-37,781 of SEQ ID NO:11.

The present invention also provides a chimeric gene comprising a heterologous promoter sequence operatively linked to the nucleic acid molecule of the invention. Further, the present invention provides a recombinant vector comprising such a chimeric gene. Still further, the present invention provides a host cell comprising such a chimeric gene. A host cell according to this aspect of the invention may be a bacterial cell, a yeast cell, or a plant

cell, preferably a plant cell. Even further, the present invention provides a plant comprising such a plant cell. Preferably, the plant is maize.

In yet another aspect, the present invention provides toxins produced by the expression of DNA molecules of the present invention.

According to one embodiment, the toxins of the invention have activity against Lepidopteran insects, preferably against *Plutella xylostella* (Diamondback Moth), *Trichoplusia ni* (Cabbage Looper), *Ostrinia nubilalis* (European Corn Borer), *Heliothis virescens* (Tobacco Budworm), *Helicoverpa zea* (Corn Earworm), *Spodoptera exigua* (Beet Armyworm), and *Spodoptera frugiperda* (Fall Armyworm).

According to another embodiment, the toxins of the invention have activity against Lepidopteran and Coleopteran insects, preferably against *Plutella xylostella* (Diamondback Moth), *Ostrinia nubilalis* (European Corn Borer), and *Manduca sexta* (Tobacco Hornworm), *Diabrotica virgifera virgifera* (Western Corn Rootworm), *Diabrotica undecimpunctata howardi* (Southern Corn Rootworm), and *Leptinotarsa decimlineata* (Colorado Potato Beetle).

In one embodiment, the toxins are produced by the *E. coli* strain designated as NRRL accession number B-21835.

In another embodiment, the toxins are produced by *E. coli* strain designated as NRRL accession number B-30077.

In still another embodiment, the toxins are produced by *E. coli* strain designated as NRRL accession number B-30078.

In one embodiment, a toxin of the invention comprises an amino acid sequence selected from the group consisting of: SEQ ID NOs:2-6.

In another embodiment, a toxin of the invention comprises an amino acid sequence selected from the group consisting of: SEQ ID NOs:12-14.

The present invention also provides a composition comprising an insecticidally effective amount of a toxin according to the invention.

In another aspect, the present invention provides a method of producing a toxin that is active against insects, comprising: (a) obtaining a host cell comprising a chimeric gene, which itself comprises a heterologous promoter sequence operatively linked to the nucleic acid molecule of the invention; and (b) expressing the nucleic acid molecule in the cell, which results in at least one toxin that is active against insects.

5

In a further aspect, the present invention provides a method of producing an insect-resistant plant, comprising introducing a nucleic acid molecule of the invention into the plant, wherein the nucleic acid molecule is expressible in the plant in an effective amount to control insects. According to one embodiment, the insects are Lepidopteran insects, preferably selected from the group consisting of: *Plutella xylostella* (Diamondback Moth), *Trichoplusia ni* (Cabbage Looper), *Ostrinia nubilalis* (European Corn Borer), *Heliothis virescens* (Tobacco Budworm), *Helicoverpa zea* (Corn Earworm), *Spodoptera exigua* (Beet Armyworm), and *Spodoptera frugiperda* (Fall Armyworm). According to another embodiment, the insects are Lepidopteran and Coleopteran insects, preferably selected from the group consisting of: *Plutella xylostella* (Diamondback Moth), *Ostrinia nubilalis* (European Corn Borer), and *Manduca sexta* (Tobacco Hornworm), *Diabrotica virgifera virgifera* (Western Corn Rootworm), *Diabrotica undecimpunctata howardi* (Southern Corn Rootworm), and *Leptinotarsa. decimlineata* (Colorado Potato Beetle).

In still a further aspect, the present invention provides a method of controlling insects comprising delivering to the insects an effective amount of a toxin according to the present invention. According to one embodiment, the insects are Lepidopteran insects, preferably selected from the group consisting of: *Plutella xylostella* (Diamondback Moth), *Trichoplusia ni* (Cabbage Looper), *Ostrinia nubilalis* (European Corn Borer), *Heliothis virescens* (Tobacco Budworm), *Helicoverpa zea* (Corn Earworm), *Spodoptera exigua* (Beet Armyworm), and *Spodoptera frugiperda* (Fall Armyworm). According to another embodiment, the insects are Lepidopteran and Coleopteran insects, preferably selected from the group consisting of: *Plutella xylostella* (Diamondback Moth), *Ostrinia nubilalis* (European Corn Borer), and *Manduca sexta* (Tobacco Hornworm), *Diabrotica virgifera virgifera* (Western Corn Rootworm), *Diabrotica undecimpunctata howardi* (Southern Corn Rootworm), and *Leptinotarsa decimlineata* (Colorado Potato Beetle). Preferably, the toxin is delivered to the insects orally.

Yet another aspect of the present invention is the provision of a method for mutagenizing a nucleic acid molecule according to the present invention, wherein the nucleic acid molecule has been cleaved into population of double-stranded random fragments of a desired size, comprising: (a) adding to the population of double-stranded random fragments one or more single- or double-stranded oligonucleotides, wherein the oligonucleotides each comprise an area of identity and an area of heterology to a double-stranded template polynucleotide; (b) denaturing the resultant mixture of double-stranded

random fragments and oligonucleotides into single-stranded fragments; (c) incubating the resultant population of single-stranded fragments with a polymerase under conditions which result in the annealing of the single-stranded fragments at the areas of identity to form pairs of annealed fragments, the areas of identity being sufficient for one member of a pair to prime replication of the other, thereby forming a mutagenized double-stranded polynucleotide; and (d) repeating the second and third steps for at least two further cycles, wherein the resultant mixture in the second step of a further cycle includes the mutagenized double-stranded polynucleotide from the third step of the previous cycle, and wherein the further cycle forms a further mutagenized double-stranded polynucleotide.

Other aspects and advantages of the present invention will become apparent to those skilled in the art from a study of the following description of the invention and non-limiting examples.

DEFINITIONS

"Activity" of the toxins of the invention is meant that the toxins function as orally active insect control agents, have a toxic effect, or are able to disrupt or deter insect feeding, which may or may not cause death of the insect. When a toxin of the invention is delivered to the insect, the result is typically death of the insect, or the insect does not feed upon the source that makes the toxin available to the insect.

"Associated with / operatively linked" refer to two nucleic acid sequences that are related physically or functionally. For example, a promoter or regulatory DNA sequence is said to be "associated with" a DNA sequence that codes for an RNA or a protein if the two sequences are operatively linked, or situated such that the regulator DNA sequence will affect the expression level of the coding or structural DNA sequence.

A "chimeric gene" is a recombinant nucleic acid sequence in which a promoter or regulatory nucleic acid sequence is operatively linked to, or associated with, a nucleic acid sequence that codes for an mRNA or which is expressed as a protein, such that the regulator nucleic acid sequence is able to regulate transcription or expression of the associated nucleic acid sequence. The regulator nucleic acid sequence of the chimeric gene is not normally operatively linked to the associated nucleic acid sequence as found in nature.

A "coding sequence" is a nucleic acid sequence that is transcribed into RNA such as mRNA, rRNA, tRNA, snRNA, sense RNA or antisense RNA. Preferably the RNA is then translated in an organism to produce a protein.

To "control" insects means to inhibit, through a toxic effect, the ability of insect pests to survive, grow, feed, and/or reproduce, or to limit insect-related damage or loss in crop plants. To "control" insects may or may not mean killing the insects, although it preferably means killing the insects.

To "deliver" a toxin means that the toxin comes in contact with an insect, resulting in toxic effect and control of the insect. The toxin can be delivered in many recognized ways, e.g., orally by ingestion by the insect or by contact with the insect via transgenic plant expression, formulated protein composition(s), sprayable protein composition(s), a bait matrix, or any other art-recognized toxin delivery system.

"Expression cassette" as used herein means a nucleic acid sequence capable of directing expression of a particular nucleotide sequence in an appropriate host cell, comprising a promoter operably linked to the nucleotide sequence of interest which is operably linked to termination signals. It also typically comprises sequences required for proper translation of the nucleotide sequence. The expression cassette comprising the nucleotide sequence of interest may be chimeric, meaning that at least one, of its components is heterologous with respect to at least one of its other components. The expression cassette may also be one which is naturally occurring but has been obtained in a recombinant form useful for heterologous expression. Typically, however, the expression cassette is heterologous with respect to the host, i.e., the particular nucleic acid sequence of the expression cassette does not occur naturally in the host cell and must have been introduced into the host cell or an ancestor of the host cell by a transformation event. The expression of the nucleotide sequence in the expression cassette may be under the control of a constitutive promoter or of an inducible promoter which initiates transcription only when the host cell is exposed to some particular external stimulus. In the case of a multicellular organism, such as a plant, the promoter can also be specific to a particular tissue, or organ, or stage of development.

A "gene" is a defined region that is located within a genome and that, besides the aforementioned coding nucleic acid sequence, comprises other, primarily regulatory, nucleic acid sequences responsible for the control of the expression, that is to say the transcription and translation, of the coding portion. A gene may also comprise other 5' and 3'

untranslated sequences and termination sequences. Further elements that may be present are, for example, introns.

"Gene of interest" refers to any gene which, when transferred to a plant, confers upon the plant a desired characteristic such as antibiotic resistance, virus resistance, insect resistance, disease resistance, or resistance to other pests, herbicide tolerance, improved nutritional value, improved performance in an industrial process or altered reproductive capability. The "gene of interest" may also be one that is transferred to plants for the production of commercially valuable enzymes or metabolites in the plant.

A "heterologous" nucleic acid sequence is a nucleic acid sequence not naturally associated with a host cell into which it is introduced, including non-naturally occurring multiple copies of a naturally occurring nucleic acid sequence.

A "homologous" nucleic acid sequence is a nucleic acid sequence naturally associated with a host cell into which it is introduced.

"Homologous recombination" is the reciprocal exchange of nucleic acid fragments between homologous nucleic acid molecules.

"Insecticidal" is defined as a toxic biological activity capable of controlling insects, preferably by killing them.

A nucleic acid sequence is "isocoding with" a reference nucleic acid sequence when the nucleic acid sequence encodes a polypeptide having the same amino acid sequence as the polypeptide encoded by the reference nucleic acid sequence.

An "isolated" nucleic acid molecule or an isolated enzyme is a nucleic acid molecule or enzyme that, by the hand of man, exists apart from its native environment and is therefore not a product of nature. An isolated nucleic acid molecule or enzyme may exist in a purified form or may exist in a non-native environment such as, for example, a recombinant host cell.

A "nucleic acid molecule" or "nucleic acid sequence" is a linear segment of single- or double-stranded DNA or RNA that can be isolated from any source. In the context of the present invention, the nucleic acid molecule is preferably a segment of DNA.

"ORF" means open reading frame.

A "plant" is any plant at any stage of development, particularly a seed plant.

A "plant cell" is a structural and physiological unit of a plant, comprising a protoplast and a cell wall. The plant cell may be in form of an isolated single cell or a cultured cell, or as a part of higher organized unit such as, for example, plant tissue, a plant organ, or a whole plant.

4

"Plant cell culture" means cultures of plant units such as, for example, protoplasts, cell culture cells, cells in plant tissues, pollen, pollen tubes, ovules, embryo sacs, zygotes and embryos at various stages of development.

"Plant material" refers to leaves, stems, roots, flowers or flower parts, fruits, pollen, egg cells, zygotes, seeds, cuttings, cell or tissue cultures, or any other part or product of a plant.

A "plant organ" is a distinct and visibly structured and differentiated part of a plant such as a root, stem, leaf, flower bud, or embryo.

"Plant tissue" as used herein means a group of plant cells organized into a structural and functional unit. Any tissue of a plant *in planta* or in culture is included. This term includes, but is not limited to, whole plants, plant organs, plant seeds, tissue culture and any groups of plant cells organized into structural and/or functional units. The use of this term in conjunction with, or in the absence of, any specific type of plant tissue as listed above or otherwise embraced by this definition is not intended to be exclusive of any other type of plant tissue.

A "promoter" is an untranslated DNA sequence upstream of the coding region that contains the binding site for RNA polymerase II and initiates transcription of the DNA. The promoter region may also include other elements that act as regulators of gene expression.

A "protoplast" is an isolated plant cell without a cell wall or with only parts of the cell wall.

"Regulatory elements" refer to sequences involved in controlling the expression of a nucleotide sequence. Regulatory elements comprise a promoter operably linked to the nucleotide sequence of interest and termination signals. They also typically encompass sequences required for proper translation of the nucleotide sequence.

In its broadest sense, the term "substantially similar", when used herein with respect to a nucleotide sequence, means a nucleotide sequence corresponding to a reference nucleotide sequence, wherein the corresponding sequence encodes a polypeptide having substantially the same structure and function as the polypeptide encoded by the reference nucleotide sequence, e.g. where only changes in amino acids not affecting the polypeptide function occur. Desirably the substantially similar nucleotide sequence encodes the polypeptide encoded by the reference nucleotide sequence. The percentage of identity between the substantially similar nucleotide sequence and the reference nucleotide sequence desirably is at least 80%, more desirably at least 85%, preferably at least 90%, more preferably at least 95%. Still more preferably at least 99%. A nucleotide sequence

"substantially similar" to reference nucleotide sequence hybridizes to the reference nucleotide sequence in 7% sodium dodecyl sulfate (SDS), 0.5 M NaPO₄, 1 mM EDTA at 50°C with washing in 2X SSC, 0.1% SDS at 50°C, more desirably in 7% sodium dodecyl sulfate (SDS), 0.5 M NaPO₄, 1 mM EDTA at 50°C with washing in 1X SSC, 0.1% SDS at 50°C, more desirably still in 7% sodium dodecyl sulfate (SDS), 0.5 M NaPO₄, 1 mM EDTA at 50°C with washing in 0.5X SSC, 0.1% SDS at 50°C, preferably in 7% sodium dodecyl sulfate (SDS), 0.5 M NaPO₄, 1 mM EDTA at 50°C with washing in 0.1X SSC, 0.1% SDS at 50°C, more preferably in 7% sodium dodecyl sulfate (SDS), 0.5 M NaPO₄, 1 mM EDTA at 50°C with washing in 0.1X SSC, 0.1% SDS at 50°C.

"Synthetic" refers to a nucleotide sequence comprising structural characters that are not present in the natural sequence. For example, an artificial sequence that resembles more closely the G+C content and the normal codon distribution of dicot and/or monocot genes is said to be synthetic.

"Transformation" is a process for introducing heterologous nucleic acid into a host cell or organism. In particular, "transformation" means the stable integration of a DNA molecule into the genome of an organism of interest.

"Transformed / transgenic / recombinant" refer to a host organism such as a bacterium or a plant into which a heterologous nucleic acid molecule has been introduced. The nucleic acid molecule can be stably integrated into the genome of the host or the nucleic acid molecule can also be present as an extrachromosomal molecule. Such an extrachromosomal molecule can be auto-replicating. Transformed cells, tissues, or plants are understood to encompass not only the end product of a transformation process, but also transgenic progeny thereof. A "non-transformed", "non-transgenic", or "non-recombinant" host refers to a wild-type organism, e.g., a bacterium or plant, which does not contain the heterologous nucleic acid molecule.

Nucleotides are indicated by their bases by the following standard abbreviations: adenine (A), cytosine (C), thymine (T), and guanine (G). Amino acids are likewise indicated by the following standard abbreviations: alanine (Ala; A), arginine (Arg; R), asparagine (Asn; N), aspartic acid (Asp; D), cysteine (Cys; C), glutamine (Gln; Q), glutamic acid (Glu; E), glycine (Gly; G), histidine (His; H), isoleucine (Ile; I), leucine (Leu; L), lysine (Lys; K), methionine (Met; M), phenylalanine (Phe; F), proline (Pro; P), serine (Ser; S), threonine (Thr; T), tryptophan (Trp; W), tyrosine (Tyr; Y), and valine (Val; V). Furthermore, (Xaa; X) represents any amino acid.



SEQ ID NO:1 is the sequence of the approximately 9.7 kb DNA fragment comprised in pCIB9359-7 which comprises the following ORFs at the specified nucleotide positions:

<u>Name</u>	<u>Start</u>	<u>End</u>
orf1	412	1665
orf2	1686	2447
orf3	2758	3318
orf4	3342	4118
orf5	4515	9269

SEQ ID NO:2 is the sequence of the ~46.4 kDa protein encoded by orf1 of SEQ ID NO:1.

SEQ ID NO:3 is the sequence of the ~28.1 kDa protein encoded by orf2 of SEQ ID NO:1.

SEQ ID NO:4 is the sequence of the ~20.7 kDa protein encoded by orf3 of SEQ ID NO:1.

SEQ ID NO:5 is the sequence of the ~28.7 kDa protein encoded by orf4 of SEQ ID NO:1.

SEQ ID NO:6 is the sequence of the ~176 kDa protein encoded by orf5 of SEQ ID NO:1.

SEQ ID NOs:7-10 are oligonucleotides.

SEQ ID NO:11 is the sequence of the approximately 38 kb DNA fragment comprised in pNOV2400, which comprises the following ORFs at the specified nucleotide positions (descending numbers and "C" indicates that the ORF is on the complementary strand):

<u>Name</u>	<u>Start</u>	<u>End</u>	
orf7	66	1898	(partial sequence)
hph3	2416	9909	
orf18	3395	2817	С
orf4	9966	14,633	
orf19	14,699	15,007	-
orf5	15,17 1	18,035	
orf22	17,398	17,072	С
orf10	19,167	18,235	С
orf14	20,116	19,385	С
orf13	20,963	20,217	С
orf11	23,086	22,172	С
hph2	23,768	31,336	
orf2	31,393	35,838	



SEQ ID NO:11 also includes the following restriction sites, some of which are used in the subcloning steps set forth in Example 17:

Restriction Site	Nucleotide Position(s)
Accill	2835
<i>Bam</i> HI	18,915
<i>Bsm</i> Bl	11,350
Bst11071	29,684
Eagl	13,590; 31,481
Eco721	34,474
<i>Mlu</i> l	2444; 5116; 9327; 26,204
Notl	13,589
Pacl	9915; 23,353; 37,888
Pvul	8816
Sapl	35,248
<i>Sex</i> Al	28,946
Sgfl .	8815
Spel	2157; 3769; 7831; 11,168
Sphl	755
Stul	35,690
<i>Tth</i> 1111	21,443

SEQ ID NO:12 is the sequence of the protein encoded by orf5 of SEQ ID NO:11.


SEQ ID NO:13 is the sequence of the protein encoded by hph2 of SEQ ID NO:11.

SEQ ID NO:14 is the sequence of the protein encoded by orf2 of SEQ ID NO:11.

SEQ ID NOs:15-22 are oligonucleotides.

DEPOSITS

The following material has been deposited with the Agricultural Research Service, Patent Culture Collection (NRRL), 1815 North University Street, Peoria, Illinois 61604, under the terms of the Budapest Treaty on the International Recognition of the Deposit of



Clone	Accession Number	Date of Deposit
pCIB9359-7	NRRL B-21835	September 17, 1997
pNOV2400	NRRL B-30077	December 3, 1998
pNOV1001	NRRL B-30078	December 3, 1998

Novel Nucleic Acid Sequences whose Expression Results in Insecticidal Toxins

This invention relates to nucleic acid sequences whose expression results in novel toxins, and to the making and using of the toxins to control insect pests. The nucleic acid sequences are derived from Photorhabdus luminescens, a member of the Enterobacteriaceae family. P. luminescens is a symbiotic bacterium of nematodes of the genus Heterorhabditis. The nematodes colonize insect larva, kill them, and their offspring feed on the dead larvae. The insecticidal activity is actually produced by the symbiotic P. luminescens bacteria. The inventors are the first to isolate the nucleic acid sequences of the present invention from P. luminescens (ATCC strain number 29999). The expression of the nucleic acid sequences of the present invention results in toxins that can be used to control Lepidopteran insects such as Plutella xylostella (Diamondback Moth), Trichoplusia ni (Cabbage Looper), Ostrinia nubilalis (European Corn Borer), Heliothis virescens (Tobacco Budworm), Helicoverpa zea (Corn Earworm), Manduca sexta (Tobacco Hornworm), Spodoptera exigua (Beet Armyworm), and Spodoptera frugiperda (Fall Armyworm), as well as Coleopteran insects such as Diabrotica virgifera virgifera (Western Corn Rootworm), Diabrotica undecimpunctata howardi (Southern Corn Rootworm), Diabrotica longicornis barberi (Northern Corn Rootworm), and Leptinotarsa decimlineata (Colorado Potato Beetle).

In one preferred embodiment, the invention encompasses an isolated nucleic acid molecule comprising a nucleotide sequence substantially similar to the approximately 9.7 kb nucleic acid sequence set forth in SEQ ID NO:1, whose expression results in insect control activity (further illustrated in Examples 1-11). Five open reading frames (ORFs) are present in the nucleic acid sequence set forth in SEQ ID NO:1, coding for proteins of predicted sizes 45 kDa, 28 kDa, 21 kDA, 29 kDa, and 176 kDa. The five ORFs are arranged in an operon-like structure. When expressed in a heterologous host, the ~ 9.7 kb DNA fragment from P.

luminescens results in insect control activity against Lepidopterans such as *Plutella xylostella* (Diamondback Moth), *Trichoplusia ni* (Cabbage Looper), *Ostrinia nubilalis* (European Corn Borer), *Heliothis virescens* (Tobacco Budworm), *Helicoverpa zea* (Corn Earworm), *Spodoptera exigua* (Beet Armyworm), and *Spodoptera frugiperda* (Fall Armyworm), showing that expression of the ~ 9.7 kb nucleotide sequence set forth in SEQ ID NO:1 is necessary and sufficient for such insect control activity. In a preferred embodiment, the invention encompasses a DNA molecule, whose expression results in an insecticidal toxin, which is deposited in the *E. coli* strain pCIB9359-7 (NRRL accession number B-21835).

In another preferred embodiment, the invention encompasses an isolated nucleic acid molecule comprising a nucleotide sequence substantially similar to the approximately 38 kb nucleic acid fragment set forth in SEQ ID NO:11 and deposited in the E. coli strain pNOV2400 (NRRL accession number B-30077), whose expression results in insect control activity (see Examples 12-18). In a more preferred embodiment, the invention encompasses an isolated nucleic acid molecule comprising a nucleotide sequence substantially similar to the ~ 22 kb DNA fragment deposited in the E. coli strain pNOV1001 (NRRL accession number B-30078), whose expression results in insect control activity. In a most preferred embodiment, the invention encompasses isolated nucleic acid molecules comprising nucleotide sequences substantially similar to the three ORFs corresponding to nucleotides 23,768-31,336 (hph2), 31,393-35,838 (orf2), and 15,171-18,035 (orf5) of the DNA fragment set forth in SEQ ID NO:11, as well as the proteins encoded thereby. When co-expressed in a heterologous host, these three ORFs result in insect control activity against Lepidopterans such as Plutella xylostella (Diamondback Moth), Ostrinia nubilalis (European Corn Borer), and Manduca sexta (Tobacco Hornworm), as well as against Coleopterans such as Diabrotica virgifera virgifera (Western Corn Rootworm), Diabrotica undecimpunctata howardi (Southern Corn Rootworm), and Leptinotarsa decimlineata (Colorado Potato Beetle), showing that co-expression of these three ORFs (hph2, orf2, and orf5) is necessary and sufficient for such insect control activity.

The present invention also encompasses recombinant vectors comprising the nucleic acid sequences of this invention. In such vectors, the nucleic acid sequences are preferably comprised in expression cassettes comprising regulatory elements for expression of the nucleotide sequences in a host cell capable of expressing the nucleotide sequences. Such regulatory elements usually comprise promoter and termination signals and preferably also

4-1

13

- 20

14 💲

comprise elements allowing efficient translation of polypeptides encoded by the nucleic acid sequences of the present invention. Vectors comprising the nucleic acid sequences are usually capable of replication in particular host cells, preferably as extrachromosomal molecules, and are therefore used to amplify the nucleic acid sequences of this invention in the host cells. In one embodiment, host cells for such vectors are microorganisms, such as bacteria, in particular E.coli. In another embodiment, host cells for such recombinant vectors are endophytes or epiphytes. A preferred host cell for such vectors is a eukaryotic cell, such as a yeast, a plant cell, or an insect cell. Plant cells such as maize cells are most preferred host cells. In another preferred embodiment, such vectors are viral vectors and are used for replication of the nucleotide sequences in particular host cells, e.g. insect cells or plant cells. Recombinant vectors are also used for transformation of the nucleotide sequences of this invention into host cells, whereby the nucleotide sequences are stably integrated into the DNA of such host cells. In one, such host cells are prokaryotic cells. In a preferred embodiment, such host cells are eukaryotic cells, such as yeast cells, insect; cells, or plant cells. In a most preferred embodiment, the host cells are plant cells, such as maize cells. ~;&

In preferred embodiments, the insecticidal toxins of the invention each comprise at least one polypeptide encoded by a nucleotide sequence of the invention. In another preferred embodiment, the insecticidal toxins are produced from a purified strain—of *P. luminescens*, such the strain with ATTC accession number 29999. The toxins of the present invention have insect control activity when tested against insect pests in bioassays; and these properties of the insecticidal toxins are further illustrated in Examples 1-18. The insecticidal toxins desribed in the present invention are further characterized in that their molecular weights are larger than 6,000, as found by size fractionation experiments. The insecticidal toxins retain full insecticidal activity after being stored at 4°C for 2 weeks. One is also shown to retain its full insecticidal activity after being freeze-dried and stored at 22°C for 2 weeks. However, the insecticidal toxins of the invention lose their insecticidal activity after incubation for 5 minutes at 100°C.

In further embodiments, the nucleotide sequences of the invention can be modified by incorporation of random mutations in a technique known as *in-vitro* recombination or DNA shuffling. This technique is described in Stemmer et al., Nature 370: 389-391 (1994) and US Patent 5,605,793, which are incorporated herein by reference. Millions of mutant copies of a nucleotide sequence are produced based on an original nucleotide sequence of

this invention and variants with improved properties, such as increased insecticidal activity, enhanced stability, or different specificity or range of target insect pests are recovered. The method encompasses forming a mutagenized double-stranded polynucleotide from a template double-stranded polynucleotide comprising a nucleotide sequence of this invention, wherein the template double-stranded polynucleotide has been cleaved into double-stranded-random fragments of a desired size, and comprises the steps of adding to the resultant population of double-stranded random fragments one or more single or double-stranded oligonucleotides, wherein said oligonucleotides comprise an area of identity and an area of heterology to the double-stranded template polynucleotide; denaturing the resultant mixture of double-stranded random fragments and oligonucleotides into single-stranded fragments; incubating the resultant population of single-stranded fragments with a polymerase under conditions which result in the annealing of said singlestranded fragments at said areas of identity to form pairs of annealed fragments, said areas of identity being sufficient for one member of a pair to prime replication of the other, thereby forming a mutagenized double-stranded polynucleotide; and repeating the second and third steps for at least two further cycles, wherein the resultant mixture in the second step of a further cycle includes the mutagenized double-stranded polynucleotide from the third step of the previous cycle, and the further cycle forms a further mutagenized double-stranded polynucleotide. In a preferred embodiment, the concentration of a single species of doublestranded random fragment in the population of double-stranded random fragments is less than 1% by weight of the total DNA. In a further preferred embodiment, the template double-stranded polynucleotide comprises at least about 100 species of polynucleotides. In another preferred embodiment, the size of the double-stranded random fragments is from about 5 bp to 5 kb. In a further preferred embodiment, the fourth step of the method comprises repeating the second and the third steps for at least 10 cycles.

Expression of the Nucleotide Sequences in Heterologous Microbial Hosts

As biological insect control agents, the insecticidal toxins are produced by expression of the nucleotide sequences in heterologous host cells capable of expressing the nucleotide sequences. In a first embodiment, *P. luminescens* cells comprising modifications of at least one nucleotide sequence of this invention at its chromosomal location are described. Such modifications encompass mutations or deletions of existing regulatory elements, thus leading to altered expression of the nucleotide sequence, or the incorporation of new regulatory elements controlling the expression of the nucleotide sequence. In another

- C. 57


1

embodiment, additional copies of one or more of the nucleotide sequences are added to *P. luminescens* cells either by insertion into the chromosome or by introduction of extrachromosomally replicating molecules containing the nucleotide sequences.

In another embodiment, at least one of the nucleotide sequences of the invention is inserted into an appropriate expression cassette, comprising a promoter and termination signals. Expression of the nucleotide sequence is constitutive, or an inducible promoter responding to various types of stimuli to initiate transcription is used. In a preferred embodiment, the cell in which the toxin is expressed is a microorganism, such as a virus, a bacteria, or a fungus. In a preferred embodiment, a virus, such as a baculovirus, contains a nucleotide sequence of the invention in its genome and expresses large amounts of the corresponding insecticidal toxin after infection of appropriate eukaryotic cells that are suitable for virus replication and expression of the nucleotide sequence. The insecticidal toxin thus produced is used as an insecticidal agent. Alternatively, baculoviruses engineered to include the nucleotide sequence are used to infect insects *in-vivo* and kill them either by expression of the insecticidal toxin or by a combination of viral infection and expression of the insecticidal toxin.

Bacterial cells are also hosts for the expression of the nucleotide sequences of the invention. In a preferred embodiment, non-pathogenic symbiotic bacteria, which are able to live and replicate within plant tissues, so-called endophytes, or non-pathogenic symbiotic bacteria, which are capable of colonizing the phyllosphere or the rhizosphere, so-called epiphytes, are used. Such bacteria include bacteria of the genera Agrobacterium, Alcaligenes, Azospirillum, Azotobacter, Bacillus, Clavibacter, Enterobacter, Erwinia, Flavobacter, Klebsiella, Pseudomonas, Rhizobium, Serratia, Streptomyces and Xanthomonas. Symbiotic fungi, such as Trichoderma and Gliocladium are also possible hosts for expression of the inventive nucleotide sequences for the same purpose.

Techniques for these genetic manipulations are specific for the different available hosts and are known in the art. For example, the expression vectors pKK223-3 and pKK223-2 can be used to express heterologous genes in *E. coli*, either in transcriptional or translational fusion, behind the *tac or trc* promoter. For the expression of operons encoding multiple ORFs, the simplest procedure is to insert the operon into a vector such as pKK223-3 in transcriptional fusion, allowing the cognate ribosome binding site of the heterologous genes to be used. Techniques for overexpression in gram-positive species such as *Bacillus* are also known in the art and can be used in the context of this invention (Quax *et al. In.*:



In another preferred embodiment, at least one of the described nucleotide sequences is transferred to and expressed in *Pseudomonas fluorescens* strain CGA267356 (described in the published application EU 0 472 494 and in WO 94/01561) which has biocontrol characteristics. In another preferred embodiment, a nucleotide sequence of the invention is transferred to *Pseudomonas aureofaciens* strain 30-84 which also has biocontrol characteristics. Expression in heterologous biocontrol strains requires the selection of vectors appropriate for replication in the chosen host and a suitable choice of promoter. Techniques are well known in the art for expression in gram-negative and gram-positive bacteria and fungi.

Expression of the Nucleotide Sequences in Plant Tissue

In a particularly preferred embodiment, at least one of the insecticidal toxins of the invention is expressed in a higher organism, e.g., a plant. In this case, transgenic plants expressing effective amounts of the toxins protect themselves from insect pests. When the insect starts feeding on such a transgenic plant, it also ingests the expressed toxins. This will deter the insect from further biting into the plant tissue or may even harm or kill the insect. A nucleotide sequence of the present invention is inserted into an expression cassette, which is then preferably stably integrated in the genome of said plant. In another preferred embodiment, the nucleotide sequence is included in a non-pathogenic self-replicating virus. Plants transformed in accordance with the present invention may be monocots or dicots and include, but are not limited to, maize, wheat, barley, rye, sweet potato, bean, pea, chicory, lettuce, cabbage, cauliflower, broccoli, turnip, radish, spinach, asparagus, onion, garlic, pepper, celery, squash, pumpkin, hemp, zucchini, apple, pear, quince, melon, plum, cherry, peach, nectarine, apricot, strawberry, grape, raspberry, blackberry, pineapple, avocado, papaya, mango, banana, soybean, tomato, sorghum, sugarcane, sugarbeet, sunflower, rapeseed, clover, tobacco, carrot, cotton, alfalfa, rice,

W.

5

potato, eggplant, cucumber, *Arabidopsis*, and woody plants such as coniferous and deciduous trees.

Once a desired nucleotide sequence has been transformed into a particular plant species, it may be propagated in that species or moved into other varieties of the same species, particularly including commercial varieties, using traditional breeding techniques.

A nucleotide sequence of this invention is preferably expressed in transgenic plants, thus causing the biosynthesis of the corresponding toxin in the transgenic plants. In this way, transgenic plants with enhanced resistance to insects are generated. For their expression in transgenic plants, the nucleotide sequences of the invention may require modification and optimization. Although in many cases genes from microbial organisms can be expressed in plants at high levels without modification, low expression in transgenic plants may result from microbial nucleotide sequences having codons that are not preferred in plants. It is known in the art that all organisms have specific preferences for codon usage, and the codons of the nucleotide sequences described in this invention can be changed to conform with plant preferences, while maintaining the amino acids encoded thereby. Furthermore, high expression in plants is best achieved from coding sequences that have at least 35% about GC content, preferably more than about 45%, more preferably more than about 50%, and most preferably more than about 60%. Microbial nucleotide sequences which have low GC contents may express poorly in plants due to the existence of ATTTA motifs which may destabilize messages, and AATAAA motifs which may cause inappropriate polyadenylation. Although preferred gene sequences may be adequately expressed in both monocotyledonous and dicotyledonous plant species, sequences can be modified to account for the specific codon preferences and GC content preferences of monocotyledons or dicotyledons as these preferences have been shown to differ (Murray et al. Nucl. Acids Res. 17: 477-498 (1989)). In addition, the nucleotide sequences are screened for the existence of illegitimate splice sites that may cause message truncation. All changes required to be made within the nucleotide sequences such as those described above are made using well known techniques of site directed mutagenesis, PCR, and synthetic gene construction using the methods described in the published patent applications EP 0 385 962 (to Monsanto), EP 0 359 472 (to Lubrizol, and WO 93/07278 (to Ciba-Geigy).

For efficient initiation of translation, sequences adjacent to the initiating methionine may require modification. For example, they can be modified by the inclusion of sequences known to be effective in plants. Joshi has suggested an appropriate consensus for plants

(NAR <u>15</u>: 6643-6653 (1987)) and Clontech suggests a further consensus translation initiator (1993/1994 catalog, page 210). These consensuses are suitable for use with the nucleotide sequences of this invention. The sequences are incorporated into constructions comprising the nucleotide sequences, up to and including the ATG (whilst leaving the second amino acid unmodified), or alternatively up to and including the GTC subsequent to the ATG (with the possibility of modifying the second amino acid of the transgene).

Expression of the nucleotide sequences in transgenic plants is driven by promoters shown to be functional in plants. The choice of promoter will vary depending on the temporal and spatial requirements for expression, and also depending on the target species. Thus, expression of the nucleotide sequences of this invention in leaves, in ears, in inflorescences (e.g. spikes, panicles, cobs. etc.), in roots, and/or seedlings is preferred. In many cases, however, protection against more than one type of insect pest is sought, and thus expression in multiple tissues is desirable. Although many promoters from dicotyledons have been shown to be operational in monocotyledons and vice versa, ideally dicotyledonous promoters are selected for expression in dicotyledons, and monocotyledonous promoters for expression in monocotyledons. However, there is no restriction to the provenance of selected promoters; it is sufficient that they are operational in driving the expression of the nucleotide sequences in the desired cell.

Preferred promoters that are expressed constitutively include promoters from genes encoding actin or ubiquitin and the CaMV 35S and 19S promoters. The nucleotide sequences of this invention can also be expressed under the regulation of promoters that are chemically regulated. This enables the insecticidal toxins to be synthesized only when the crop plants are treated with the inducing chemicals. Preferred technology for chemical induction of gene expression is detailed in the published application EP 0 332 104 (to Ciba-Geigy) and US patent 5,614,395. A preferred promoter for chemical induction is the tobacco PR-1a promoter.

A preferred category of promoters is that which is wound inducible. Numerous promoters have been described which are expressed at wound sites and also at the sites of phytopathogen infection. Ideally, such a promoter should only be active locally at the sites of infection, and in this way the insecticidal toxins only accumulate in cells which need to synthesize the insecticidal toxins to kill the invading insect pest. Preferred promoters of this kind include those described by Stanford *et al.* Mol. Gen. Genet. 215: 200-208 (1989), Xu *et al.* Plant Molec. Biol. 22: 573-588 (1993), Logemann *et al.* Plant Cell 1: 151-158 (1989),

笔数

دين

7 E 1

7.5

3 - 3

Rohrmeier & Lehle, Plant Molec. Biol. <u>22</u>: 783-792 (1993), Firek *et al.* Plant Molec. Biol. <u>22</u>: 129-142 (1993), and Warner *et al.* Plant J. <u>3</u>: 191-201 (1993).


Preferred tissue specific expression patterns include green tissue specific, root specific, stem specific, and flower specific. Promoters suitable for expression in green tissue include many which regulate genes involved in photosynthesis and many of these have been cloned from both monocotyledons and dicotyledons. A preferred promoter is the maize PEPC promoter from the phosphoenol carboxylase gene (Hudspeth & Grula, Plant Molec. Biol. 12: 579-589 (1989)). A preferred promoter for root specific expression is that described by de Framond (FEBS 290: 103-106 (1991); EP 0 452 269 to Ciba-Geigy). A preferred stem specific promoter is that described in US patent 5,625,136 (to Ciba-Geigy) and which drives expression of the maize *trpA* gene.

Especially preferred embodiments of the invention are transgenic plants expressing at least one of the nucleotide sequences of the invention in a root-preferred or root-specific fashion. Further preferred embodiments are transgenic plants expressing the nucleotide sequences in a wound-inducible or pathogen infection-inducible manner.

In addition to the selection of a suitable promoter, constructions for expression of an insecticidal toxin in plants require an appropriate transcription terminator to be attached downstream of the heterologous nucleotide sequence. Several such terminators are available and known in the art (e.g. tm1 from CaMV, E9 from rbcS). Any available terminator known to function in plants can be used in the context of this invention.

Numerous other sequences can be incorporated into expression cassettes described in this invention. These include sequences which have been shown to enhance expression such as intron sequences (e.g. from Adh1 and bronze1) and viral leader sequences (e.g. from TMV, MCMV and AMV).

It may be preferable to target expression of the nucleotide sequences of the present invention to different cellular localizations in the plant. In some cases, localization in the cytosol may be desirable, whereas in other cases, localization in some subcellular organelle may be preferred. Subcellular localization of transgene encoded enzymes is undertaken using techniques well known in the art. Typically, the DNA encoding the target peptide from a known organelle-targeted gene product is manipulated and fused upstream of the nucleotide sequence. Many such target sequences are known for the chloroplast and their functioning in heterologous constructions has been shown. The expression of the



Vectors suitable for plant transformation are described elsewhere in this specification. For Agrobacterium-mediated transformation, binary vectors or vectors carrying at least one T-DNA border sequence are suitable, whereas for direct gene transfer any vector is suitable and linear DNA containing only the construction of interest may be preferred. In the case of direct gene transfer, transformation with a single DNA species or co-transformation can be used (Schocher et al. Biotechnology 4: 1093-1096 (1986)). For both direct gene transfer and Agrobacterium-mediated transfer, transformation is usually (but not necessarily) undertaken with a selectable marker which may provide resistance to an antibiotic (kanamycin, hygromycin or methotrexate) or a herbicide (basta). The choice of selectable marker is not, however, critical to the invention.

In another preferred embodiment, a nucleotide sequence of the present invention is directly transformed into the plastid genome. A major advantage of plastid transformation is that plastids are generally capable of expressing bacterial genes without substantial modification, and plastids are capable of expressing multiple open reading frames under control of a single promoter. Plastid transformation technology is extensively described in U.S. Patent Nos. 5,451,513, 5,545,817, and 5,545,818, in PCT application no. WO 95/16783, and in McBride et al. (1994) Proc. Natl. Acad. Sci. USA 91, 7301-7305. The basic technique for chloroplast transformation involves introducing regions of cloned plastid DNA flanking a selectable marker together with the gene of interest into a suitable target tissue, e.g., using biolistics or protoplast transformation (e.g., calcium chloride or PEG mediated transformation). The 1 to 1.5 kb flanking regions, termed targeting sequences, facilitate homologous recombination with the plastid genome and thus allow the replacement or modification of specific regions of the plastome. Initially, point mutations in the chloroplast 16S rRNA and rps12 genes conferring resistance to spectinomycin and/or streptomycin are utilized as selectable markers for transformation (Svab, Z., Hajdukiewicz, P., and Maliga, P. (1990) Proc. Natl. Acad. Sci. USA 87, 8526-8530; Staub, J. M., and Maliga, P. (1992) Plant Cell 4, 39-45). This resulted in stable homoplasmic transformants at a frequency of approximately one per 100 bombardments of target leaves. The presence of cloning sites between these markers allowed creation of a plastid targeting vector for introduction of foreign genes (Staub, J.M., and Maliga, P. (1993) EMBO J. 12, 601-606). Substantial increases in transformation frequency are obtained by replacement of the recessive rRNA or r-protein antibiotic resistance genes with a dominant selectable marker, the bacterial

1

18.

. 32

i'è

aadA encoding the spectinomycin-detoxifying enzyme aminoglycoside-3'adenyltransferase (Svab, Z., and Maliga, P. (1993) Proc. Natl. Acad. Sci. USA 90, 913-917). Previously, this marker had been used successfully for high-frequency transformation of the plastid genome of the green alga Chlamydomonas reinhardtii (Goldschmidt-Clermont, M. (1991) Nucl. Acids Res. 19: 4083-4089). Other selectable markers useful for plastid transformation are known in the art and encompassed within the scope of the invention. Typically, approximately 15-20 cell division cycles following transformation are required to reach a homoplastidic state. Plastid expression, in which genes are inserted by homologous recombination into all of the several thousand copies of the circular plastid genome present in each plant cell, takes advantage of the enormous copy number advantage over nuclearexpressed genes to permit expression levels that can readily exceed 10% of the total soluble plant protein. In a preferred embodiment, a nucleotide sequence of the present invention is inserted into a plastid targeting vector and transformed into the plastid genome of a desired plant host. Plants homoplastic for plastid genomes containing a nucleotide sequence of the present invention are obtained, and are preferentially capable, of high expression of the nucleotide sequence.

Formulation of Insecticidal Compositions

The invention also includes compositions comprising at least one of the insecticidal toxins of the present invention. In order to effectively control insect pests such compositions preferably contain sufficient amounts of toxin. Such amounts vary depending on the crop to be protected, on the particular pest to be targeted, and on the environmental conditions, such as humidity, temperature or type of soil. In a preferred embodiment, compositions comprising the insecticidal toxins comprise host cells expressing the toxins without additional purification. In another preferred embodiment, the cells expressing the insecticidal toxins are lyophilized prior to their use as an insecticidal agent. In another embodiment, the insecticidal toxins are engineered to be secreted from the host cells. In cases where purification of the toxins from the host cells in which they are expressed is desired, various degrees of purification of the insecticidal toxins are reached.

The present invention further embraces the preparation of compositions comprising at least one insecticidal toxin of the present invention, which is homogeneously mixed with one or more compounds or groups of compounds described herein. The present invention also relates to methods of treating plants, which comprise application of the insecticidal toxins or compositions containing the insecticidal toxins, to plants. The insecticidal toxins

can be applied to the crop area in the form of compositions or plant to be treated, simultaneously or in succession, with further compounds. These compounds can be both fertilizers or micronutrient donors or other preparations that influence plant growth. They can also be selective herbicides, insecticides, fungicides, bactericides, nematicides, molluscicides or mixtures of several of these preparations, if desired together with further carriers, surfactants or application-promoting adjuvants customarily employed in the art of formulation. Suitable carriers and adjuvants can be solid or liquid and correspond to the substances ordinarily employed in formulation technology, e.g. natural or regenerated mineral substances, solvents, dispersants, wetting agents, tackifiers, binders or fertilizers.

A preferred method of applying insecticidal toxins of the present invention is by spraying to the environment hosting the insect pest like the soil, water, or foliage of plants. The number of applications and the rate of application depend on the type and intensity of infestation by the insect pest. The insecticidal toxins can also penetrate the plant through the roots via the soil (systemic action) by impregnating the locus of the plant with a liquid composition, or by applying the compounds in solid form to the soil, e.g. in granular form (soil application). The insecticidal toxins may also be applied to seeds (coating) by impregnating the seeds either with a liquid formulation containing insecticidal toxins, or coating them with a solid formulation. In special cases, further types of application are also possible, for example, selective treatment of the plant stems or buds. The insecticidal toxins can also be provided as bait located above or below the ground.

The insecticidal toxins are used in unmodified form or, preferably, together with the adjuvants conventionally employed in the art of formulation, and are therefore formulated in known manner to emulsifiable concentrates, coatable pastes, directly sprayable or dilutable solutions, dilute emulsions, wettable powders, soluble powders, dusts, granulates, and also encapsulations, for example, in polymer substances. Like the nature of the compositions, the methods of application, such as spraying, atomizing, dusting, scattering or pouring, are chosen in accordance with the intended objectives and the prevailing circumstances.

The formulations, compositions or preparations containing the insecticidal toxins and, where appropriate, a solid or liquid adjuvant, are prepared in known manner, for example by homogeneously mixing and/or grinding the insecticidal toxins with extenders, for example solvents, solid carriers and, where appropriate, surface-active compounds (surfactants).

Suitable solvents include aromatic hydrocarbons, preferably the fractions having 8 to 12 carbon atoms, for example, xylene mixtures or substituted naphthalenes, phthalates

بيجنو

u-33

YET

. 20

0.

للقريزاء

such as dibutyl phthalate or dioctyl phthalate, aliphatic hydrocarbons such as cyclohexane or paraffins, alcohols and glycols and their ethers and esters, such as ethanol, ethylene glycol monomethyl or monoethyl ether, ketones such as cyclohexanone, strongly polar solvents such as N-methyl-2-pyrrolidone, dimethyl sulfoxide or dimethyl formamide, as well as epoxidized vegetable oils such as epoxidized coconut oil or soybean oil or water.

The solid carriers used e.g. for dusts and dispersible powders, are normally natural mineral fillers such as calcite, talcum, kaolin, montmorillonite or attapulgite. In order to improve the physical properties it is also possible to add highly dispersed silicic acid or highly dispersed absorbent polymers. Suitable granulated adsorptive carriers are porous types, for example pumice, broken brick, sepiolite or bentonite; and suitable nonsorbent carriers are materials such as calcite or sand. In addition, a great number of pregranulated materials of inorganic or organic nature can be used, e.g. especially dolomite or pulverized plant residues.

Suitable surface-active compounds are nonionic, cationic and/or anionic surfactants having good emulsifying, dispersing and wetting properties. The term "surfactants" will also be understood as comprising mixtures of surfactants. Suitable anionic surfactants can be both water-soluble soaps and water-soluble synthetic surface-active compounds.

Suitable soaps are the alkali metal salts, alkaline earth metal salts or unsubstituted or substituted ammonium salts of higher fatty acids (chains of 10 to 22 carbon atoms), for example the sodium or potassium salts of oleic or stearic acid, or of natural fatty acid mixtures which can be obtained for example from coconut oil or tallow oil. The fatty acid methyltaurin salts may also be used.

More frequently, however, so-called synthetic surfactants are used, especially fatty sulfonates, fatty sulfates, sulfonated benzimidazole derivatives or alkylarylsulfonates.

The fatty sulfonates or sulfates are usually in the form of alkali metal salts, alkaline earth metal salts or unsubstituted or substituted ammonium salts and have a 8 to 22 carbon alkyl radical which also includes the alkyl moiety of alkyl radicals, for example, the sodium or calcium salt of lignonsulfonic acid, of dodecylsulfate or of a mixture of fatty alcohol sulfates obtained from natural fatty acids. These compounds also comprise the salts of sulfuric acid esters and sulfonic acids of fatty alcohol/ethylene oxide adducts. sulfonated benzimidazole derivatives preferably contain 2 sulfonic acid groups and one fatty acid radical containing 8 to 22 carbon atoms. Examples of alkylarylsulfonates are the sodium, calcium triethanolamine salts of dodecylbenzenesulfonic dibutylnapthalenesulfonic acid. or of a naphthalenesulfonic acid/formaldehyde

condensation product. Also suitable are corresponding phosphates, e.g. salts of the phosphoric acid ester of an adduct of p-nonylphenol with 4 to 14 moles of ethylene oxide.

Non-ionic surfactants are preferably polyglycol ether derivatives of aliphatic or cycloaliphatic alcohols, or saturated or unsaturated fatty acids and alkylphenols, said derivatives containing 3 to 30 glycol ether groups and 8 to 20 carbon atoms in the (aliphatic) hydrocarbon moiety and 6 to 18 carbon atoms in the alkyl moiety of the alkylphenols.

Further suitable non-ionic surfactants are the water-soluble adducts of polyethylene oxide with polypropylene glycol, ethylenediamine propylene glycol and alkylpolypropylene glycol containing 1 to 10 carbon atoms in the alkyl chain, which adducts contain 20 to 250 ethylene glycol ether groups and 10 to 100 propylene glycol ether groups. These compounds usually contain 1 to 5 ethylene glycol units per propylene glycol unit.

Representative examples of non-ionic surfactants are nonylphenolpolyethoxyethanols, castor oil polyglycol ethers, polypropylene/polyethylene oxide tributylphenoxypolyethoxyethanol, polyethylene glycol and octylphenoxyethoxyethanol. Fatty acid esters of polyoxyethylene sorbitan and polyoxyethylene sorbitan trioleate are also suitable non-ionic surfactants.

Cationic surfactants are preferably quaternary ammonium salts which have, as N-substituent, at least one C8-C22 alkyl radical and, as further substituents, lower unsubstituted or halogenated alkyl, benzyl or lower hydroxyalkyl radicals. The salts are preferably in the form of halides, methylsulfates or ethylsulfates, e.g. stearyltrimethylammonium chloride or benzyldi(2-chloroethyl)ethylammonium bromide.

The surfactants customarily employed in the art of formulation are described, for example, in "McCutcheon's Detergents and Emulsifiers Annual," MC Publishing Corp. Ringwood, New Jersey, 1979, and Sisely and Wood, "Encyclopedia of Surface Active Agents," Chemical Publishing Co., Inc. New York, 1980.

30

5



The invention will be further described by reference to the following detailed examples. These examples are provided for purposes of illustration only, and are not intended to be limiting unless otherwise specified. Standard recombinant DNA and molecular cloning techniques used here are well known in the art and are described by Ausubel (ed.), Current Protocols in Molecular Biology, John Wiley and Sons, Inc. (1994); T. Maniatis, E. F. Fritsch and J. Sambrook, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor laboratory, Cold Spring Harbor, NY (1989); and by T.J. Silhavy, M.L. Berman, and L.W. Enquist, Experiments with Gene Fusions, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1984).

A. Isolation Of Nucleotide Sequences Whose Expression Results In Toxins Active Against Lepidopteran Insects

Example 1: Construction of Cosmid Library from Photorhabdus luminescens

Photorhabdus luminescens strain ATCC 29999 is grown in nutrient broth at 25°C for three days as described in the ATCC protocol for bioassay. The culture is grown for 24 hours for DNA isolation. Total DNA is isolated by treating freshly grown cells resuspended in 100 mM Tris pH 8, 10 mM EDTA with 2 mg/ml lysozyme for 30 minutes at 37°C. Proteinase K is added to a final concentration of 100 mg/ml, SDS is added to a final concentration of 0.5% SDS and the sample is incubated at 45°C. After the solution becomes clear and viscous, the SDS concentration is raised to 1%, and 300 mM NaCl and an equal volume of phenol-chloroform-isoamyl alcohol are added, mixed gently for 5 minutes and centrifuged at 3K. The phenol-chloroform-isoamyl alcohol extraction is repeated twice. The aqueous phase is mixed with 0.7 volumes isopropanol, and the sample is centrifuged. The pellet is washed 3 times with 70% ethanol and the nucleic acids are gently resuspended in 0.5X TE.

The DNA is treated with 0.3 units of Sau3A per mg DNA at 37°C for 3.5 minutes in 100 ml volume containing a total of 6 mg DNA. The reaction is then heated for 30 minutes at 65°C to inactivate the enzyme. Then 2 units of Calf Intestinal Alkaline Phosphatase are added and incubated for 30 minutes at 37°C. The sample is mixed with an equal volume of

phenol-chloroform-isoamyl alcohol and centrifuged. The aqueous phase is removed, precipitated with 0.7 volume isopropanol and centrifuged. The supernatant is transferred to a fresh tube, precipitated with ethanol, and the nucleic acids are resuspended in 0.5X TE at a concentration of 100 hg/ml.


SuperCos cosmid vector (Stratagene, La Jolla, CA) is prepared as described by the supplier utilizing the *BamHI* cloning site. Prepared SuperCos at 100 hg/ml is ligated with the *Sau3A* digested *P.luminescens* DNA at a molar ratio of 2:1 in a 5 ml volume overnight at 6°C. The ligation mixture is packaged using Gigapack XL III (Stratagene), as described by the supplier. Packaged phages are used to infect XL-1MR (Stratagene) cells as described by the supplier. The cosmid library is plated on L-agar with 50 mg/ml kanamycin and incubated 16 hours at 37°C. 500 colonies are patched onto fresh L-kan plates at 50 colonies per plate. From the other plates the cells are washed off with L broth and mixed with 20% glycerol and frozen at -80°C.

Example 2: Insect Bioassays

Plutella xylostella bioassays are performed by aliquoting of 50 μl of the *E. coli* culture on the solid artificial *Plutella xylostella* diet (Biever and Boldt, *Annals of Entomological Society of America*, 1971; Shelton et al., *J. Ent. Sci.* 26:17). 4 ml of the diet is poured into 1 oz. clear plastic cups (Bioserve product #9051). 5 neonate *P. xylostella* from a diet adapted lab colony are placed in each diet-containing cup and then covered with a white paper lid (Bioserve product #9049). 10 larvae are assayed per concentration. Trays of cups are placed in an incubator for 3 days at 72°F with a 14:10 (hours) light:dark cycle. Then, the number of live larvae in each cup is recorded. Bioassays for other insects are performed as described for *Plutella xylostella*, but using the diet required by the insect to be tested.

The broth of *P. luminescens* undiluted and diluted 1:100 gives 100% mortality against *P. xylostella*. The broth of *P. luminescens* also gives 100% mortality against *Diabrotica virgifera virgifera*. Three clones with activity against *P. xylostella* and *Heliothis virescens* are obtained after screening 500 *E. coli* clones by insect bioassay. These cosmid clones are given the numbers pClB9349, pClB9350, and pClB9351.

. 2



The three clones pClB9349, pClB9350 and pClB9351 are found to be overlapping cosmids by restriction enzyme mapping. After digestion with Pacl, clones pCIB9349 and pCIB9351 give two DNA fragments each, and pCIB9350 gives three DNA fragments. Each fragment is isolated and is self-ligated. The enzyme Pac does not cut the SuperCos vector; therefore, only fragments linked to it are re-isolated. The ligation mixtures are transformed into DH5α E. coli cells. Isolated transformed bacterial colonies are grown in L broth with 50 μg/ml kanamycin, and plasmid DNA is isolated by using the alkaline miniprep protocol as described in Sambrook, et al. DNA is digested with Notl/Pacl and two clones, pCIB9355 and pClB9356, are found by bioassay to still contain the insecticidal activity. Clone pCIB9355 is digested with Notl and a 17 kb and a 4 kb DNA fragment are generated. The 17 kb fragment is isolated and ligated into Bluescript vector previously cut with Notl and transformed into DH5 α E. coli cells. The isolated transformed bacterial colonies are grown as described and plasmid DNA is isolated by the alkaline miniprep protocol. A clone containing the 17 kb insert is named pCIB9359 and tested by bioassay. The results are shown in Example 5. 3 µg of the 17 kb insert is isolated and treated with 0.3 unit of Sau3A per µg DNA for 4, 6, and 8 minutes at 37°C, heated at 75°C for 15 minutes. The samples are pooled and ligated into pUC19 previously cut with BamHI and treated with calf intestinal alkaline phosphatase. The ligation is transformed into DH5α cells and plated on L agar with Xgal/Amp as described in Sambrook et al. and grown overnight at 37°C. White colonies are picked and grown in L broth with 100 μg/ml and plasmid DNA is isolated as previously described. DNA is digested with EcoRI/HindIII and novel restriction patterns are sequenced. Sequencing primers are ordered from Genosys Biotechnologies (Woodlands, TX). Sequencing is performed using the dideoxy chain-termination method. Sequencing is completed using Applied Biosystems Inc. model 377 automated DNA sequencer (Foster City, CA). Sequence is assembled using 3.0 from Gene Codes Corporation (Ann Arbor, MI).



pClB9359 is digested with *EcoRI* and *XbaI* and the DNA is run on a 0.8% Seaplaque/TBE gel. The 9.7 kb fragment (SEQ ID NO:1) is isolated and ligated into pUC19 previously digested with *EcoRI* and *XbaI*. The ligation mixture is transformed into DH5 α *E. coli* cells. Transformed bacteria are grown and plasmid DNA is isolated as previously described. The vector containing the 9.7 kb fragment in pUC19 is designated pClB9359-7 and bioassay results are shown in Example 5.

Example 5: Bioassay Results for Cosmid Clones pClB9359 and pClB9359-7

Cultures of *E. coli* strains 9359 and 9359-7 containing clones pClB9359 and pClB9359-7, respectively, are tested for insecticidal activity against the following insects in insect bioassays:

Insects	Clones
	pCIB9359 and pCIB9359-7
Plutella xylostella (Diamondback Moth (DBM))	+++
Heliothis virescens (Tobacco Budworm (TBW))	++
Helicoverpa zea (Corn Earworm (CEW))	+++
Spodoptera exigua (Beet Armyworm (BAW))	+ .
Spodoptera frugiperda (Fall Armyworm (FAW))	+
Trichoplusia ni (Cabbage Looper (CL))	+++
Ostrinia nubilalis (European Corn Borer (ECB))	++
Manduca sexta (Tobacco Hornworm (THW)	na
Diabrotica virgifera (Western Corn Rootworm (WCR))	na
Agrotis ipsilon (Black Cutworm (BCW))	na

na = not active

- + = significant growth inhibition
- ++ = >40% mortality, but less than 100%
- +++ = 100% mortality

The clones show insecticidal activity against *P. xylostella*, *H. virescens*, *H. zea*, *T. ni*, and *O. nubilalis*, and significant insect control activity against *S. exigua* and *S. frugiperda*.

Example 6: Identification of Active Region of pClB9359-7 By Subcloning

Cultures of *E. coli* strains containing subclones of pCIB9359-7 are tested for insecticidal activity in insect bioassays against *P. xylostella*.

Restriction	Nucleotide Position Relative to 9.7 kb		Insecticidal Activity Against	
Fragment	EcoRI/Xbal fragment (SEQ ID NO:1)		Plutella xylostella	1
	from pCIB9539-7 and Size in kb			
EcoRI/Xbal	1 to 9712	9.7 kb	+++	
EcoRV	(-912) to 2309	3.2 kb	na	#- [*]
HindIII	665 to 5438	4.7 kb	na	• • • • • • • • • • • • • • • • • • •
Kpnl	1441 to 8137	6.9 kb	na	
Sacl/Xbal	2677 to 9712	7.0 kb	na	5 7FF

na = not active

Example 7: Characterization of pCIB9359-7 Insect Control Activity By Titration

Dilutions of a culture of *E.coli* strain 9359-7 containing pCIB9359-7 are tested for insecticidal activity in insect bioassays. Dilutions are prepared in a culture of *E.coli* XL-1 in a total volume of 100 μ l and are transferred to diet cups with 5 insects per cup. The results show the percentage (%) of insect mortality.

^{+ =} significant growth inhibition

^{++ = &}gt;40% mortality, but less than 100%

^{+++=100%} mortality

μ l 9359-7 Culture	Px	Hv	Hz	Tn	
100	100	72	48	100	
50	100	84	68	92	
25	100	52	32	100	
12.5	96	52	36	68	
6.25	88	20	4	32	
0	36	20	24	0	

Px = P. xylostella, Hv = H. virescens, Hz = H. zea, Tn = T. ni.

Cultures of E. coli 9359-7 still show substantial insecticidal activity after dilution.

Example 8: Stability of pCIB9359-7 Activity

The stability of the toxins is tested after storage for 2 weeks at different temperatures and conditions. 300 ml of Luria broth containing 100 (µg/ml ampicillin is inoculated with *E. coli* strain 9359-7 and grown overnight at 37°C. Samples are placed in sterile 15 ml screw cap tubes and stored at 22°C and 4°C. Another sample is centrifuged; the supernatant is removed, freeze dried and stored at 22°C. The samples are stored under these conditions for 2 weeks and then a bioassay is conducted against *P. xylostella*. The freeze dried material is resuspended in the same volume as before. All samples are resuspended by vortexing.

Conditions	Results
22°C (2 weeks)	+++
4°C (2 weeks)	+++
Freeze Dried (2 weeks)	+++

na = not active; + = significant growth inhibition; ++ = >40% mortality, but less than 100%; +++ = 100% mortality

This demonstrates that the toxins retain their activity for at least two weeks at 22°C, 4°C, and freeze-dried, and are therefore very stable.

Example 9: Size Fraction of pClB9359-7 Activity

The approximate sizes of the insecticidal toxins are determined. P. luminescens cosmid clones pCIB9359-7 and pUC19 in E. coli host DH5α are grown in media consisting of 50% Terrific broth and 50% Luria broth, supplemented with 50 μg/ml ampicillin. Cultures (three tubes of each strain) are inoculated into 3 ml of the above media in culture tubes and incubated on a roller wheel overnight at 37°C. Cultures of each strain are combined and sonicated using a Branson Model 450 Sonicator, micro tip, for approximately six 10 second cycles with cooling on ice between cycles. The sonicates are centrifuged in a Sorvall SS34 rotor at 6000 RPM for 10 minutes. The resultant supernatants are filtered through a 0.2 µ filter. The 3 ml fractions of the filtrates are applied to Bio-Rad Econo-Pac 10DG columns that have been previously equilibrated with 10 ml of 50mM NaCl, 25 mM Tris base, pH 7.0. The flow through collected during sample loading is discarded. The samples are fractionated with two subsequent additions of 4 ml each of the NaCl - Tris equilibration buffer. The two four ml fractions are saved for testing. The first fraction contains all material above about 6,000 mol. wt; the second fraction contains material smaller than 6,000 mol. wt. A sample of the whole culture broth, the sonicate, and the filtered supernatant on the sonicate are tested along with the three fractions from the 10DG column for activity on *P. xylostella* neonates in bioassays.

The culture, the sonicate, and the filtered supernatant of the sonicate, and the first column fraction from the 9359-7 sample are highly active on *P. xylostella*. The second column fraction from 9359-7 is slightly active (some stunting only). No activity is found in the third fraction from 9359-7. The sample from DH5-pUC19 does not have any activity. This indicates that the molecular weights of the toxins are above 6,000.

Example 10: Heat Inactivitation of pCIB9359-7 Activity

The heat stability of the toxins is determined. Overnight cultures of the *E. coli* strain pClB9359-7 are grown in a 50:50 mixture of Luria broth and Terrific broth. Cultures are grown at 37°C in culture tubes on a tube roller. A one ml sample of the culture is placed in

a 1.5 ml eppendorf tube and placed in a boiling water bath. The sample is removed after five minutes and allowed to cool to room temperature. This sample along with an untreated portion of the culture is assayed on *P. xylostella*. 50µl of sample of sample is spread on diet, allowed to dry and neonate larvae *P. xylostella* applied to the surface. The assay is incubated for 5 days at room temperature.

The untreated sample causes 100% mortality. The heat treated sample and a diet alone control do not cause any observable mortality, showing the toxins are heat sensitive.

Example 11: Leaf Dip Bioassay of pCIB9359-7

Insecticidal activity of the toxins is tested in a leaf dip bioassay. Six leaves approximately 2cm in diameter each are cut from seedlings of turnip and placed in a 1oz. plastic cup (Jet Plastica) with 4ml-5ml of the resuspended toxin, covered tightly, and shaken until thoroughly wetted. The treated leaves are placed in 50mm petri dishes (Gelman Sciences) on absorbent pads moistened with 300µl of water. The dish covers are left open until the leaf surface appears dry and then placed on tightly so that the leaves do not dry out.

Ten neonate *P. xylostella* larvae are placed in each petri dish arena. Also, a treatment of 0.1% Bond spreader/sticker with no toxin is set up as a control. The arenas are monitored daily for signs of drying leaves, and water is added or leaves replaced if necessary. After 3 days the leaves and arenas are examined under a dissecting microscope, and the number of live larvae in each arena is recorded.

100% mortality is found for 9359-7 and none in the no-toxin control, showing that the toxins are also insecticidal in a leaf dip assay.

B. Isolation Of Nucleic Acid Sequences Whose Expression Results In Toxins Active Against Lepidopteran and Coleopteran Insects

Example 12: Total DNA Isolation from Photorhabdus luminescens

Photorhabdus luminescens strain ATCC 29999 is grown 14-18 hours in L broth. Total DNA is isolated from 1.5 mls of culture resuspended in 0.5% SDS, 100μg/ml proteinase K, TE to a final volume of 600 μl. After a 1 hour incubation at 37°C, 100μl 5M

NaCl and 80μl CTAB/NaCl are added and the culture is incubated at 65°C for 10 minutes. An equal volume of chloroform is added; the culture is mixed gently and spun. The aqueous phase is extracted once with phenol and once with chloroform. The nucleic acids are treated with 10 μg RNase A for 30 minutes at room temperature. The aqueous phase is mixed with 0.6 volumes isopropanol and the sample is centrifuged. The pellet is washed once with 70% ethanol and the nucleic acids are gently resuspended in 100-200ul TE.

Example 13: PCR Amplification of Probes

Two probes are PCR amplified from *Photorhabdus luminescens* strain ATCC 29999 genomic DNA using oligos 5'-ACACAGCAGGTTCGTCAG-3' (SEQ ID NO:7) and 5'-GGCAGAAGCACTCAACTC-3' (SEQ ID NO:8) to amplify probe #1 and oligos 5'-ATTGATAGCACGCGGCGACC-3' (SEQ ID NO:9) and 5'-

TTGTAACGTGGAGCCGAACTGG-3' (SEQ ID NO:10) to amplify probe #2. The oligos are ordered from Genosys Biotechnologies, Inc. (Texas). Approximately 10-50 ng of genomic DNA is used as the template. 0.8µM of oligos, 200µM of dNTPs, 1X Taq DNA Polymerase buffer and 2.5 units of Taq DNA Polymerase are included in the reaction. The reaction conditions are as follows:

94°C - 1 minute

94°C - 30 seconds / 60°C - 30 seconds / 72°C - 30 seconds (25 cycles)


72°C - 5 minutes

4°C - indefinite soak

The reactions are preferably carried out in a PCR System 9600 (Perkin Elmer) thermocycler.

Example 14: Probing a Photorhabdus luminescens Library

600 clones from the *P. luminescens* cosmid library described in Example 1 are patched to L-amp plates in duplicate. The colonies are grown overnight then moved to 4°C. The colonies are lifted onto Colony/Plaque Screen Hybridization Transfer Membranes (Biotechnology Systems NEN Research Products). The membranes are incubated 2-3 minutes in 0.75ml 0.5N NaOH twice. The membranes are then incubated 2-3 minutes in



Probe #1 and probe #2 described in Example 13 are labeled using the DECAprime II Kit as described by the manufacturer (Ambion cat# 1455). Unincorporated nucleotides are removed from the labeled probes using Quick Spin Columns as described by the manufacturer (Boehringer Mannheim cat #1273973). The labeled probes are measured for incorporated radioactivity and the specific activity is 10,000,000 cpm. Membranes are prewetted with 2X SSC and hybridized with the probes for 12-16 hours at 65°C. One set of colony lifts is hybridized with probe #1 and the other set is hybridized with probe #2. The membranes are washed with wash CHURCH solutions 1 and 2 (Church and Gilbert, *Proc. Natl. Acad. Sci. USA* 81:1991-1995 (1984)) and exposed to Kodak film.

Twenty one clones are identified that hybridize to probe #1 and seven clones are identified that hybridize to probe #2. The gene in the clones isolated with probe #1 is named hph1 and the gene in the clones isolated with probe #2 is named hph2.

Example 15: Insect Bioassays

The clones identified in Example 14 are tested for insecticidal activity against the following insects in insect bioassays: *Diabrotica virgifera virgifera* (Western Corn Rootworm (WCR)), *Diabrotica undecimpunctata howardi* (Southern Corn Rootworm (SCR)), *Ostrinia nubilalis* (European Corn Borer (ECB)), and *Plutella xylostella* (Diamondback Moth (DBM)).

Diabrotica virgifera virgifera (Western Corn Rootworm) and Diabrotica undecimpunctata howardi (Southern Corn Rootworm) assays are performed using a diet incorporation method. 500μl of an overnight culture of the cosmid library in XL-1 Blue MR cells (Stratagene) is sonicated and then mixed with 500μl of diet. Once the diet solidifies, it is dispensed in a petri dish and 20 larvae are introduced over the diet. Trays of dishes are placed in an incubator for 3-5 days, and percent mortality is recorded at the end of the assay period.

Ostrinia nubilalis (European Corn Borer) and Plutella xylostella (Diamondback Moth) assays are performed by a surface treatment method. The diet is poured in the petri dish and allowed it to solidify. The E. coli culture of 200 -300µl volume is dispensed over the diet surface and entire diet surface is covered to spread the culture with the help of bacterial loop. Once the surface is dry, 10 larvae are introduced over the diet surface. Trays of

理

dishes are placed in an incubator for 3-5 days. The assay with European Corn Borer is incubated at 30°C in complete darkness; the assay with Diamondback Moth is incubated at 72°F with a 14:10 (hours) light:dark cycle. Percent mortality is recorded at the end of the assay period.

Cosmids containing *hph2* are identified with a range of activities, including: WCR only; SCR only; WCR and SCR; SCR and ECB; WCR, SCR, and ECB; or WCR, SCR, ECB, and DBM activity.

In addition to probing the *P. luminescens* cosmid library with DNA probes, 600 clones are screened by Western Corn Rootworm bioassay. A clone is identified with activity against Western Corn Rootworm. This clone hybridizes with probe #2.

From these bioassays, cosmid 514, having activity against WCR, SCR, ECB, and DBM, is selected for sequencing.

Example 16: Sequencing of Cosmid 514

Cosmid 514 is sequenced using dye terminator chemistry on an ABI 377 instrument. The nucleotide sequence of cosmid 514 is set forth as SEQ ID NO:11. Cosmid 514 is designated pNOV2400 and deposited with the NRRL in *E. coli* DH5α and assigned accession no. B-30077.

Example 17: Subcloning Insecticidal Regions of Cosmid 514

514a

An 9011 base pair fragment within cosmid 514 (SEQ ID NO:11) is removed by digesting the cosmid with the restriction endonuclease *Spel* (New England Biolabs (Massachusetts), and ligating (T4 DNA Ligase, NEB) the remainder of 514. Subclone 514a consists of cosmid 514 DNA from base pairs 1-2157 ligated to base pairs 11,169-37,948.

H2O2/pET34

hph2 and orf2 (SEQ ID NO:11, base pairs 23,768-35,838) are cloned into pET34b (Novagen, Wisconsin). Restriction sites are engineered on both ends of each gene to facilitate cloning. PCR is used to add the restriction sites to the genes. A BamHI site is on the 5' end of hph2 immediately upstream of the ATG of hph2, and a Sac site is added to

the 3' end of *hph2* immediately following the DNA triplet encoding the stop codon. A guanidine is added between the *Bam*HI site and the start codon of *hph2* to put the *hph2* gene in frame with the Cellulose Binding Domain tag in pET34b. *Orf2* has a *Sac*I site upstream of the 56 base pairs between the stop codon of *hph2* and the start codon of *orf2*. The 56 base pairs are included in the *hph2-orf2* construct to mimic their setup in the 514 cosmid. *Orf2* has an *Xho*I site on the 3' end immediately following the stop codon. The oligos used to add the restriction sites to *hph2* and *orf2* are as follows:

hph2-A	5'-CGGGATCCGATGATTTTAAAAGG-3' (SEQ ID NO:15)
hph2-B	5'-GCGCCATTGATTTGAG-3' (SEQ ID NO:16)
hph2-C	5'-CATTAGAGGTCGAACGTAC-3' (SEQ ID NO:17)
hph2-D	5'-GAGCGAGCTCTTACTTAATGGTGTAG-3' (SEQ ID NO:18)
orf2-A3	5'-CAGCGAGCTCCATGCAGAATTCACAGAC-3' (SEQ ID NO:19)
orf2-B	5'-GGCAATGGCAGCGATAAG-3' (SEQ ID NO:20)
orf2-C	5'-CATTAACGCAGGAAGAGC-3' (SEQ ID NO:21)
orf2-D	5'-GACCTCGAGTTACACGAGCGCGTCAG-3' (SEQ ID NO:22)

The BamHI-Sac 7583 base pair fragment, corresponding to the hph2 gene, and the Sacl-Xhol 4502 base pair orf2 (including the 56 base pairs between hph2 and orf2 open reading frames), corresponding to orf2, are ligated with BamHI-Xhol-digested vector DNA pET34b.

Orf5/pBS (Noti-BamHI)

The 5325 base pair Notl-BamHI fragment of cosmid 514 is cloned into pBS-SK using AffIII-Notl (415 bp) and BamHI-AffIII (2530 bp) fragments of pBS-SK.

05-H2-O2

The 12,031 base pair *BamHI-Xho*I fragment of H2O2/pET34 is cloned into the 8220 base pair *XhoI-BamHI* fragment of Orf5/pBS.


O51011H2O2

A 7298 base pair *Bam*HI-*Mlu*I fragment from subclone 514a is ligated (T4 DNA Ligase, NEB) with 9588 bp *Mlu*I-*Xho*I and 8220 bp *Xho*I-*Bam*HI fragments of subclone O5-H2-O2. The resulting ~ 22 kb subclone O51011H2O2, which has activity against WCR and

營.

. . . ·

被禮



AKH2O2

A 12,074 base pair *BamHI-AvrII* fragment of H2O2/pET34 is ligated (T4 DNA Ligase, NEB) into pK184 *Nhel-BamHI* fragment (2228 bp), generating a clone containing hph2 and orf2 in a p15a origin of replication, kanamycin-resistant vector.

Example 18: Insecticidal Activity of Subclones

Bioassays as described above are performed with *E. coli* cultures that express the above subclones, both singly and in combination. Coexpressing AKH2O2 and Orf5/pBS in *E. coli*, for example in DH5α or HB101, is found to give insecticidal activity against the Lepidopterans *Plutella xylostella* (Diamondback Moth), *Ostrinia nubilalis* (European Corn Borer), and *Manduca sexta* (Tobacco Hornworm), as well as against the Coleopterans *Diabrotica virgifera virgifera* (Western Corn Rootworm), *Diabrotica undecimpunctata howardi* (Southern Corn Rootworm), and *Leptinotarsa decimlineata* (Colorado Potato Beetle). Thus, coexpression of hph2 (SEQ ID NO:11, base pairs 23,768-31,336), orf2 (SEQ ID NO:11, base pairs 31,393-35,838), and orf5 (SEQ ID NO:11, base pairs 15,171-18,035) is sufficient to control these insects. In addition, expression of each of these three ORFs on separate plasmids gives insect control activity, demonstrating that they do not have to be genetically linked to be active, so long as all three gene products are present.

C. Expression of the Nucleic Acid Sequences of the Invention in Heterologous Microbial Hosts

Microorganisms which are suitable for the heterologous expression of the nucleotide sequences of the invention are all microorganisms which are capable of colonizing plants or the rhizosphere. As such they will be brought into contact with insect pests. These include gram-negative microorganisms such as *Pseudomonas, Enterobacter* and *Serratia*, the gram-positive microorganism *Bacillus* and the fungi *Trichoderma*, *Gliocladium*, and *Saccharomyces cerevisiae*. Particularly preferred heterologous hosts are *Pseudomonas fluorescens*, *Pseudomonas putida*, *Pseudomonas cepacia*, *Pseudomonas aureofaciens*,

Pseudomonas aurantiaca, Enterobacter cloacae, Serratia marscesens, Bacillus subtilis, Bacillus cereus, Trichoderma viride, Trichoderma harzianum, Gliocladium virens, and Saccharomyces cerevisiae.

Example 19: Expression of the Nucleotide Sequences in *E. coli* and Other Gram-Negative Bacteria

Many genes have been expressed in gram-negative bacteria in a heterologous manner. Expression vector pKK223-3 (Pharmacia catalogue # 27-4935-01) allows expression in *E. coli*. This vector has a strong *tac* promoter (Brosius, J. *et al.*, *Proc. Natl. Acad. Sci. USA 81*) regulated by the *lac* repressor and induced by IPTG. A number of other expression systems have been developed for use in *E. coli*. The thermoinducible expression vector pPL (Pharmacia #27-4946-01) uses a tightly regulated bacteriophage λ promoter which allows for high level expression of proteins. The *lac* promoter provides another means of expression but the promoter is not expressed at such high levels as the *tac* promoter. With the addition of broad host range replicons to some of these expression system vectors, expression of the nucleotide sequence in closely related gram negative-bacteria such as *Pseudomonas*, *Enterobacter*, *Serratia* and *Erwinia* is possible. For example, pLRKD211 (Kaiser & Kroos, Proc. Natl. Acad. Sci. USA 81: 5816-5820 (1984)) contains the broad host range replicon *ori T* which allows replication in many gram-negative bacteria.

In *E. coli*, induction by IPTG is required for expression of the *tac* (*i.e. trp-lac*) promoter. When this same promoter (*e.g.* on wide-host range plasmid pLRKD211) is introduced into *Pseudomonas* it is constitutively active without induction by IPTG. This *trp-lac* promoter can be placed in front of any gene or operon of interest for expression in *Pseudomonas* or any other closely related bacterium for the purposes of the constitutive expression of such a gene. Thus, a nucleotide sequence whose expression results in an insecticidal toxin can therefore be placed behind a strong constitutive promoter, transferred to a bacterium which has plant or rhizosphere colonizing properties turning this organism to an insecticidal agent. Other possible promoters can be used for the constitutive expression of the nucleotide sequence in gram-negative bacteria. These include, for example, the promoter from the *Pseudomonas* regulatory genes *gafA* and *lemA* (WO 94/01561) and the

Ø.

雷雪

200

Pseudomonas savastanoi IAA operon promoter (Gaffney et al., J. Bacteriol. 172: 5593-5601 (1990).

Example 20: Expression of the Nucleotide Sequences in Gram-Positive Bacteria

Heterologous expression of the nucleotides sequence in gram-positive bacteria is another means of producing the insecticidal toxins. Expression systems for *Bacillus* and *Streptomyces* are the best characterized. The promoter for the erythromycin resistance gene (*ermR*) from *Streptococcus pneumoniae* has been shown to be active in gram-positive aerobes and anaerobes and also in *E.coli* (Trieu-Cuot *et al.*, Nucl Acids Res 18: 3660 (1990)). A further antibiotic resistance promoter from the thiostreptone gene has been used in *Streptomyces* cloning vectors (Bibb, Mol Gen Genet 199: 26-36 (1985)). The shuttle vector pHT3101 is also appropriate for expression in *Bacillus* (Lereclus, FEMS Microbiol Lett 60: 211-218 (1989)). A significant advantage of this approach is that many grampositive bacteria produce spores which can be used in formulations that produce insecticidal agents with a longer shelf life. *Bacillus* and *Streptomyces* species are aggressive colonizers of soils

Example 21: Expression of the Nucleotide Sequences in Fungi

Trichoderma harzianum and Gliocladium virens have been shown to provide varying levels of biocontrol in the field (US 5,165,928 and US 4,996,157, both to Cornell Research Foundation). A nucleotide sequence whose expression results in an insecticidal toxin could be expressed in such a fungus. This could be accomplished by a number of ways which are well known in the art. One is protoplast-mediated transformation of the fungus by PEG or electroporation-mediated techniques. Alternatively, particle bombardment can be used to transform protoplasts or other fungal cells with the ability to develop into regenerated mature structures. The vector pAN7-1, originally developed for Aspergillus transformation and now used widely for fungal transformation (Curragh et al., Mycol. Res. 97(3): 313-317 (1992); Tooley et al., Curr. Genet. 21: 55-60 (1992); Punt et al., Gene 56: 117-124 (1987)) is engineered to contain the nucleotide sequence. This plasmid contains the E. coli the hygromycin B resistance gene flanked by the Aspergillus nidulans gpd promoter and the trpC terminator (Punt et al., Gene 56: 117-124 (1987)).

In a preferred embodiment, the nucleic acid sequences of the invention are expressed in the yeast *Saccharomyces cerevisiae*. Each of the three ORF's of SEQ ID NO:11 (hph2, orf2 and orf5), which together confer insecticidal activity, are cloned into individual vectors with the GAL1 inducible promoter and the CYC1 terminator. Each vector has ampicillin resistance and the 2 micron replicon. The vectors differ in their yeast growth markers. hph2 is cloned into p424 (TRP1, ATCC 87329), orf2 into p423 (HIS3, ATCC 87327), and orf5 into p425 (LEU2, ATCC 87331). The three constructs are transformed into *S. cerevisiae* independently and together. The three ORFs are expressed together and tested for protein expression and insecticidal activity.

D. Expression of the Nucleotide Sequences in Transgenic Plants

The nucleic acid sequences described in this application can be incorporated into plant cells using conventional recombinant DNA technology. Generally, this involves inserting a coding sequence of the invention into an expression system to which the coding sequence is heterologous (i.e., not normally present) using standard cloning procedures known in the art. The vector contains the necessary elements for the transcription and translation of the inserted protein-coding sequences. A large number of vector systems known in the art can be used, such as plasmids, bacteriophage viruses and other modified viruses. Suitable vectors include, but are not limited to, viral vectors such as lambda vector systems λgtl1, λgtl0 and Charon 4; plasmid vectors such as pBl121, pBR322, pACYC177, pACYC184, pAR series, pKK223-3, pUC8, pUC9, pUC18, pUC19, pLG339, pRK290, pKC37, pKC101, pCDNAII; and other similar systems. The components of the expression system may also be modified to increase expression. For example, truncated sequences, nucleotide substitutions or other modifications may be employed. The expression systems described herein can be used to transform virtually any crop plant cell under suitable Transformed cells can be regenerated into whole plants such that the conditions. nucleotide sequence of the invention confer insect resistance to the transgenic plants.

Example 22: Modification of Coding Sequences and Adjacent Sequences

The nucleotide sequences described in this application can be modified for expression in transgenic plant hosts. A host plant expressing the nucleotide sequences and

1

.

编

ij.

which produces the insecticidal toxins in its cells has enhanced resistance to insect attack and is thus better equipped to withstand crop losses associated with such attack.

The transgenic expression in plants of genes derived from microbial sources may require the modification of those genes to achieve and optimize their expression in plants. In particular, bacterial ORFs which encode separate enzymes but which are encoded by the same transcript in the native microbe are best expressed in plants on separate transcripts. To achieve this, each microbial ORF is isolated individually and cloned within a cassette which provides a plant promoter sequence at the 5' end of the ORF and a plant transcriptional terminator at the 3' end of the ORF. The isolated ORF sequence preferably includes the initiating ATG codon and the terminating STOP codon but may include additional sequence beyond the initiating ATG and the STOP codon. In addition, the ORF may be truncated, but still retain the required activity; for particularly long ORFs, truncated versions which retain activity may be preferable for expression in transgenic organisms. By "plant promoter" and "plant transcriptional terminator" it is intended to mean promoters and transcriptional terminators which operate within plant cells. This includes promoters and transcription terminators which may be derived from non-plant sources such as viruses (an example is the Cauliflower Mosaic Virus).

In some cases, modification to the ORF coding sequences and adjacent sequence is not required. It is sufficient to isolate a fragment containing the ORF of interest, and to insert it downstream of a plant promoter. For example, Gaffney et al. (Science 261: 754-756 (1993)) have expressed the *Pseudomonas nahG* gene in transgenic plants under the control of the CaMV 35S promoter and the CaMV tml terminator successfully without modification of the coding sequence and with x bp of the *Pseudomonas* gene upstream of the ATG still attached, and y bp downstream of the STOP codon still attached to the *nahG* ORF. Preferably as little adjacent microbial sequence should be left attached upstream of the ATG and downstream of the STOP codon. In practice, such construction may depend on the availability of restriction sites.

In other cases, the expression of genes derived from microbial sources may provide problems in expression. These problems have been well characterized in the art and are particularly common with genes derived from certain sources such as *Bacillus*. These problems may apply to the nucleotide sequence of this invention and the modification of these genes can be undertaken using techniques now well known in the art. The following problems may be encountered:

1. Codon Usage.

The preferred codon usage in plants differs from the preferred codon usage in certain microorganisms. Comparison of the usage of codons within a cloned microbial ORF to usage in plant genes (and in particular genes from the target plant) will enable an identification of the codons within the ORF which should preferably be changed. Typically plant evolution has tended towards a strong preference of the nucleotides C and G in the third base position of monocotyledons, whereas dicotyledons often use the nucleotides A or T at this position. By modifying a gene to incorporate preferred codon usage for a particular target transgenic species, many of the problems described below for GC/AT content and illegitimate splicing will be overcome.

2. GC/AT Content.


Plant genes typically have a GC content of more than 35%. ORF sequences which are rich in A and T nucleotides can cause several problems in plants. Firstly, motifs of ATTTA are believed to cause destabilization of messages and are found at the 3' end of many short-lived mRNAs. Secondly, the occurrence of polyadenylation signals such as AATAAA at inappropriate positions within the message is believed to cause premature truncation of transcription. In addition, monocotyledons may recognize AT-rich sequences as splice sites (see below).

3. Sequences Adjacent to the Initiating Methionine.

Plants differ from microorganisms in that their messages do not possess a defined ribosome binding site. Rather, it is believed that ribosomes attach to the 5' end of the message and scan for the first available ATG at which to start translation. Nevertheless, it is believed that there is a preference for certain nucleotides adjacent to the ATG and that expression of microbial genes can be enhanced by the inclusion of a eukaryotic consensus translation initiator at the ATG. Clontech (1993/1994 catalog, page 210, incorporated herein by reference) have suggested one sequence as a consensus translation initiator for the expression of the *E. coli uidA* gene in plants. Further, Joshi (NAR 15: 6643-6653 (1987), incorporated herein by reference) has compared many plant sequences adjacent to the ATG and suggests another consensus sequence. In situations where difficulties are encountered in the expression of microbial ORFs in plants, inclusion of one of these sequences at the initiating ATG may improve translation. In such cases the last three

E E

蒌



Position Before the Initiating ATG in 14 Maize Genes:

	<u>-10</u>	<u>-9</u>	<u>-8</u>	<u>-7</u>	<u>-6</u>	<u>-5</u>	<u>-4</u>	<u>-3</u>	<u>-2</u>	<u>-1</u>
С	3	8	4	6	2	5	6	0	10	7
T	3	0	3	4	3	2	1	1	1	0
A	2	3	1	4	3	2	3	7	2	3
G	6	3	6	0	6	5	4	6	1	5

This analysis can be done for the desired plant species into which the nucleotide sequence is being incorporated, and the sequence adjacent to the ATG modified to incorporate the preferred nucleotides.

4. Removal of Illegitimate Splice Sites.

Genes cloned from non-plant sources and not optimized for expression in plants may also contain motifs which may be recognized in plants as 5' or 3' splice sites, and be cleaved, thus generating truncated or deleted messages. These sites can be removed using the techniques well known in the art.

Techniques for the modification of coding sequences and adjacent sequences are well known in the art. In cases where the initial expression of a microbial ORF is low and it is deemed appropriate to make alterations to the sequence as described above, then the construction of synthetic genes can be accomplished according to methods well known in the art. These are, for example, described in the published patent disclosures EP 0 385 962 (to Monsanto), EP 0 359 472 (to Lubrizol) and WO 93/07278 (to Ciba-Geigy), all of which are incorporated herein by reference. In most cases it is preferable to assay the expression of gene constructions using transient assay protocols (which are well known in the art) prior to their transfer to transgenic plants.





Coding sequences intended for expression in transgenic plants are first assembled in expression cassettes behind a suitable promoter expressible in plants. The expression cassettes may also comprise any further sequences required or selected for the expression of the transgene. Such sequences include, but are not restricted to, transcription terminators, extraneous sequences to enhance expression such as introns, vital sequences, and sequences intended for the targeting of the gene product to specific organelles and cell compartments. These expression cassettes can then be easily transferred to the plant transformation vectors described below. The following is a description of various components of typical expression cassettes.

1. Promoters

The selection of the promoter used in expression cassettes will determine the spatial and temporal expression pattern of the transgene in the transgenic plant. Selected promoters will express transgenes in specific cell types (such as leaf epidermal cells, mesophyll cells, root cortex cells) or in specific tissues or organs (roots, leaves or flowers, for example) and the selection will reflect the desired location of accumulation of the gene product. Alternatively, the selected promoter may drive expression of the gene under various inducing conditions. Promoters vary in their strength, i.e., ability to promote transcription. Depending upon the host cell system utilized, any one of a number of suitable promoters can be used, including the gene's native promoter. The following are non-limiting examples of promoters that may be used in expression cassettes.

a. Constitutive Expression, the Ubiquitin Promoter:

Ubiquitin is a gene product known to accumulate in many cell types and its promoter has been cloned from several species for use in transgenic plants (e.g. sunflower - Binet et al. Plant Science 79: 87-94 (1991); maize - Christensen et al. Plant Molec. Biol. 12: 619-632 (1989); and Arabidopsis - Norris et al., Plant Mol. Biol. 21:895-906 (1993)). The maize ubiquitin promoter has been developed in transgenic monocot systems and its sequence and vectors constructed for monocot transformation are disclosed in the patent publication EP 0 342 926 (to Lubrizol) which is herein incorporated by reference. Taylor et al. (Plant Cell Rep. 12: 491-495 (1993)) describe a vector (pAHC25) that comprises the maize ubiquitin promoter and first intron and its high activity in cell suspensions of numerous

75

10

3

- 23

-77



monocotyledons when introduced via microprojectile bombardment. The *Arabidopsis* ubiquitin promoter is ideal for use with the nucleotide sequences of the present invention. The ubiquitin promoter is suitable for gene expression in transgenic plants, both monocotyledons and dicotyledons. Suitable vectors are derivatives of pAHC25 or any of the transformation vectors described in this application, modified by the introduction of the appropriate ubiquitin promoter and/or intron sequences.

b. Constitutive Expression, the CaMV 35S Promoter:

Construction of the plasmid pCGN1761 is described in the published patent application EP 0 392 225 (Example 23), which is hereby incorporated by reference. pCGN1761 contains the "double" CaMV 35S promoter and the tml transcriptional terminator with a unique EcoRI site between the promoter and the terminator and has a pUC-type backbone. A derivative of pCGN1761 is constructed which has a modified polylinker which includes NotI and XhoI sites in addition to the existing EcoRI site. This derivative is designated pCGN1761ENX. pCGN1761ENX is useful for the cloning of cDNA sequences or coding sequences (including microbial ORF sequences) within its polylinker for the purpose of their expression under the control of the 35S promoter in transgenic plants. The entire 35S promoter-coding sequence-tml terminator cassette of such a construction can be excised by HindIII, Sphl, Sall, and Xbal sites 5' to the promoter and Xbal, BamHI and Ball sites 3' to the terminator for transfer to transformation vectors such as those described below. Furthermore, the double 35S promoter fragment can be removed by 5' excision with HindIII, SphI, Sall, XbaI, or PstI, and 3' excision with any of the polylinker restriction sites (EcoRI, NotI or XhoI) for replacement with another promoter. If desired, modifications around the cloning sites can be made by the introduction of sequences that may enhance translation. This is particularly useful when overexpression is desired. For example, pCGN1761ENX may be modified by optimization of the translational initiation site as described in Example 37 of U.S. Patent No. 5,639,949, incorporated herein by reference.

c. Constitutive Expression, the Actin Promoter:

Several isoforms of actin are known to be expressed in most cell types and consequently the actin promoter is a good choice for a constitutive promoter. In particular, the promoter from the rice *Actl* gene has been cloned and characterized (McElroy *et al.* Plant Cell 2: 163-171 (1990)). A 1.3kb fragment of the promoter was found to contain all

the regulatory elements required for expression in rice protoplasts. Furthermore, numerous expression vectors based on the ActI promoter have been constructed specifically for use in monocotyledons (McElroy et al. Mol. Gen. Genet. 231: 150-160 (1991)). These incorporate the Actl-intron 1, Adhl 5' flanking sequence and Adhl-intron 1 (from the maize alcohol dehydrogenase gene) and sequence from the CaMV 35S promoter. Vectors showing highest expression were fusions of 35S and Actl intron or the Actl 5' flanking sequence and the Actl intron. Optimization of sequences around the initiating ATG (of the GUS reporter gene) also enhanced expression. The promoter expression cassettes described by McElroy et al. (Mol. Gen. Genet. 231: 150-160 (1991)) can be easily modified for gene expression and are particularly suitable for use in monocotyledonous hosts. For example, promotercontaining fragments is removed from the McElroy constructions and used to replace the double 35S promoter in pCGN1761ENX, which is then available for the insertion of specific gene sequences. The fusion genes thus constructed can then be transferred to appropriate transformation vectors. In a separate report, the rice ActI promoter with its first intron has also been found to direct high expression in cultured barley cells (Chibbar et al. Plant Cell Rep. 12: 506-509 (1993)).

d. Inducible Expression, the PR-1 Promoter:

The double 35S promoter in pCGN1761ENX may be replaced with any other promoter of choice that will result in suitably high expression levels. By way of example, one of the chemically regulatable promoters described in U.S. Patent No. 5,614,395 may replace the double 35S promoter. The promoter of choice is preferably excised from its source by restriction enzymes, but can alternatively be PCR-amplified using primers that carry appropriate terminal restriction sites. Should PCR-amplification be undertaken, then the promoter should be re-sequenced to check for amplification errors after the cloning of the amplified promoter in the target vector. The chemically/pathogen regulatable tobacco PR-1a promoter is cleaved from plasmid pCIB1004 (for construction, see example 21 of EP 0 332 104, which is hereby incorporated by reference) and transferred to plasmid pCGN1761ENX (Uknes et al., 1992). pCIB1004 is cleaved with *Ncol* and the resultant 3' overhang of the linearized fragment is rendered blunt by treatment with T4 DNA polymerase. The fragment is then cleaved with *HindIII* and the resultant PR-1a promoter-containing fragment is gel purified and cloned into pCGN1761ENX from which the double 35S promoter has been removed. This is done by cleavage with *Xhol* and blunting with T4

-133

23

19


polymerase, followed by cleavage with *HindIII* and isolation of the larger vector-terminator containing fragment into which the pCIB1004 promoter fragment is cloned. This generates a pCGN1761ENX derivative with the PR-1a promoter and the *tml* terminator and an intervening polylinker with unique *EcoRI* and *NotI* sites. The selected coding sequence can be inserted into this vector, and the fusion products (*i.e.* promoter-gene-terminator) can subsequently be transferred to any selected transformation vector, including those described *infra*. Various chemical regulators may be employed to induce expression of the selected coding sequence in the plants transformed according to the present invention, including the benzothiadiazole, isonicotinic acid, and salicylic acid compounds disclosed in U.S. Patent Nos. 5,523,311 and 5,614,395.

e. Inducible Expression, an Ethanol-Inducible Promoter:

A promoter inducible by certain alcohols or ketones, such as ethanol, may also be used to confer inducible expression of a coding sequence of the present invention. Such a promoter is for example the *alcA* gene promoter from *Aspergillus nidulans* (Caddick et al. (1998) *Nat. Biotechnol* 16:177-180). In *A. nidulans*, the *alcA* gene encodes alcohol dehydrogenase I, the expression of which is regulated by the AlcR transcription factors in presence of the chemical inducer. For the purposes of the present invention, the CAT coding sequences in plasmid palcA:CAT comprising a *alcA* gene promoter sequence fused to a minimal 35S promoter (Caddick et al. (1998) *Nat. Biotechnol* 16:177-180) are replaced by a coding sequence of the present invention to form an expression cassette having the coding sequence under the control of the *alcA* gene promoter. This is carried out using methods well known in the art.

f. Inducible Expression, a Glucocorticoid-Inducible Promoter:

Induction of expression of a nucleic acid sequence of the present invention using systems based on steroid hormones is also contemplated. For example, a glucocorticoid-mediated induction system is used (Aoyama and Chua (1997) *The Plant Journal* 11: 605-612) and gene expression is induced by application of a glucocorticoid, for example a synthetic glucocorticoid, preferably dexamethasone, preferably at a concentration ranging from 0.1mM to 1mM, more preferably from 10mM to 100mM. For the purposes of the present invention, the luciferase gene sequences are replaced by a nucleic acid sequence of the invention to form an expression cassette having a nucleic acid sequence of the



g. Root Specific Expression:

Another pattern of gene expression is root expression. A suitable root promoter is described by de Framond (FEBS 290: 103-106 (1991)) and also in the published patent application EP 0 452 269, which is herein incorporated by reference. This promoter is transferred to a suitable vector such as pCGN1761ENX for the insertion of a selected gene and subsequent transfer of the entire promoter-gene-terminator cassette to a transformation vector of interest.


h. Wound-Inducible Promoters:

Wound-inducible promoters may also be suitable for gene expression. Numerous such promoters have been described (e.g. Xu et al. Plant Molec. Biol. 22: 573-588 (1993), Logemann et al. Plant Cell 1: 151-158 (1989), Rohrmeier & Lehle, Plant Molec. Biol. 22: 783-792 (1993), Firek et al. Plant Molec. Biol. 22: 129-142 (1993), Warner et al. Plant J. 3: 191-201 (1993)) and all are suitable for use with the instant invention. Logemann et al. describe the 5' upstream sequences of the dicotyledonous potato wunl gene. Xu et al. show that a wound-inducible promoter from the dicotyledon potato (pin2) is active in the monocotyledon rice. Further, Rohrmeier & Lehle describe the cloning of the maize Wipl cDNA which is wound induced and which can be used to isolate the cognate promoter using standard techniques. Similar, Firek et al. and Warner et al. have described a wound-induced gene from the monocotyledon Asparagus officinalis, which is expressed at local wound and pathogen invasion sites. Using cloning techniques well known in the art, these

쐽

Ú÷.

-3



i. Pith-Preferred Expression:

Patent Application WO 93/07278, which is herein incorporated by reference, describes the isolation of the maize *trpA* gene, which is preferentially expressed in pith cells. The gene sequence and promoter extending up to -1726 bp from the start of transcription are presented. Using standard molecular biological techniques, this promoter, or parts thereof, can be transferred to a vector such as pCGN1761 where it can replace the 35S promoter and be used to drive the expression of a foreign gene in a pith-preferred manner. In fact, fragments containing the pith-preferred promoter or parts thereof can be transferred to any vector and modified for utility in transgenic plants.

j. Leaf-Specific Expression:


A maize gene encoding phosphoenol carboxylase (PEPC) has been described by Hudspeth & Grula (Plant Molec Biol 12: 579-589 (1989)). Using standard molecular biological techniques the promoter for this gene can be used to drive the expression of any gene in a leaf-specific manner in transgenic plants.

k. Pollen-Specific Expression:

WO 93/07278 describes the isolation of the maize calcium-dependent protein kinase (CDPK) gene which is expressed in pollen cells. The gene sequence and promoter extend up to 1400 bp from the start of transcription. Using standard molecular biological techniques, this promoter or parts thereof, can be transferred to a vector such as pCGN1761 where it can replace the 35S promoter and be used to drive the expression of a nucleic acid sequence of the invention in a pollen-specific manner.

2. Transcriptional Terminators

A variety of transcriptional terminators are available for use in expression cassettes. These are responsible for the termination of transcription beyond the transgene and its correct polyadenylation. Appropriate transcriptional terminators are those that are known to function in plants and include the CaMV 35S terminator, the *tml* terminator, the nopaline synthase terminator and the pea *rbcS* E9 terminator. These can be used in both



3. Sequences for the Enhancement or Regulation of Expression

Numerous sequences have been found to enhance gene expression from within the transcriptional unit and these sequences can be used in conjunction with the genes of this invention to increase their expression in transgenic plants.

Various intron sequences have been shown to enhance expression, particularly in monocotyledonous cells. For example, the introns of the maize *Adhl* gene have been found to significantly enhance the expression of the wild-type gene under its cognate promoter when introduced into maize cells. Intron 1 was found to be particularly effective and enhanced expression in fusion constructs with the chloramphenicol acetyltransferase gene (Callis *et al.*, Genes Develop. 1: 1183-1200 (1987)). In the same experimental system, the intron from the maize *bronze1* gene had a similar effect in enhancing expression. Intron sequences have been routinely incorporated into plant transformation vectors, typically within the non-translated leader.

A number of non-translated leader sequences derived from viruses are also known to enhance expression, and these are particularly effective in dicotyledonous cells. Specifically, leader sequences from Tobacco Mosaic Virus (TMV, the "W-sequence"), Maize Chlorotic Mottle Virus (MCMV), and Alfalfa Mosaic Virus (AMV) have been shown to be effective in enhancing expression (e.g. Gallie et al. Nucl. Acids Res. 15: 8693-8711 (1987); Skuzeski et al. Plant Molec. Biol. 15: 65-79 (1990)).

4. Targeting of the Gene Product Within the Cell

Various mechanisms for targeting gene products are known to exist in plants and the sequences controlling the functioning of these mechanisms have been characterized in some detail. For example, the targeting of gene products to the chloroplast is controlled by a signal sequence found at the amino terminal end of various proteins which is cleaved during chloroplast import to yield the mature protein (*e.g.* Comai *et al.* J. Biol. Chem. <u>263</u>: 15104-15109 (1988)). These signal sequences can be fused to heterologous gene products to effect the import of heterologous products into the chloroplast (van den Broeck, et al. Nature <u>313</u>: 358-363 (1985)). DNA encoding for appropriate signal sequences can be isolated from the 5' end of the cDNAs encoding the RUBISCO protein, the CAB protein, the


. 4

19

48

3/1

-3



Other gene products are localized to other organelles such as the mitochondrion and the peroxisome (e.g. Unger et al. Plant Molec. Biol. 13: 411-418 (1989)). The cDNAs encoding these products can also be manipulated to effect the targeting of heterologous gene products to these organelles. Examples of such sequences are the nuclear-encoded ATPases and specific aspartate amino transferase isoforms for mitochondria. Targeting cellular protein bodies has been described by Rogers et al. (Proc. Natl. Acad. Sci. USA 82: 6512-6516 (1985)).

In addition, sequences have been characterized which cause the targeting of gene products to other cell compartments. Amino terminal sequences are responsible for targeting to the ER, the apoplast, and extracellular secretion from aleurone cells (Koehler & Ho, Plant Cell 2: 769-783 (1990)). Additionally, amino terminal sequences in conjunction with carboxy terminal sequences are responsible for vacuolar targeting of gene products (Shinshi *et al.* Plant Molec. Biol. 14: 357-368 (1990)).

By the fusion of the appropriate targeting sequences described above to transgene sequences of interest it is possible to direct the transgene product to any organelle or cell compartment. For chloroplast targeting, for example, the chloroplast signal sequence from the RUBISCO gene, the CAB gene, the EPSP synthase gene, or the GS2 gene is fused in frame to the amino terminal ATG of the transgene. The signal sequence selected should include the known cleavage site, and the fusion constructed should take into account any amino acids after the cleavage site which are required for cleavage. In some cases this requirement may be fulfilled by the addition of a small number of amino acids between the cleavage site and the transgene ATG or, alternatively, replacement of some amino acids within the transgene sequence. Fusions constructed for chloroplast import can be tested for efficacy of chloroplast uptake by in vitro translation of in vitro transcribed constructions followed by in vitro chloroplast uptake using techniques described by Bartlett et al. In: Edelmann et al. (Eds.) Methods in Chloroplast Molecular Biology, Elsevier pp 1081-1091 (1982) and Wasmann et al. Mol. Gen. Genet. <u>205</u>: 446-453 (1986). These construction techniques are well known in the art and are equally applicable to mitochondria and peroxisomes.

The above-described mechanisms for cellular targeting can be utilized not only in conjunction with their cognate promoters, but also in conjunction with heterologous promoters so as to effect a specific cell-targeting goal under the transcriptional regulation of a promoter that has an expression pattern different to that of the promoter from which the targeting signal derives.

Example 24: Construction of Plant Transformation Vectors

Numerous transformation vectors available for plant transformation are known to those of ordinary skill in the plant transformation arts, and the genes pertinent to this invention can be used in conjunction with any such vectors. The selection of vector will depend upon the preferred transformation technique and the target species for transformation. For certain target species, different antibiotic or herbicide selection markers may be preferred. Selection markers used routinely in transformation include the *nptll* gene, which confers resistance to kanamycin and related antibiotics (Messing & Vierra. Gene 19: 259-268 (1982); Bevan et al., Nature 304:184-187 (1983)), the *bar* gene, which confers resistance to the herbicide phosphinothricin (White et al., Nucl. Acids Res 18: 1062 (1990), Spencer et al. Theor. Appl. Genet 79: 625-631 (1990)), the *hph* gene, which confers resistance to the antibiotic hygromycin (Blochinger & Diggelmann, Mol Cell Biol 4: 2929-2931), and the *dhfr* gene, which confers resistance to methatrexate (Bourouis et al., EMBO J. 2(7): 1099-1104 (1983)), and the EPSPS gene, which confers resistance to glyphosate (U.S. Patent Nos. 4,940,935 and 5,188,642).

1. Vectors Suitable for Agrobacterium Transformation

Many vectors are available for transformation using *Agrobacterium tumefaciens*. These typically carry at least one T-DNA border sequence and include vectors such as pBIN19 (Bevan, Nucl. Acids Res. (1984)) and pXYZ. Below, the construction of two typical vectors suitable for *Agrobacterium* transformation is described.

a. pClB200 and pClB2001:

The binary vectors pclB200 and pClB2001 are used for the construction of recombinant vectors for use with *Agrobacterium* and are constructed in the following manner. pTJS75kan is created by *Narl* digestion of pTJS75 (Schmidhauser & Helinski, J.

.

- 22

. 🦈

· 1

. .

益

Bacteriol. 164: 446-455 (1985)) allowing excision of the tetracycline-resistance gene, followed by insertion of an Accl fragment from pUC4K carrying an NPTII (Messing & Vierra, Gene 19: 259-268 (1982): Bevan et al., Nature 304: 184-187 (1983): McBride et al., Plant Molecular Biology 14: 266-276 (1990)). Xhol linkers are ligated to the EcoRV fragment of PCIB7 which contains the left and right T-DNA borders, a plant selectable nos/nptII chimeric gene and the pUC polylinker (Rothstein et al., Gene 53: 153-161 (1987)), and the Xholdigested fragment are cloned into Sall-digested pTJS75kan to create pClB200 (see also EP 0 332 104, example 19). pCIB200 contains the following unique polylinker restriction sites: EcoRI, SstI, KpnI, BgIII, XbaI, and SaII. pCIB2001 is a derivative of pCIB200 created by the insertion into the polylinker of additional restriction sites. Unique restriction sites in the polylinker of pClB2001 are EcoRI, Sstl, Kpnl, BgIII, Xbal, Sall, Miul, Bcll, Avril, Apal, Hpal, and Stul. pCIB2001, in addition to containing these unique restriction sites also has plant and bacterial kanamycin selection, left and right T-DNA borders for Agrobacterium-mediated transformation, the RK2-derived trfA function for mobilization between E. coli and other hosts, and the OriT and OriV functions also from RK2. The pClB2001 polylinker is suitable for the cloning of plant expression cassettes containing their own regulatory signals.

b. pCIB10 and Hygromycin Selection Derivatives thereof:

The binary vector pClB10 contains a gene encoding kanamycin resistance for selection in plants and T-DNA right and left border sequences and incorporates sequences from the wide host-range plasmid pRK252 allowing it to replicate in both *E. coli* and *Agrobacterium*. Its construction is described by Rothstein *et al.* (Gene <u>53</u>: 153-161 (1987)). Various derivatives of pClB10 are constructed which incorporate the gene for hygromycin B phosphotransferase described by Gritz *et al.* (Gene <u>25</u>: 179-188 (1983)). These derivatives enable selection of transgenic plant cells on hygromycin only (pClB743), or hygromycin and kanamycin (pClB715, pClB717).

2. Vectors Suitable for non-Agrobacterium Transformation

Transformation without the use of *Agrobacterium tumefaciens* circumvents the requirement for T-DNA sequences in the chosen transformation vector and consequently vectors lacking these sequences can be utilized in addition to vectors such as the ones described above which contain T-DNA sequences. Transformation techniques that do not rely on *Agrobacterium* include transformation via particle bombardment, protoplast uptake

(e.g. PEG and electroporation) and microinjection. The choice of vector depends largely on the preferred selection for the species being transformed. Below, the construction of typical vectors suitable for non-Agrobacterium transformation is described.

a. pClB3064:

pClB3064 is a pUC-derived vector suitable for direct gene transfer techniques in combination with selection by the herbicide basta (or phosphinothricin). pCIB246 comprises the CaMV 35S promoter in operational fusion to the E. coli GUS gene and the CaMV 35S transcriptional terminator and is described in the PCT published application WO 93/07278. The 35S promoter of this vector contains two ATG sequences 5' of the start site. These sites are mutated using standard PCR techniques in such a way as to remove the ATGs and generate the restriction sites Sspl and Pvull. The new restriction sites are 96 and 37 bp away from the unique Sall site and 101 and 42 bp away from the actual start site. The resultant derivative of pCIB246 is designated pCIB3025. The GUS gene is then excised from pCIB3025 by digestion with Sall and Sacl, the termini rendered blunt and religated to generate plasmid pClB3060. The plasmid pJIT82 is obtained from the John Innes Centre, Norwich and the a 400 bp Smal fragment containing the bar gene from Streptomyces viridochromogenes is excised and inserted into the Hpal site of pCIB3060 (Thompson et al. EMBO J 6: 2519-2523 (1987)). This generated pCIB3064, which comprises the bar gene under the control of the CaMV 35S promoter and terminator for herbicide selection, a gene for ampicillin resistance (for selection in E. coli) and a polylinker with the unique sites Sphl, Pstl, HindIII, and BamHI. This vector is suitable for the cloning of plant expression cassettes containing their own regulatory signals.

b. pSOG19 and pSOG35:

pSOG35 is a transformation vector that utilizes the *E. coli* gene dihydrofolate reductase (DFR) as a selectable marker conferring resistance to methotrexate. PCR is used to amplify the 35S promoter (-800 bp), intron 6 from the maize Adh1 gene (-550 bp) and 18 bp of the GUS untranslated leader sequence from pSOG10. A 250-bp fragment encoding the *E. coli* dihydrofolate reductase type II gene is also amplified by PCR and these two PCR fragments are assembled with a *SacI-PstI* fragment from pB1221 (Clontech) which comprises the pUC19 vector backbone and the nopaline synthase terminator. Assembly of these fragments generates pSOG19 which contains the 35S promoter in fusion

歪

with the intron 6 sequence, the GUS leader, the DHFR gene and the nopaline synthase terminator. Replacement of the GUS leader in pSOG19 with the leader sequence from Maize Chlorotic Mottle Virus (MCMV) generates the vector pSOG35. pSOG19 and pSOG35 carry the pUC gene for ampicillin resistance and have *HindIII*, *SphI*, *PstI* and *EcoRI* sites available for the cloning of foreign substances.


Example 25: Transformation

Once a nucleic acid sequence of the invention has been cloned into an expression system, it is transformed into a plant cell. Methods for transformation and regeneration of plants are well known in the art. For example, Ti plasmid vectors have been utilized for the delivery of foreign DNA, as well as direct DNA uptake, liposomes, electroporation, microinjection, and microprojectiles. In addition, bacteria from the genus *Agrobacterium* can be utilized to transform plant cells. Below are descriptions of representative techniques for transforming both dicotyledonous and monocotyledonous plants.

1. Transformation of Dicotyledons

Transformation techniques for dicotyledons are well known in the art and include Agrobacterium-based techniques and techniques that do not require Agrobacterium. Non-Agrobacterium techniques involve the uptake of exogenous genetic material directly by protoplasts or cells. This can be accomplished by PEG or electroporation mediated uptake, particle bombardment-mediated delivery, or microinjection. Examples of these techniques are described by Paszkowski et al., EMBO J 3: 2717-2722 (1984), Potrykus et al., Mol. Gen. Genet. 199: 169-177 (1985), Reich et al., Biotechnology 4: 1001-1004 (1986), and Klein et al., Nature 327: 70-73 (1987). In each case the transformed cells are regenerated to whole plants using standard techniques known in the art.

Agrobacterium-mediated transformation is a preferred technique for transformation of dicotyledons because of its high efficiency of transformation and its broad utility with many different species. Agrobacterium transformation typically involves the transfer of the binary vector carrying the foreign DNA of interest (e.g. pClB200 or pClB2001) to an appropriate Agrobacterium strain which may depend of the complement of vir genes carried by the host Agrobacterium strain either on a co-resident Ti plasmid or chromosomally (e.g. strain ClB542 for pClB200 and pClB2001 (Uknes et al. Plant Cell 5: 159-169 (1993)). The




Transformation of the target plant species by recombinant *Agrobacterium* usually involves co-cultivation of the *Agrobacterium* with explants from the plant and follows protocols well known in the art. Transformed tissue is regenerated on selectable medium carrying the antibiotic or herbicide resistance marker present between the binary plasmid T-DNA borders.

Another approach to transforming plant cells with a gene involves propelling inert or biologically active particles at plant tissues and cells. This technique is disclosed in U.S. Patent Nos. 4,945,050, 5,036,006, and 5,100,792 all to Sanford et al. Generally, this procedure involves propelling inert or biologically active particles at the cells under conditions effective to penetrate the outer surface of the cell and afford incorporation within the interior thereof. When inert particles are utilized, the vector can be introduced into the cell by coating the particles with the vector containing the desired gene. Alternatively, the target cell can be surrounded by the vector so that the vector is carried into the cell by the wake of the particle. Biologically active particles (e.g., dried yeast cells, dried bacterium or a bacteriophage, each containing DNA sought to be introduced) can also be propelled into plant cell tissue.

2. Transformation of Monocotyledons

Transformation of most monocotyledon species has now also become routine. Preferred techniques include direct gene transfer into protoplasts using PEG or electroporation techniques, and particle bombardment into callus tissue. Transformations can be undertaken with a single DNA species or multiple DNA species (*i.e.* cotransformation) and both these techniques are suitable for use with this invention. Cotransformation may have the advantage of avoiding complete vector construction and of generating transgenic plants with unlinked loci for the gene of interest and the selectable marker, enabling the removal of the selectable marker in subsequent generations, should this be regarded desirable. However, a disadvantage of the use of co-transformation is the

1



Patent Applications EP 0 292 435, EP 0 392 225, and WO 93/07278 describe techniques for the preparation of callus and protoplasts from an elite inbred line of maize, transformation of protoplasts using PEG or electroporation, and the regeneration of maize plants from transformed protoplasts. Gordon-Kamm *et al.* (Plant Cell 2: 603-618 (1990)) and Fromm *et al.* (Biotechnology 8: 833-839 (1990)) have published techniques for transformation of A188-derived maize line using particle bombardment. Furthermore, WO 93/07278 and Koziel *et al.* (Biotechnology 11: 194-200 (1993)) describe techniques for the transformation of elite inbred lines of maize by particle bombardment. This technique utilizes immature maize embryos of 1.5-2.5 mm length excised from a maize ear 14-15 days after pollination and a PDS-1000He Biolistics device for bombardment.

Transformation of rice can also be undertaken by direct gene transfer techniques utilizing protoplasts or particle bombardment. Protoplast-mediated transformation has been described for *Japonica*-types and *Indica*-types (Zhang *et al.* Plant Cell Rep 7: 379-384 (1988); Shimamoto *et al.* Nature 338: 274-277 (1989); Datta *et al.* Biotechnology 8: 736-740 (1990)). Both types are also routinely transformable using particle bombardment (Christou *et al.* Biotechnology 9: 957-962 (1991)). Furthermore, WO 93/21335 describes techniques for the transformation of rice via electroporation.

Patent Application EP 0 332 581 describes techniques for the generation, transformation and regeneration of Pooideae protoplasts. These techniques allow the transformation of *Dactylis* and wheat. Furthermore, wheat transformation has been described by Vasil *et al.* (Biotechnology 10: 667-674 (1992)) using particle bombardment into cells of type C long-term regenerable callus, and also by Vasil *et al.* (Biotechnology 11: 1553-1558 (1993)) and Weeks *et al.* (Plant Physiol. 102: 1077-1084 (1993)) using particle bombardment of immature embryos and immature embryo-derived callus. A preferred technique for wheat transformation, however, involves the transformation of wheat by particle bombardment of immature embryos and includes either a high sucrose or a high maltose step prior to gene delivery. Prior to bombardment, any number of embryos (0.75-1 mm in length) are plated onto MS medium with 3% sucrose (Murashiga & Skoog, Physiologia Plantarum 15: 473-497 (1962)) and 3 mg/l 2,4-D for induction of somatic embryos, which is allowed to proceed in the dark. On the chosen day of bombardment, embryos are removed from the induction medium and placed onto the osmoticum (*i.e.*

induction medium with sucrose or maltose added at the desired concentration, typically 15%). The embryos are allowed to plasmolyze for 2-3 h and are then bombarded. Twenty embryos per target plate is typical, although not critical. An appropriate gene-carrying plasmid (such as pCIB3064 or pSG35) is precipitated onto micrometer size gold particles using standard procedures. Each plate of embryos is shot with the DuPont Biolistics® helium device using a burst pressure of ~1000 psi using a standard 80 mesh screen. After bombardment, the embryos are placed back into the dark to recover for about 24 h (still on osmoticum). After 24 hrs, the embryos are removed from the osmoticum and placed back onto induction medium where they stay for about a month before regeneration. Approximately one month later the embryo explants with developing embryogenic callus are transferred to regeneration medium (MS + 1 mg/liter NAA, 5 mg/liter GA), further containing the appropriate selection agent (10 mg/l basta in the case of pCIB3064 and 2 mg/l methotrexate in the case of pSOG35). After approximately one month, developed shoots are transferred to larger sterile containers known as "GA7s" which contain half-strength MS, 2% sucrose, and the same concentration of selection agent.


Tranformation of monocotyledons using *Agrobacterium* has also been described. *See*, WO 94/00977 and U.S. Patent No. 5,591,616, both of which are incorporated herein by reference.

E. Breeding and Seed Production

Example 26: Breeding


The plants obtained via tranformation with a nucleic acid sequence of the present invention can be any of a wide variety of plant species, including those of monocots and dicots; however, the plants used in the method of the invention are preferably selected from the list of agronomically important target crops set forth *supra*. The expression of a gene of the present invention in combination with other characteristics important for production and quality can be incorporated into plant lines through breeding. Breeding approaches and techniques are known in the art. See, for example, Welsh J. R., *Fundamentals of Plant Genetics and Breeding*, John Wiley & Sons, NY (1981); *Crop Breeding*, Wood D. R. (Ed.) American Society of Agronomy Madison, Wisconsin (1983); Mayo O., *The Theory of Plant Breeding*, Second Edition, Clarendon Press, Oxford (1987); Singh, D.P., *Breeding for*

T. Farm



The genetic properties engineered into the transgenic seeds and plants described above are passed on by sexual reproduction or vegetative growth and can thus be maintained and propagated in progeny plants. Generally said maintenance and propagation make use of known agricultural methods developed to fit specific purposes such as tilling, sowing or harvesting. Specialized processes such as hydroponics or greenhouse technologies can also be applied. As the growing crop is vulnerable to attack and damages caused by insects or infections as well as to competition by weed plants, measures are undertaken to control weeds, plant diseases, insects, nematodes, and other adverse conditions to improve yield. These include mechanical measures such a tillage of the soil or removal of weeds and infected plants, as well as the application of agrochemicals such as herbicides, fungicides, gametocides, nematicides, growth regulants, ripening agents and insecticides.

Use of the advantageous genetic properties of the transgenic plants and * seeds according to the invention can further be made in plant breeding, which aims at the development of plants with improved properties such as tolerance of pests, herbicides, or stress, improved nutritional value, increased yield, or improved structure causing less loss from lodging or shattering. The various breeding steps are characterized by well-defined human intervention such as selecting the lines to be crossed, directing pollination of the parental lines, or selecting appropriate progeny plants. Depending on the desired properties, different breeding measures are taken. The relevant techniques are well known in the art and include but are not limited to hybridization, inbreeding, backcross breeding, multiline breeding, variety blend, interspecific hybridization, aneuploid techniques, etc. Hybridization techniques also include the sterilization of plants to yield male or female sterile plants by mechanical, chemical, or biochemical means. Cross pollination of a male sterile plant with pollen of a different line assures that the genome of the male sterile but female fertile plant will uniformly obtain properties of both parental lines. Thus, the transgenic seeds and plants according to the invention can be used for the breeding of improved plant lines, that for example, increase the effectiveness of conventional methods such as herbicide or pestidice treatment or allow one to dispense with said methods due to their modified genetic properties. Alternatively new crops with improved stress tolerance can be obtained, which, due to their optimized genetic "equipment", yield harvested product of



Example 27: Seed Production

In seed production, germination quality and uniformity of seeds are essential product characteristics, whereas germination quality and uniformity of seeds harvested and sold by the farmer is not important. As it is difficult to keep a crop free from other crop and weed seeds, to control seedborne diseases, and to produce seed with good germination, fairly extensive and well-defined seed production practices have been developed by seed producers, who are experienced in the art of growing, conditioning and marketing of pure seed. Thus, it is common practice for the farmer to buy certified seed meeting specific quality standards instead of using seed harvested from his own crop. Propagation material to be used as seeds is customarily treated with a protectant coating comprising herbicides, insecticides, fungicides, bactericides, nematicides, molluscicides, or mixtures thereof. Customarily used protectant coatings comprise compounds such as captan, carboxin, thiram (TMTD*), methalaxyl (Apron*), and pirimiphos-methyl (Actellic*). If desired, these compounds are formulated together with further carriers, surfactants or applicationpromoting adjuvants customarily employed in the art of formulation to provide protection against damage caused by bacterial, fungal or animal pests. The protectant coatings may be applied by impregnating propagation material with a liquid formulation or by coating with a combined wet or dry formulation. Other methods of application are also possible such as treatment directed at the buds or the fruit.

It is a further aspect of the present invention to provide new agricultural methods, such as the methods examplified above, which are characterized by the use of transgenic plants, transgenic plant material, or transgenic seed according to the present invention.

The seeds may be provided in a bag, container or vessel comprised of a suitable packaging material, the bag or container capable of being closed to contain seeds. The bag, container or vessel may be designed for either short term or long term storage, or both, of the seed. Examples of a suitable packaging material include paper, such as kraft paper, rigid or pliable plastic or other polymeric material, glass or metal. Desirably the bag, container, or vessel is comprised of a plurality of layers of packaging materials, of the same or differing type. In one embodiment the bag, container or vessel is provided so as to

izi Va

exclude or limit water and moisture from contacting the seed. In one example, the bag, container or vessel is sealed, for example heat sealed, to prevent water or moisture from entering. In another embodiment water absorbent materials are placed between or adjacent to packaging material layers. In yet another embodiment the bag, container or vessel, or packaging material of which it is comprised is treated to limit, suppress or prevent disease, contamination or other adverse affects of storage or transport of the seed. An example of such treatment is sterilization, for example by chemical means or by exposure to radiation. Comprised by the present invention is a commercial bag comprising seed of a transgenic plant comprising a gene of the present invention that is expressed in said transformed plant at higher levels than in a wild type plant, together with a suitable carrier, together with label instructions for the use thereof for conferring broad spectrum disease resistance to plants.



SUDAPLET TREATY ON THE INTERNATIONAL RECOGNITION OF THE DEPOSIT OF MICROORGANISHS FOR THE PURPOSE OF PATENT PROCEDURES

INTERNATIONAL PORM

TO

Novartis AG Novartie Corporation 3054 Cornwallis Rd. Research Triangle Park, NC 27709

VIABILITY STATEMENT

issued pursuant to Rule 10.2 by the INTERNATIONAL DEPOSITARY AUTHORITY identified at the bottom of this page

NAME AND ADDRESS OF THE PARTY TO WHOM

THE VIABILITY STATEMENT IS ISSUED			
I. DEPOSITOR	II. IDENTIFICATION OF THE KICKOORGANISK		
Name: Novartis AG Novartis Corporation Address: 3054 Cornwallis Rd. Research Triangle Park, NC 27709	Depositor's taxonomic designation and accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY: Escherichia coli NRRL B-30077 Date of: October 28, 1998 X 1 Original Deposit 1 New Deposit 1 Repropagation of Original Deposit		
III. (a) VIABILITY STATEMENT			
Deposit was found: X Viable Nonviable on October 31, 1998 (Date) International Depositary Authority's preparation was found viable on December 8, 1996 (Date)			
III. (b) DEPOSITOR'S EQUIVALENCY DECLAR	ATION		
Depositor determined the International Depositary Authority's preparation was			
Signature of Depositor Not equivalent to deposit on 1-6-99 (Date)			
IV. CONDITIONS UNDER WHICH THE VIABILITY TEST WAS PERFORMED (Depositors/Depositary)			
The dried culture was put into 2 mls LB ampurgume, and grown at 37°C overnight with shaking. Some of the liquid culture was streaked to an LB plate + grown at 37°C overnight.			
V. INTERNATIONAL DEPOSITARY AUTHORITY			
Name: Agricultural Research Culture Collection (NRRL) International Depositary Authority	Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s):		
Address: 1815 N. University Street Peoria, Illinois 61604 U.S.A.	12-3-77		

[:] Indicate the date of the original deposit or when a new deposit has been made.

! Mark with a cross the applicable Dox.

! In the cases referred to in Rule 10.2(a)(ii) and (iii), refer to the most recent viability test.

! Fill in if the information has been requested.

き



BUDAPEST TREATY ON THE INTERNATIONAL RECOGNITION OF THE DEPOSIT OF MICROCRGANISMS FOR THE PURPOSE OF PATENT PROCEDURES

INTERNATIONAL FORM

TO
Novartis AQ
Novartis Corporation
3054 Cornwellis Rd.
Research Triangle Park,
NC 27709

RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT issued pursuant to Rule 7.1 by the INTERNATIONAL DEPOSITARY AUTHORITY identified at the bottom of this page

NAME AND ADDRESS

OF DEPOSITOR				
I. IDENTIFICATION OF THE MICROORGANISM				
Identification reference given by the DEPOSITOR:	Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY:			
Escherichia coli pNOV2400	NRRL B-30077			
II. SCIENTIFIC DESCRIPTION AND/OR PROPOSE	ED TAXONOMIC DESIGNATION			
The microorganism identified under I. above was accompanied by:				
a scientific description	:			
x a proposed taxonomic designation				
(Mark with a cross where applicable)	· <u> </u>			
III. RECEIPT AND ACCEPTANCE	. S.			
This International Depositary Authority accepts the microorganism identified under I. above, which was received by it on October 28, 1998(date of the original deposit)'				
IV. RECEIPT OF REQUEST FOR CONVERSION				
The microorganism identified under I. above was received by this International Depositary Authority on (date of the original deposit) and a request to convert the original deposit to a deposit under the Sudapest Treaty was received by it on (date of receipt of request for conversion).				
V. INTERNATIONAL DEPOSITARY AUTHORITY				
Name: Agricultural Research Culture Collection (NRRL) International Depositary Authority	Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s):			
Address: 1815 N. University Street Pe ria, Illinois 61604 U.S.A.	Date: 12 3-91			

Where Rule 6.4(d) applies, such date is the date on which the status of international depositary authority was acquired.



BUDAPEST TREATY ON THE INTERNATIONAL RECOGNITION OF THE DEPOSIT OF MICROORGANISMS FOR THE PURPOSE OF PATENT PROCEDURES

INTERNATIONAL FORK

TO Novertis AG Novertis Corporation 3054 Cornwallis Rd. Research Triangle Park, NC 27709 RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT issued pursuant to Rule 7.1 by the INTERNATIONAL DEPOSITARY AUTHORITY identified at the bottom of this page

NAME AND ADDRESS

OF DEPOSITOR				
I. IDENTIFICATION OF THE MICROORGANISM				
Identification reference given by the DEPOSITOR:	Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY:			
Escherichia coli pNOV1001	NRRL 8-30078			
II. SCIENTIFIC DESCRIPTION AND/OR PROPO	SED TAXONOMIC DESIGNATION			
The microorganism identified under I. abo	we was accompanied by:			
a scientific description				
a proposed taxonomic designation				
(Mark_with_s_cross_where_applicable)				
III. RECEIPT AND ACCEPTANCE				
This International Depositary Authority above, which was received by it on October	coepts the microorganism identified under I. 28, 1998(date of the original deposit)1			
IV. RECEIPT OF REQUEST FOR CONVERSION				
The microorganism identified under I. above was received by this International Depositary Authority on (date of the original deposit) and a request to convert the original deposit to a deposit under the Budupest Treaty was received by it on (date of receipt of request for conversion).				
V. INTERNATIONAL DEPOSITARY AUTHORITY				
Name: Agricultural Research Culture Collection (NRRL) International Depositary Authority	Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s):			
Address: 1815 N. University Street Peoria, Illinois 61604 U.S.A.	Date:			

^{&#}x27; Where Rule 6.4(d) applies, such date is the date on which the status of international depositary authority was acquired.

100 i.C

- 2

्ड् - ज्य



BUDAPEST TREATY ON THE INTERNATIONAL RECOGNITION OF THE DEPOSIT OF MICROORGANISMS FOR THE PURPOSE OF PATENT PROCEDURES

INTERNATIONAL FORM

TO

VIABILITY STATEMENT

Novertie AG Novartis Corporation 3054 Cornwallia Rd. Research Triangle Park, NC 27709

issued pursuant to Rule 10.2 by the INTERNATIONAL DEPOSITARY AUTHORITY identified at the bottom of this page

NAME AND ADDRESS OF THE PARTY TO WHOM THE VIRELLITY STATEMENT IS ISSUED

I. DEPOSI	TOR	II. IDENTIFICATION OF THE MICROORGANISM		
	Novartis AG Novartis Corporation 3054 Cornwallis Rd. Research Triangle Park, NC 27709	Depositor's taxonomic designation and accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY: Sscherichia coli NRRL B-30078 Date of: October 28, 1998 2 Original Deposit 2 New Deposit 3 Repropagation of Original Deposit		
III. (a)	VIRBILITY STATEMENT			
•		tration was found viable on December 8, 1998 (Date)		
III. (b)	DEPOSITOR'S EQUIVALENCY DECLARA			
Z · Ednīv	alent 2 Not equivalent to de	posit on(Date)		
IV. CONDI	TIONS UNDER WHICH THE VIABILITY	TEST WAS PERFORMED (Depositors/Depositary)		
The dried	s culture was put into 2m with shaking. Some of the grown at 37°C overnight:	els LBamp(19mg/ml) and grown at 37°C liquid culture was streaked to an LBamp 19mg/me		
V. INTE	RNATIONAL DEPOSITARY AUTHORITY			
Co	cultural Research Culture llection (NRRL) rnational Depositary Authority	Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s):		
Address: 1815 N. University Street Peoria, Illinois 61604 U.S.A. Pate:				

^{&#}x27; Indicate the date of the original deposit or when a new deposit has been made.
' Mark with a cross the applicable box.
' In the cases referred to in Rule 10.2(a)(ii) and (iii), refer to the most recent viability test.
' Fill in if the information has been requested.



BUDAPEST TREATY ON THE INTERNATIONAL RECOGNITION OF THE DEPOSIT OF MICROORGANISMS FOR THE PURPOSE OF PATENT PROCEDURES

INTERNATIONAL FORM

ro

Novartis Corp. c/o Novartis AG p. O. Box 12257

Research Triangle Park, NC 27709

RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT issued pursuant to Rule 7.1 by the INTERNATIONAL DEPOSITARY AUTHORITY identified at the bottom of this page

NAME AND ADDRESS

I. IDENTIFICATION OF THE MICROORGANISM				
Identification reference given by the DEPOSITOR:	Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY:			
Bacteria sp. pCIB 9359-7	NRRL B-21835			
II. SCIENTIFIC DESCRIPTION AND/OR PROPOS	ED TAXONOMIC DESIGNATION			
The microorganism identified under I. above was accompanied by:				
a scientific description				
a proposed taxonomic designation				
(Mark with a cross where applicable)				
III. RECEIPT AND ACCEPTANCE				
This International Depositary Authority accepts the microorganism identified under I. above, which was received by it on September 17, 1997 (date of the original deposit)				
IV RECEIPT OF REQUEST FOR CONVERSION				
The microorganism identified under I. above was received by this International Depositary Authority on (date of the original deposit) and a request to convert the original deposit to a deposit under the Budapest Treaty was received by it on (date of receipt of request for conversion).				
V INTERNATIONAL DEPOSITARY AUTHORITY				
Name: Agricultural Research Culture Collection (NRRL) International Depositary Authority Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s):				
Address: 1815 N. University Street Peoria, Illinois 61604 U.S.A. Date: 11-13-47				

^{&#}x27;Where Rule 6.4(d) applies, such date is the date on which the status of international depositary authority was acquired.

-54

 $= \frac{Tt}{2\pi r}$

STO 47

BUDAPEST TREATY ON THE INTERNATIONAL RECOGNITION OF THE DEPOSIT OF MICROORGANIEMS FOR THE PURPOSE OF PATENT PROCEDURES

INTERNATIONAL FORM

TO

VIABILITY STATEMENT

Novartis Comp. c/o Novartis AG P. O. Box 12257 Research Triangle Park, NC 27709

issued pursuant to Rule 10.2 by the INTERNATIONAL DEPOSITARY AUTHORITY identified at the bottom of this page

NAME AND ADDRESS OF THE PARTY TO WHOM TUR VIABILITY STATEMENT IS ISSUED

INB VERSION	والمتحدد والمرابق في مساورة والمنافعة والمنافع									
I. DEPOSITOR	II. IDENTIFICATION OF THE MICROORGANISM									
Name: Novartis Corp c/o Novartis AG Address: P. O. Box 12257 Research Triangle Park, NC 27709	Depositor's taxonomic designation and accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY: Bacteria sp. NRRL B-21835 Date of:September 17, 1997 2 Original Deposit 1 New Deposit: 2 Repropagation of Original Deposit									
III. (a) VIABILITY STATEMENT										
Deposit was found: Viable Nonviable on September 18, 1997 (Date) International Depositary Authority's preparation was found viable on September 25, 1997 (Date)										
III. (b) DEFOSITOR'S EQUIVALENCY DECLARA	ATION									
Depositor datermined the International Dep										
Signature of Dapositor	posit on(Date)									
COMPANIONS INDEED WITCH THE VINELLING	TEST WAS PERFORMED (Depositors/Depositary)									
IV. CORDITIONS DAMAR WATCH THE VINSIBILITY	1831 HAS PERFORMED (DEDUBICOTE) POSSESSER!									
V INTERNATIONAL DEPOSITARY AUTHORITY										
Name: Agricultural Research Culture Collection (NRRL) International Depositary Authority	Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s):									
Address: 1815 N. University Street Peoria, Illinois 61604 U.S.A.	Para: 11-13:77									

Indicate the date of the original deposit or when a new duposit had been made.

^{*} Indicate the date of the obligable depart of when 3 now duposit has soon made.

* Mark with a cross the applicable bear.

* In the cases referred to in Rule 10.2(a)(ii) and (iii), rotur to the mass secure viability test.

* Fill in if the information has been requested.



What is claimed is:

- 1. An isolated nucleic acid molecule comprising:
 - a nucleotide sequence substantially similar to a nucleotide sequence selected from the group consisting of: nucleotides 412-1665 of SEQ ID NO:1, nucleotides 1686-2447 of SEQ ID NO:1, nucleotides 2758-3318 of SEQ ID NO:1, nucleotides 3342-4118 of SEQ ID NO:1, nucleotides 4515-9269 of SEQ ID NO:1, nucleotides 15,171-18,035 of SEQ ID NO:11, and nucleotides 31,393-35,838 of SEQ ID NO:11;
 - (b) a nucleotide sequence comprising nucleotides 23,768-31,336 of SEQ ID NO:11; or
- (c) a nucleotide sequence isocoding with the nucleotide sequence of (a) or (b); wherein expression of said nucleic acid molecule results in at least one toxin that is active against insects.
- 2. An isolated nucleic acid molecule comprising a 20 base pair nucleotide portion identical in sequence to a consecutive 20 base pair nucleotide portion of a nucleotide sequence selected from the group consisting of: nucleotides 412-1665 of SEQ ID NO:1, nucleotides 1686-2447 of SEQ ID NO:1, nucleotides 2758-3318 of SEQ ID NO:1, nucleotides 3342-4118 of SEQ ID NO:1, nucleotides 4515-9269 of SEQ ID NO:1, nucleotides 15,171-18,035 of SEQ ID NO:11, and nucleotides 31,393-35,838 of SEQ ID NO:11, wherein expression of said nucleic acid molecule results in at least one toxin that is active against insects.
- 3. An isolated nucleic acid molecule comprising a nucleotide sequence from *Photorhabdus luminescens* selected from the group consisting of: nucleotides 412-1665 of SEQ ID NO:1, nucleotides 1686-2447 of SEQ ID NO:1, nucleotides 2758-3318 of SEQ ID NO:1, nucleotides 3342-4118 of SEQ ID NO:1, nucleotides 4515-9269 of SEQ ID NO:1, nucleotides 66-1898 of SEQ ID NO:11, nucleotides 2416-9909 of SEQ ID NO:11, the complement of nucleotides 2817-3395 of SEQ ID NO:11, nucleotides 9966-14,633 of SEQ ID NO:11, nucleotides 14,699-15,007 of SEQ ID NO:11, nucleotides 15,171-18,035 of SEQ ID NO:11, the complement of nucleotides 17,072-17,398 of SEQ ID NO:11, the complement of nucleotides 19,385-20,116 of SEQ ID NO:11, the complement of nucleotides 20,217-20,963 of SEQ ID NO:11,

the complement of nucleotides 22,172-23,086 of SEQ ID NO:11, nucleotides 23,768-31,336 of SEQ ID NO:11, nucleotides 31,393-35,838 of SEQ ID NO:11, the complement of nucleotides 35,383-35,709 of SEQ ID NO:11, the complement of nucleotides 36,032-36,661 of SEQ ID NO:11, and the complement of nucleotides 36,654-37,781 of SEQ ID NO:11.

- 4. An isolated nucleic acid molecule according to claim 1, wherein said nucleotide sequence is substantially similar to nucleotides 412-1665 of SEQ ID NO:1, nucleotides 1686-2447 of SEQ ID NO:1, nucleotides 2758-3318 of SEQ ID NO:1, nucleotides 3342-4118 of SEQ ID NO:1, or nucleotides 4515-9269 of SEQ ID NO:1.
- 5. An isolated nucleic acid molecule according to claim 1, wherein said nucleotide sequence encodes an amino acid sequence selected from the group consisting of SEQ ID NOs:2-6.
- 6. An isolated nucleic acid molecule according to claim 1, wherein said nucleotide sequence comprises nucleotides 412-1665 of SEQ ID NO:1, nucleotides 1686-2447 of SEQ ID NO:1, nucleotides 2758-3318 of SEQ ID NO:1, nucleotides 3342-4118 of SEQ ID NO:1, or nucleotides 4515-9269 of SEQ ID NO:1.
- 7. An isolated nucleic acid molecule according to claim 1, wherein said nucleotide sequence is substantially similar to nucleotides 15,171-18,035 or 31,393-35,838 of SEQ ID NO:11.
- 8. An isolated nucleic acid molecule according to claim 1, wherein said nucleotide sequence encodes the amino acid sequence set forth in SEQ ID NOs:12-14.
- 9. An isolated nucleic acid molecule according to claim 1, wherein said nucleotide sequence comprises nucleotides 15,171-18,035; 23,768-31,336; or 31,393-35,838 of SEQ ID NO:11.
- 10. An isolated nucleic acid molecule according to claim 2, comprising a 20 base pair nucleotide portion identical in sequence to a consecutive 20 base pair nucleotide portion of nucleotides 412-1665 of SEQ ID NO:1, nucleotides 1686-2447 of SEQ ID NO:1, nucleotides


WO 99/42589



2758-3318 of SEQ ID NO:1, nucleotides 3342-4118 of SEQ ID NO:1, or nucleotides 4515-9269 of SEQ ID NO:1.

- 11. An isolated nucleic acid molecule according to claim 2, comprising a 20 base pair nucleotide portion identical in sequence to a consecutive 20 base pair nucleotide portion of nucleotides 15,171-18,035 or 31,393-35,838 of SEQ ID NO:11.
- 12. A chimeric gene comprising a heterologous promoter sequence operatively linked to the nucleic acid molecule of claim 1 or claim 2.
- 13. A recombinant vector comprising the chimeric gene of claim 12.
- 14. A host cell comprising the chimeric gene of claim 12.
- 15. A host cell according to claim 14, which is a bacterial cell.
- 16. A host cell according to claim 14, which is a yeast cell.
- 17. A host cell according to claim 14, which is a plant cell.
- 18. A plant comprising the plant cell of claim 17.
- 19. A plant according to claim 18, which is maize.
- 20. A toxin produced by the expression of a DNA molecule according to claim 1 or claim 2.
- 21. A toxin according to claim 20, wherein said toxin has activity against Lepidopteran insects.
- 22. A toxin according to claim 21, wherein said toxin has activity against *Plutella xylostella* (Diamondback Moth), *Trichoplusia ni* (Cabbage Looper), *Ostrinia nubilalis* (European Corn Borer), *Heliothis virescens* (Tobacco Budworm), *Helicoverpa zea* (Corn Earworm), *Spodoptera exigua* (Beet Armyworm), and *Spodoptera frugiperda* (Fall Armyworm).

- 23. A toxin according to claim 20, wherein said toxin has activity against Lepidopteran and Coleopteran insects.
- 24. A toxin according to claim 23, wherein said toxin has insecticidal activity against Plutella xylostella (Diamondback Moth), Ostrinia nubilalis (European Corn Borer), and Manduca sexta (Tobacco Hornworm), Diabrotica virgifera virgifera (Western Corn Rootworm), Diabrotica undecimpunctata howardi (Southern Corn Rootworm), and Leptinotarsa decimlineata (Colorado Potato Beetle).
- 25. A toxin according to claim 20, wherein said toxin comprises an amino acid sequence selected from the group consisting of: SEQ ID NOs:2-6.
- 26. A toxin according to claim 20, wherein said toxin comprises an amino acid sequence selected from the group consisting of: SEQ ID NOs:12-14.
- 27. A composition comprising an insecticidally effective amount of a toxin according to claim 20.
- 28. A method of producing a toxin that is active against insects, comprising:
 - (a) obtaining the host cell of claim 14; and
 - (b) expressing the nucleic acid molecule in said cell, which results in at least one toxin that is active against insects.
- 29. A method of producing an insect-resistant plant, comprising introducing a nucleic acid molecule according to claim 1 into said plant, wherein said nucleic acid molecule is expressible in said plant in an effective amount to control insects.
- 30. A method of controlling insects comprising delivering to the insects an effective amount of a toxin according to claim 44.
- 31. The method of claim 29 or claim 30, wherein the insects are Lepidopteran insects.



- 33. The method of claim 29 or claim 30, wherein the insects are Lepidopteran and Coleopteran insects.
- 34. The method of claim 33, wherein the insects are selected from the group consisting of: Plutella xylostella (Diamondback Moth), Ostrinia nubilalis (European Corn Borer), and Manduca sexta (Tobacco Hornworm), Diabrotica virgifera virgifera (Western Corn Rootworm), Diabrotica undecimpunctata howardi (Southern Corn Rootworm), and Leptinotarsa decimlineata (Colorado Potato Beetle).
- 35. The method of claim 30, wherein the toxin is delivered to the insects orally.
- 36. A method for mutagenizing a nucleic acid molecule according to claim 1, wherein the nucleic acid molecule has been cleaved into population of double-stranded random fragments of a desired size, comprising:
 - (a) adding to the population of double-stranded random fragments one or more single- or double-stranded oligonucleotides, wherein said oligonucleotides each comprise an area of identity and an area of heterology to a doublestranded template polynucleotide;
 - (b) denaturing the resultant mixture of double-stranded random fragments and oligonucleotides into single-stranded fragments;
 - (c) incubating the resultant population of single-stranded fragments with a polymerase under conditions which result in the annealing of said single-stranded fragments at said areas of identity to form pairs of annealed fragments, said areas of identity being sufficient for one member of a pair to prime replication of the other, thereby forming a mutagenized double-stranded polynucleotide; and



(d) repeating the second and third steps for at least two further cycles, wherein the resultant mixture in the second step of a further cycle includes the mutagenized double-stranded polynucleotide from the third step of the previous cycle, and wherein the further cycle forms a further mutagenized double-stranded polynucleotide.

```
SEQUENCE LISTING
<110> Novartis AG
<120> Novel Toxins And Uses Thereof
<130> PI/5-30421/A/CGC 1963
<140>
<141>
<160> 22
<170> PatentIn Ver. 2.0
<210> 1
<211> 9717
<212> DNA
<213> Photorhabdus luminescens
 <220>
 <221> CDS
 <222> (412)..(1665)
 <223> orf1 ~46.4 kDa
 <220>
 <221> CDS
 <222> (1686)..(2447)
 <223> orf2 ~28.1kDa
 <220>
 <221> CDS
 <222> (2758)..(3318)
 <223> orf3 ~20.7 kDa
 <220>
 <221> CDS
 <222> (3342)..(4118)
  <223> orf4 ~28.7 kDa
  <220>
  <221> CDS
  <222> (4515)..(9269)
  <223> orf5 ~176 kDa
  <400> 1
  gaattcatat gctatgaaat aaacagttgg cgcaataatt aaagctatta tttttatttt 60
  gtttttatac aatgatatgc tttattaaac agaataatga gttaatgata aataaatcct 120
  cgggatttat catgatatta tggccgaatg tgatgtgaac aattatttta taattagatt 180
  aataatataa tggtattaaa ataacaatat atttattcat gggtatttat catcggtttt 240
  attacatggg gaataatcta taaattagtt ttacataatt cacaaatagc gattccatta 300
  accaggaata ttaaaaatac ttatttatga ttatggtgat atatcttcat tagcctactt 360
  ttataactag aaaaattgac attttcaatc catgtataaa tggtaaccaa t atg cag 417
                                                             Met Gln
                                                               1
   aga gct caa cga gtt gtt att aca ggt atg ggt gcc gta aca ccg att
   Arg Ala Gln Arg Val Val Ile Thr Gly Met Gly Ala Val Thr Pro Ile
```

15

								caa Gln								513
								gac Asp								561
				_				tcc Ser	_							609
								tgc Cys 75								657
								ttc Phe								705
								gly ggc								753
								cat His								801
								ctt Leu								849
acg Thr	gct Ala	gca Ala	tgt Cys 150	tcg Ser	att Ile	atg Met	tat Tyr	gga Gly 155	cta Leu	cgt Arg	ggt Gly	tat Tyr	caa Gln 160	aat Asn	acc Thr	897
gtt Val	atg Met	gct Ala 165	gcc Ala	tgc Cys	gca Ala	acg Thr	ggc Gly 170	aca Thr	atg Met	gcg Ala	ata Ile	ggc Gly 175	gat Asp	gcc Ala	ttt Phe	945
								aaa Lys								993
								att Ile								1041
gca Ala	tta Leu	tcg Ser	aaa Lys	gaa Glu 215	caa Gln	gcg Ala	gac Asp	cca Pro	aat Asn 220	ctt Leu	gca Ala	tgt Cys	tgt Cys	cca Pro 225	ttt Phe	1089
agc Ser	ctt Leu	gat Asp	cgc Arg 230	Ser	gga Gly	ttt Phe	gta Val	tta Leu 235	gcc Ala	gaa Glu	gga Gly	gcg Ala	gcg Ala 240	Val	gtt Val	1137
			Asn					atc Ile					Thr			1185
		Ile					Glr	tat Tyr				Val			acc Thr	1233



A	gg rg 75	cca Pro	a ac	a	gaa Glu	ga A	sp	att Ile 280	gaa Glu	CO P	ct ro	aaa Lys	at Il	Le .	tta Leu 285	gc	ga al	ata [le	ac Th	t a	aaa Lys	gc Al 29	a	128	l.
a	itt :le	gaq Glu	g ca u Gi	ag ln	gca Ala	a G	ag ln 95	att Ile	tcg Ser	g Co	cg ro	aaa Lys	As	at sp	att Ile	ga As	c t	tac Iyr	at Il	e A	aat Asn 305	gc Al	t a	132	9
E	at Iis	gg Gl	t a y T	ct hr	tct Set	r T	ca hr	ccg Pro	tta Lei	a a ı A	at sn	gat Asp 315	L	tt eu	tat Tyr	ga Gl	a a .u '	act Thr	ca Gl 32	n 4	gca Ala	at Il	.t .e	137	7
]	aaa Lys	gc Al	a A	ca la 25	ct	g g u G	gc Sly	caa Glr	ta Ty	r A	ct la 30	tat Tyr	c G	ag ln	gta Val	. Pr	0	ata Ile 335	Se	a er	agc Ser	ac Th	a r	142	5
	aaa Lys	tc Se 34	r I	at 'yr	ac Th	c ç r (ggc 31y	cac His	ct Le 34	u I	itt [le	gct Ala	2 g a A	icc La	gco	ı G.	gt ly 50	agt Ser	tt Pl	t ne	gaa Glu	ac T1	eg nr	147	73
	att Ile 355	Va	a t	gt Ys	gt Va	g a	aaa Lys	gca Ala 360	a Le	a g eu <i>I</i>	yct Ala	ga: Gl:	a a u A	at Asn	tgo Cy: 36!	s L	tg eu	cca Pro	ago A	ca la	aca Thr	· L	tg eu 70	152	21
	aat Asr	tt Le	ca d eu I	cac	: Cg	g,	gcc Ala 375	ga Asj	t co p Pr	a q	gat Asp	tg Cy	s A	gat Asp 380	ct Le	c a u A	at sn	tai Ty	t r L	tg eu	Pro 385	A	at sn	15	69
	caa Glr	a ca n H	at is (tgc Cys	T	ac /r 90	acc Thr	gc Al	t ca a G	aa (ln	cca Pro	ga Gl 39	u '	gtg Val	ac Th	a c r L	tc eu	aa As	n I	tt le 00	ago Se:	c g r A	ca la	16	17
	ggt Gly	t t y P	he	gg(Gl ₎ 40:	/ G	gg Ly	cat His	: aa : As	n A	la	gcg Ala 410	ı Le	g (eu '	gtt Val	at Il	c g e A	jct Ma	aa Ly 41	s /	rta 7al	ag Ar	g t	aa	16	65
	ct	gat	atg	tt	ga	ttt	ttç	gca	atg Met	ga Gl 42	\mathbf{u}	gat Asp	at Il	t c	gaa Slu	cat His	3 T	gg rp 25	tcg Sei	g a	at sn	tto Phe	tc e Se	t 17 r	'18
	gg Gl 43	y P	at Sp	tt Ph	t a e A	ac sn	cc Pr	c at o II 43	le H	at lis	ta: Ty:	t to r Se	eg er	gcg Ala	a Li	aa a /s : 10	agc Ser	ga G]	ıg (tct Ser	tt Le	eu A	ege Arg 445	17	766
	aa As	it a m I	ata [le	ca Gl	g c n C	ln	Hi	c co s P: 0	ro ۱	/al	Gl	n G	ly.	Me	tĿ	eu ∶	Sei	c Le	eu.	Leu	ta 1 Ty 46	nr i	gta Val	18	314
	CÇ Aı	g (caa Gln	ca Gl	n I	tt Phe 165	Se	t c	aa t ln I	ta Leu	ac Th	ur S	cc er 70	gc Al	t t a P	tt he	aca Thi	a ao	nr	gga Gly 479	γI.	a le	ttg Leu	1	862
	aa As	ac a	att Ile	As	at g sp 2 30	gcc Ala	to Se	t t er P	tc (cgc Arg	Gl 48	n T	at 'yr	gt Va	t t 1 T	at yr	aco Th	r A	ca la 90	tt: Le	a co u P:	ro	cat His	1	910
	G.	ln	ctg Leu 495	. Aı	gg i	att Ile	: aa : As	at a sn I	hr	aaa Lys 500	: As	ac a an I	aa .ys	ac Tr	g t r F	tt he	aa Ly 50	s L	ta eu	ga Gl	aa uA	at sn	ccc Pro	1	.958
	S	gt er 10	aaa Lys	gi G	aa lu	aac Asr	ac n Th	ır I	eu Eu	ttc Phe	gg G	gc a ly <i>l</i>	aat Asn	ac Th	ur S	igc Ser 520	gt Va	a g 1 G	ag lu	aa As	t a n T	ca hr	atg Met 525		2006
	g	ag	tca	a	tt	gaa	a g	at t	gg	atc	g	tt (cag	ga	at a	at	tg	rt c	aa	aa	a c	ta	acc	г 2	2054

.3.

Glu S	er	Ile	Glu	Asp 530	Trp	Ile	Val	Gln	Asp 535	Asn	Cys	Gln	Lys	Leu 540	Thr	
ata a Ile T	ica Thr	Gly ggg	gag Glu 545	gaa Glu	gtt Val	tgt Cys	gaa Glu	aag Lys 550	tat Tyr	gct Ala	gtc Val	ttt Phe	aga Arg 555	tac Tyr	tat Tyr	2102
ttc c Phe P																2150
cat c His L 5																2198
ttt a Phe A 590																2246
ggg c	aa Sln	gcg Ala	att Ile	aaa Lys 610	atc Ile	agg Arg	aag Lys	gag Glu	att Ile 615	gtt Val	aat Asn	agt Ser	aca Thr	gta Val 620	tta Leu	2294
tta t Leu S	ct Ser	tca Ser	ccg Pro 625	gat Asp	atc Ile	tgt Cys	gtt Val	gaa Glu 630	tta Leu	aat Asn	cct Pro	cct Pro	tta Leu 635	ttg Leu	att Ile	2342
aag a Lys A	at Isn	ggc Gly 640	gat. Asp	aaa Lys	gat Asp	tat Tyr	att Ile 645	cgt Arg	att Ile	ttc Phe	tat Tyr	tat Tyr 650	cga Arg	tgt Cys	tta Leu	2390
tat g Tyr A 6	gat Asp 555	aaa Lys	aaa Lys	cct Pro	att Ile	ttt Phe 660	gta Val	tca Ser	aag Lys	act Thr	tca Ser 665	att Ile	atc Ile	tct Ser	aag Lys	2438
atg a Met L 670		taa	aag	gaaaq	gcg a	aatq	gccaa	ac ad	caaaq	gtgai	t at	tttc	actg			2487
aaata	aaag	gaa t	taga	atati	ta at	gat	gaag	g ata	ataga	aaga	tga	agaa	ata a	acac	cagagt	2547
cctct	ttt	gt 1	ttcg	cttga	aa t	tgai	tagto	c ttg	gact	atgt	gga	aatc	caa q	gttt	ttgtgt	2607
tggaa	agco	gta 1	tggta	attg	tg ct	taa	agcc	gaad	cttt	tttc	aaa	tcat	tct a	attt	caacat	2667
taaat	tgaç	gct (cact	gact	at t	caạaa	atca	a aat	tgt	aatc	tga	attt	tta (ctta	attatg	2727
tttt	ttca	acc a	atta	acati	ta ag	gaggi	ttat	a ato	gaa LAsı	c gt n Vai 67	l Le	a ga u Gli	a ca: u Gli	a gg n Gly	t aag y Lys 680	2781
gtt g Val A	gct Ala	gct Ala	tta Leu	tat Tyr 685	tca Ser	gcc Ala	tat Tyr	tcg Ser	gaa Glu 690	aca Thr	gaa Glu	ggt Gly	tct Ser	tcg Ser 695	tgg Trp	2829
gtg g Val G	gga Gly	aac Asn	ttg Leu 700	tgc Cys	tgt Cys	ttt Phe	tca Ser	agt Ser 705	gat Asp	cgg Arg	gag Glu	cat His	ttg Leu 710	cct Pro	att Ile	2877
atc g Ile V	gtg Val	aat Asn 715	ggg Gly	cgt Arg	cgt Arg	ttc Phe	ttg Leu 720	att Ile	gaa Glu	ttt Phe	gtt Val	att Ile 725	cca Pro	gat Asp	cat His	2925
tta c Leu L	ctt Leu	gat Asp	aaa Lys	acg Thr	gtt Val	aaa Lys	ccc Pro	aga Arg	gta Val	ttc Phe	gat Asp	ttg Leu	gat Asp	atc Ile	aat Asn	2973




730	735	740		
aaa caa ttt tta ctg cgt Lys Gln Phe Leu Leu Arg 745 750	Arg Asp His	cgt gag ata Arg Glu Ile 755	aat att tat ctt Asn Ile Tyr Leu 760	3021
tta ggt gaa gga aat ttt Leu Gly Glu Gly Asn Phe 765	atg gat agg Met Asp Arg	acg acg aca Thr Thr Thr 770	gat aaa aat cta Asp Lys Asn Leu 775	3069
ttc gag tta aat gag gat Phe Glu Leu Asn Glu Asp 780	ggt tca cta Gly Ser Leu 785	ttt att aag Phe Ile Lys	acg tta cgc cat Thr Leu Arg His 790	3117
gct ctt ggt aaa tat gt! Ala Leu Gly Lys Tyr Va: 795	gct att aat l Ala Ile Asn 800	cct tca act Pro Ser Thr	acg caa ttt atc Thr Gln Phe Ile 805	3165
ttc ttt gca caa gga aa Phe Phe Ala Gln Gly Ly 810	g tac agt gaa s Tyr Ser Glu 815	ttt atc atg Phe Ile Met 820	Asn Ala Leu Lys	3213
aca gtt gaa gac gaa tt Thr Val Glu Asp Glu Le 825 83	u Ser Lys Arg	tat cga gtc g Tyr Arg Val 835	aga att att cct Arg Ile Ile Pro 840	3261
gaa ttg caa ggg ccg ta Glu Leu Gln Gly Pro Ty 845	at tat ggc tti r Tyr Gly Phe	t gaa ctt gat e Glu Leu Asg 850	att ctt tct att o Ile Leu Ser Ile 855	3309
aca gct taa ttcacaatat Thr Ala	tatggagagt (gtt atg gaa a Met Glu I 860	aag aaa ata aca ac Lys Lys Ile Thr Th 865	a 3362 m
ttt acc att gag aaa ac Phe Thr Ile Glu Lys T 870	ct gat gac aa nr Asp Asp As 87	n Phe Tyr Ali	t aat ggg cgt cat a Asn Gly Arg His 880	3410
caa tgt atg gta aaa a Gln Cys Met Val Lys I 885	tc tct gta ct le Ser Val Le 890	t aaa caa ga eu Lys Gln Gl	a tat agg aat ggt u Tyr Arg Asn Gly 895	3,458
gat tgg ata aaa tta g Asp Trp Ile Lys Leu A 900	ca ctt agt ga la Leu Ser Gl 905	ag gct gaa aa lu Ala Glu Ly 91	s Arg Ser lie Gin	3506
gtg gcg gca tta agt g Val Ala Ala Leu Ser A 915	at agc ctc a sp Ser Leu I 220	ta tat gac ca le Tyr Asp Gl 925	aa tta aaa atg cct In Leu Lys Met Pro 930)
tca ggt tgg aca acg a Ser Gly Trp Thr Thr 1 935	aca gat gca a Thr Asp Ala A	ga aat aaa ti rg Asn Lys Pl 940	tt gat ctt ggg tta he Asp Leu Gly Leu 945	3602
tta aat ggt gtt tat o Leu Asn Gly Val Tyr i 950	His Ala Asp A	ct ttt att ga la Phe Ile A 55	ac gaa cag gta aca sp Glu Gln Val Th 960	a 3650
gat cgt gcg gga gat Asp Arg Ala Gly Asp 965	tgc tgc aca a Cys Cys Thr A 970	uat gaa aac t usn Glu Asn T	at cag aac agt gte yr Gln Asn Ser Va 975	g 3698 1
aaa agt gtt cct gaa Lys Ser Val Pro Glu 980	att atc tat o Ile Ile Tyr <i>P</i> 985	arg Tyr Val S	igt agt aat aga ac Ser Ser Asn Arg Th 190	a 3746 r

agc aca gaa tac cta atg gca aaa atg aca ttt gaa gat acg gat ggg Ser Thr Glu Tyr Leu Met Ala Lys Met Thr Phe Glu Asp Thr Asp Gly 995 1000 1005 1010	3794
aaa cgc aca tta aca acg aat atg tca gtt ggt gat gaa gtt ttt gac Lys Arg Thr Leu Thr Thr Asn Met Ser Val Gly Asp Glu Val Phe Asp 1015 1020 1025	3842
agc aag gtt tta tta aaa gcc att gct cct tat gca att aat aca aat Ser Lys Val Leu Leu Lys Ala Ile Ala Pro Tyr Ala Ile Asn Thr Asn 1030 1035 1040	3890
caa ttg cat gaa aac atc aat aca ttg ttt gat aaa aca gaa gag ccg Gln Leu His Glu Asn Ile Asn Thr Leu Phe Asp Lys Thr Glu Glu Pro 1045 1050 1055	3938
aca aaa tcc gat act cat cat caa ata att aat ctt tat cgc tgg aca Thr Lys Ser Asp Thr His His Gln Ile Ile Asn Leu Tyr Arg Trp Thr 1060 1065 1070	3986
ttg cca tat cat ttg agg att ctt gaa ggg aat gac agt act gtt aat Leu Pro Tyr His Leu Arg Ile Leu Glu Gly Asn Asp Ser Thr Val Asn 1075 1080 1085 1090	4034
aga ata tat gtc ctt ggt aaa gag cca tca aat gat aga ttc ctg aca Arg Ile Tyr Val Leu Gly Lys Glu Pro Ser Asn Asp Arg Phe Leu Thr 1095 1100 1105	4082
aga gga agg gta ttt aaa cga gga act cat atg tga atgcacgtga Arg Gly Arg Val Phe Lys Arg Gly Thr His Met 1110 1115	4128
taatgtgagt ggaggatgtg ttatggacta tgcttatacc gtaactattc cggacacgca	4188
gcttgctgct gaagtgcttc atgtgacagg gtgttcgtgg acgagtggtt attatgatgg	4248
atatcatgat gtcacaatca ttgataacta cggttgtcag cataaattta gaatttcttc	4308
ggttaatatt ggacgtgcgc taagcatagc gagaataagt tgattttcct tagtaaaaaa	4368
cetttgttta tgetggtaaa egeatgtgeg tttgeeagea attaatatat teeattattg	4428
aaataggaat atagccatat etgtaattat acataaacga atttttaete gaatataatt	4488
ttaattgatc aaacaggaaa tttaaa atg aaa gct acc gat ata tat tcc aat Met Lys Ala Thr Asp Ile Tyr Ser Asn 1120 1125	4541
get tit aat tie ggt tet tat att aat act ggt gte gat eee aga aca Ala Phe Asn Phe Gly Ser Tyr Ile Asn Thr Gly Val Asp Pro Arg Thr 1130 1135 1140	4589
ggt caa tat agt gca aat att aat att atc acg tta aga cct aat aat Gly Gln Tyr Ser Ala Asn Ile Asn Ile Ile Thr Leu Arg Pro Asn Asn 1145 1150 1155	4637
gtg ggt aat tcg gaa caa aca ttg agc cta tca ttc tcg cca tta aca Val Gly Asn Ser Glu Gln Thr Leu Ser Leu Ser Phe Ser Pro Leu Thr 1160 1165 1170 1175	4685
acg tta aac aat ggc ttt ggt att ggc tgg cgc ttt tca tta aca aca Thr Leu Asn Asn Gly Phe Gly Ile Gly Trp Arg Phe Ser Leu Thr Thr 1180 1185 1190	4733




Leu Asp Ile Lys Thr Leu Thr Phe Ser Arg Ala Asn Gly Glu Gln Phe 1195 1200 1205	781
aaa tgt aag cca ttg ccg cct aat aat gat ctt agt ttt aaa gat 49 Lys Cys Lys Pro Leu Pro Pro Asn Asn Asn Asp Leu Ser Phe Lys Asp 1210 1215 1220	829
aaa aaa cta aaa gat ttg cgc gta tat aag ctc gat agc aat act ttt 4 Lys Lys Leu Lys Asp Leu Arg Val Tyr Lys Leu Asp Ser Asn Thr Phe 1225 1230 1235	.877
tat gtt tat aac aaa aac ggc att ata gag ata ctt aaa cga att ggg 4 Tyr Val Tyr Asn Lys Asn Gly Ile Ile Glu Ile Leu Lys Arg Ile Gly 1240 1245 1250 1255	1925
tcg agt gat att gca aaa aca gtt gca ctt gaa ttt cct gat ggt gaa 4 Ser Ser Asp Ile Ala Lys Thr Val Ala Leu Glu Phe Pro Asp Gly Glu 1260 1265 1270	1973
gca ttt gat tta att tat aat tca aga ttt gca ttg tcc gaa ata aaa s Ala Phe Asp Leu Ile Tyr Asn Ser Arg Phe Ala Leu Ser Glu Ile Lys 1275 1280 1285	5021
tac cgt gtg aca ggt aaa act tat ctt aaa ctc aat tac tct gga aat Tyr Arg Val Thr Gly Lys Thr Tyr Leu Lys Leu Asn Tyr Ser Gly Asn 1290 1295 1300	5069
aac tgt aca tca gtg gaa tac cct gat gat aat aat att tct gcg aaa Asn Cys Thr Ser Val Glu Tyr Pro Asp Asp Asn Asn Ile Ser Ala Lys 1305 1310 1315	5117
ata gca ttc gat tat cgt aac gat tac ctt att acg gtg act gta cct Ile Ala Phe Asp Tyr Arg Asn Asp Tyr Leu Ile Thr Val Thr Val Pro 1320 1325 1330 1335	5165
tac gat gct tct ggt cct att gat tct gcc cga ttt aag atg acc tat Tyr Asp Ala Ser Gly Pro Ile Asp Ser Ala Arg Phe Lys Met Thr Tyr 1340 1345 1350	5213
cag aca tta aaa ggc gta ttt cca gtt atc agc acc ttc cgt aca cca Gln Thr Leu Lys Gly Val Phe Pro Val Ile Ser Thr Phe Arg Thr Pro 1355 1360 1365	5261
acc ggt tat gtt gag ctg gtg agt tat aaa gag aat ggg cat aaa gtg Thr Gly Tyr Val Glu Leu Val Ser Tyr Lys Glu Asn Gly His Lys Val 1370 1375 1380	5309
acg gac acg gaa tat att cct tat gcg gct gca ctc act att caa ccc Thr Asp Thr Glu Tyr Ile Pro Tyr Ala Ala Ala Leu Thr Ile Gln Pro 1385 1390 1395	5357
ggc aat gga caa cct gcg gtc agc aaa tcc tat gaa tat agt tca gta Gly Asn Gly Gln Pro Ala Val Ser Lys Ser Tyr Glu Tyr Ser Ser Val 1400 1405 1410 1415	5405
cat aac ttc ttg ggc tat tct tct ggc cgg aca agc ttt gat tcc agt His Asn Phe Leu Gly Tyr Ser Ser Gly Arg Thr Ser Phe Asp Ser Ser 1420 1425 1430	5453
caa gat aat ttg tat ttg gtc aca ggg aaa tac act tat tca tcc att Gln Asp Asn Leu Tyr Leu Val Thr Gly Lys Tyr Thr Tyr Ser Ser Ile 1435 1440 1445	5501
gaa cgg gtt tta gat ggt caa agt gtg gtt tca gta ata gaa cga gta	5549

Ÿ





1705	1710	1715		
ccc ggc Pro Gly 1720	acg gca aga gaa att a Thr Ala Arg Glu Ile L 1725	aa cgt aat tac gtt tat ys Arg Asn Tyr Val Tyr 1730	caa tat ccc Gln Tyr Pro 1735	6365
ggc ggt Gly Gly	gac gaa aat gat ttt t Asp Glu Asn Asp Phe 1 1740	gg ccg gtg atg ata gaa rp Pro Val Met Ile Glu 1745	gtt gat tet Val Asp Ser 1750	6413
caa ggc Gln Gly	gtc aga cgt aaa acc c Val Arg Arg Lys Thr I 1755	eat tac gat gga atg gga His Tyr Asp Gly Met Gly 1760	cgt att tgt Arg Ile Cys 1765	6461
tcg att Ser Ile	Glu Glu Gln Asp Asp A	gat ggc gcc tgg ggc aca Asp Gly Ala Trp Gly Thr 775 1780	tcg ggg att Ser Gly Ile	6509
tat caa Tyr Glr 1785	Gly Thr Tyr Arg Lys	gtt ctt gcc aga caa tat Val Leu Ala Arg Gln Tyr 1795	gat gtt ttg Asp Val Leu	6557
ggg caq Gly Glr 1800	g ttg agc aag gaa att n Leu Ser Lys Glu Ile 1805	tca aat gat tgg tta tgg Ser Asn Asp Trp Leu Tr 1810	aat tta tct Asn Leu Ser 1815	6605
gcc aat Ala Asi	c cet ttg gtt cgt ett n Pro Leu Val Arg Leu 1820	gct acc ccg ttg gtt aca Ala Thr Pro Leu Val Thr 1825	a acg aaa acc Thr Lys Thr 1830	6653
tat aa Tyr Ly	a tat gat ggt tgg gga s Tyr Asp Gly Trp Gly 1835	aat ctt tac agc acg ga Asn Leu Tyr Ser Thr Gl 1840	a tac agt gat u Tyr Ser Asp 1845	6701
ggt cg Gly Ar	g Ile Glu Leu Glu Ile	cat gat cct att acg ag His Asp Pro Ile Thr Ar 1855 186	g inr lie inr	6749
caa gg Gln Gl 186	y Val Lys Gly Leu Gly	atg tta aat att cag ca Met Leu Asn Ile Gln Gl 1875	a aat aat ttt n Asn Asn Phe	6797
gag ca Glu G 1880	na ccg gct tcg atc aaa In Pro Ala Ser Ile Lys 1885	gct gtg tat cct gat gg Ala Val Tyr Pro Asp Gl 1890	nt acg ata tat Ly Thr Ile Tyr 1895	6845
agc a Ser T	ec egt act tat egt tat or Arg Thr Tyr Arg Tyn 1900	gat gga ttt ggt cgt ac Asp Gly Phe Gly Arg T 1905	ca gtg acg gaa nr Val Thr Glu 1910	6893
aca g Thr A	at gca gaa ggt cat gc sp Ala Glu Gly His Ala 1915	t acc caa att gga tat g a Thr Gln Ile Gly Tyr A 1920	at gtg ttt gat sp Val Phe Asp 1925	6941
cgt a Arg I	ta gtg aaa aaa acg tt le Val Lys Lys Thr Le 1930	g cca gac gga aca ata t u Pro Asp Gly Thr Ile L 1935 19	ta gaa tcc gct eu Glu Ser Ala 40	6989
Tyr A	ca agc ttt agc cat ga la Ser Phe Ser His Gl 145 195	a gaa tta att tcg gca c u Glu Leu Ile Ser Ala I 0 1955	tg aac gtg aat eu Asn Val Asn	7037
ggc a Gly 1 1960	aca cag ttg ggg gca tt Thr Gln Leu Gly Ala Le 1965	a gtt tat gat ggt ctt q au Val Tyr Asp Gly Leu (1970	ggg cgg gta ata Gly Arg Val Ile 1975	



att aag cgg ctc gat aat aca tat cga gat ggt aag gaa acg gtg gat 7901 Ile Lys Arg Leu Asp Asn Thr Tyr Arg Asp Gly Lys Glu Thr Val Asp 2235 2240 2245
tat cat ttc agt caa gcc gat cca act caa ctt att cgt att acc agc 7949 Tyr His Phe Ser Gln Ala Asp Pro Thr Gln Leu Ile Arg Ile Thr Ser 2250 2255 2260
gac aaa cag cag ata gag tta agt tat gat gct aat ggc aac cta aca 7997 Asp Lys Gln Gln Ile Glu Leu Ser Tyr Asp Ala Asn Gly Asn Leu Thr 2265 2270 2275
cgt gac gaa aaa ggg caa acg ctc att tac gat cag aat aat cgc ttg 8045 Arg Asp Glu Lys Gly Gln Thr Leu Ile Tyr Asp Gln Asn Asn Arg Leu 2280 2285 2290 2295
gta cag gtc aaa gac cgg ttg ggc aat ctg gtg tgc agc tac cag tat 8093 Val Gln Val Lys Asp Arg Leu Gly Asn Leu Val Cys Ser Tyr Gln Tyr 2300 2305 2310
gat gca ttg aac aaa tta acc gca cag gtt ttg gcg aat ggt acc gtt 8141 Asp Ala Leu Asn Lys Leu Thr Ala Gln Val Leu Ala Asn Gly Thr Val 2315 2320 2325
aat cga cag cat tat gct tcc ggt aaa gtg acg aat att caa ttg ggt 8189 Asn Arg Gln His Tyr Ala Ser Gly Lys Val Thr Asn Ile Gln Leu Gly 2330 2335 2340
gat gaa gcg att act tgg ttg agc agt gat aag caa cga att gga cat 8237 Asp Glu Ala Ile Thr Trp Leu Ser Ser Asp Lys Gln Arg Ile Gly His 2345 2350 2355
caa agc gcc aag aat ggt caa tca gtc tac tat caa tat ggt att gac 8285 Gln Ser Ala Lys Asn Gly Gln Ser Val Tyr Tyr Gln Tyr Gly Ile Asp 2360 2365 2370 2375
cat aac agt acg gtt atc gcc agt cag aac gaa aac gag ttg atg gct 8333 His Asn Ser Thr Val Ile Ala Ser Gln Asn Glu Asn Glu Leu Met Ala 2380 2385 2390
tta tcc tat aca cct tat ggc ttt agg agt tta att tcc tca tta ccg 8381 Leu Ser Tyr Thr Pro Tyr Gly Phe Arg Ser Leu Ile Ser Ser Leu Pro 2395 2400 2405
ggt ttg aat ggc gca cag gtt gat cca gta aca ggc tgg tac ttc tta 8429 Gly Leu Asn Gly Ala Gln Val Asp Pro Val Thr Gly Trp Tyr Phe Leu 2410 2415 2420
ggt aac gga tat cgt gtt ttc aac ccg gtt ctc atg agg ttt cac agc 8477 Gly Asn Gly Tyr Arg Val Phe Asn Pro Val Leu Met Arg Phe His Ser 2425 2430 2435
ccc gat agt tgg agt cct ttt ggt cgg gga ggg att aac cct tat acc 8525 Pro Asp Ser Trp Ser Pro Phe Gly Arg Gly Gly Ile Asn Pro Tyr Thr 2440 2445 2450 2455
tat tgc caa ggc gat ccc ata aac cgg att gat ctg aac ggt cat ctt 8573 Tyr Cys Gln Gly Asp Pro Ile Asn Arg Ile Asp Leu Asn Gly His Leu 2460 2465 2470
agt gcc ggc ggg ata tta ggc att gtg cta ggg gca att ggc atc att 8621 Ser Ala Gly Gly Ile Leu Gly Ile Val Leu Gly Ala Ile Gly Ile Ile 2475 2480 2485
gtc ggg att gta tca ctg gga gcc gga gcg gcg att agc gcg ggt ctc 8669

Val Gly Ile Val Ser Leu Gly Ala Gly Ala Ala Ile Ser Ala Gly Leu 2490 2495 2500	
att get geg ggg gge get ttg ggg geg att get tet ace age geg ett Ile Ala Ala Gly Gly Ala Leu Gly Ala Ile Ala Ser Thr Ser Ala Leu 2505 2510 2515	17
gca gtt act gcg act gtc att gga ttg gct gcc gat tcg ata ggg att Ala Val Thr Ala Thr Val Ile Gly Leu Ala Ala Asp Ser Ile Gly Ile 2520 2535 2530 2535	55
gcg tca gca gca tta tcg gaa aaa gat ccg aaa aca tct ggg ata tta 881 Ala Ser Ala Ala Leu Ser Glu Lys Asp Pro Lys Thr Ser Gly Ile Leu 2540 2545 2550	13
aat tgg att agt gcg gga ttg ggg gtt tta agc ttt ggt atc agc gca 886 Asn Trp Ile Ser Ala Gly Leu Gly Val Leu Ser Phe Gly Ile Ser Ala 2555 2560 2565	61
ata acc ttt acc tct tcg ctg gta aaa tcg gca cgg agt ggt tct cag Ile Thr Phe Thr Ser Ser Leu Val Lys Ser Ala Arg Ser Gly Ser Gln 2570 2575 2580	09
gca gtc agc gcg ggt gtt atc ggg tca gtg cct ctt gaa ttt ggt gaa 899 Ala Val Ser Ala Gly Val Ile Gly Ser Val Pro Leu Glu Phe Gly Glu 2585 2590 2595	57
gtt gct agc cgt tcc agc aga cga tgg gat att gcg tta tct tcg ata Val Ala Ser Arg Ser Ser Arg Arg Trp Asp Ile Ala Leu Ser Ser Ile 2600 2605 2610 2615	05
tcg ttg ggc gca aat gcg gcg tct ctc tct acg ggg ata gcg gcg gcg Ser Leu Gly Ala Asn Ala Ala Ser Leu Ser Thr Gly Ile Ala Ala Ala 2620 2625 2630	53
gcg gtt gca gac agt aat gcg aat gca gct aat att ctg gga tgg gta Ala Val Ala Asp Ser Asn Ala Asn Ala Ala Asn Ile Leu Gly Trp Val 2635 2640 2645	.01
tcc ttt ggt ttt ggt gca gta tcg aca acc tca gga ata att gag ctt 91. Ser Phe Gly Phe Gly Ala Val Ser Thr Thr Ser Gly Ile Ile Glu Leu 2650 2655 2660	.49
acg cgt aca gct tat gca gtg aat cat cag act tgg gaa ctg agt tca 91 Thr Arg Thr Ala Tyr Ala Val Asn His Gln Thr Trp Glu Leu Ser Ser 2665 2670 2675	.97
tca gca ggt act tcg gag gaa gtg aag cct ata cgt tgt ctc gtt tca 92 Ser Ala Gly Thr Ser Glu Glu Val Lys Pro Ile Arg Cys Leu Val Ser 2680 2685 2690 2695	245
cac cgc tgg aat cag aag cag tga atgttaaccc tcctcgggca gttgagttaa 92 His Arg Trp Asn Gln Lys Gln 2700	299
tcaaacgttt cgaaatagta ccgggaacta tttagccaat cgtccattga aacccgtaat 93	359
gtgttgcgac gtcgtttgac aatataaaga ttctgcgaac cgattggtta agtctcacga 94	119
aaaataacta ttaggcgaca tttgcgtcgc cttttttaag gaactttatc aggttacatt 94	179
tataagaagc tattttgttt tcgacggatg ttggtttctc tgagataaaa aatagaggga 95	539
aatgatgtca agggtgataa tggttaattg taaaatatgt gatattattc gcatttatat 95	599



<210> 2 <211> 417 <212> PRT

<213> Photorhabdus luminescens

<400> 2

Met Gln Arg Ala Gln Arg Val Val Ile Thr Gly Met Gly Ala Val Thr $1 \hspace{1cm} 5 \hspace{1cm} 10 \hspace{1cm} 15$

Pro Ile Gly Glu Asp Val Glu Ser Cys Trp Gln Ser Ile Ile Glu Lys 20 25 30

Gln His Arg Phe His Arg Ile Glu Phe Pro Asp Ser Phe Ile Asn Ser 35 40 45

Arg Phe Phe Ser Phe Leu Ala Pro Asn Pro Ser Arg Tyr Gln Leu Leu 50 55 60

Pro Lys Lys Leu Thr His Thr Leu Ser Asp Cys Gly Lys Ala Ala Leu 65 70 75 80

Lys Ala Thr Tyr Gln Ala Phe Thr Gln Ala Phe Gly Val Asn Ile Ser 85 90 95

Pro Val Glu Tyr Tyr Asp Lys Tyr Glu Cys Gly Val Ile Leu Gly Ser 100 105 110

Gly Trp Gly Ala Ile Asp Asn Ala Gly Asp His Ala Cys Gln Tyr Lys 115 120 125

Gln Ala Lys Leu Ala His Pro Met Ser Asn Leu Ile Thr Met Pro Ser 130 135 140

Ser Met Thr Ala Ala Cys Ser Ile Met Tyr Gly Leu Arg Gly Tyr Gln 145 150 155 160

Asn Thr Val Met Ala Ala Cys Ala Thr Gly Thr Met Ala Ile Gly Asp 165 170 175

Ala Phe Glu Ile Ile Arg Ser Gly Arg Ala Lys Cys Met Ile Ala Gly 180 185 190

Ala Ala Glu Ser Leu Thr Arg Glu Cys Asn Ile Trp Ser Ile Asp Val 195 200 205

Leu Asn Ala Leu Ser Lys Glu Gln Ala Asp Pro Asn Leu Ala Cys Cys 210 215 220

Pro Phe Ser Leu Asp Arg Ser Gly Phe Val Leu Ala Glu Gly Ala Ala 225 230 235 240

Val Val Cys Leu Glu Asn Tyr Asp Ser Ala Ile Ala Arg Gly Ala Thr 245 250 255

Ile Leu Ala Glu Ile Lys Gly Tyr Ala Gln Tyr Ser Asp Ala Val Asn 260 265 270

Leu Thr Arg Pro Thr Glu Asp Ile Glu Pro Lys Ile Leu Ala Ile Thr 275 280 285

Lys	Ala 290	Ile	Glu	Gln	Ala	Gln 295	Ile	Ser	Pro	Lys	Asp 300	Ile	Asp	Tyr	Ile
Asn 305	Ala	His	Gly	Thr	Ser 310	Thr	Pro	Leu	Asn	Asp 315	Leu	Tyr	Glu	Thr	Gln 320
Ala	Ile	Lys	Ala	Ala 325	Leu	Gly	Gln	Tyr	Ala 330	Tyr	Gln	Val	Pro	Ile 335	Ser
Ser	Thr	Lys	Ser 340	Tyr	Thr	Gly	His	Leu 345	Ile	Ala	Ala	Ala	Gly 350	Ser	Phe
Glu	Thr	Ile 355	Val	Cys	Val	Lys	Ala 360	Leu	Ala	Glu	Asn	Cys 365	Leu	Pro	Ala
Thr	Leu 370	Asn	Leu	His	Arg	Ala 375	Asp	Pro	Asp	Cys	Asp 380	Leu	Asn	Tyr	Leu
Pro 385	Asn	Gln	His	Cys	Tyr 390	Thr	Ala	Gln	Pro	Glu 395	Val	Thr	Leu	Asn	Ile 400
Ser	Ala	Gly	Phe	Gly 405	Gly	His	Asn	Ala	Ala 410	Leu	Val	Ile	Ala	Lys 415	Val
Arg															
<213 <212)> 3 l> 29 2> PF 3> Pf	T S	rhabo	dus I	Lumii	nesc	ens								
	O> 3 Glu	Asp	Ile	Glu 5	His	Trp	Ser	Asn	Phe 10	Ser	Gly	Asp	Phe	Asn 15	Pro
Ile	His	Tyr	Ser 20	Ala	Lys	Ser	Glu	Ser 25	Leu	Arg	Asn	Ile	Gln 30	Gln	His
Pro	Val	Gln 35	Gly	Met	Leu	Ser	Leu 40	Leu	Tyr	Val	Arg	Gln 45	Gln	Phe	Ser
Gln	Leu 50	Thr	Ser	Ala	Phe	Thr 55	Thr	Gly	Ile	Leu	Asn 60	Ile	Asp	Ala	Ser
Phe 65	Arg	Gln	Tyr	Val	Туг 70	Thr	Ala	Leu	Pro	His 75	Gln	Leu	Arg	Ile	Asn 80
Thr	Lys	Asn	Lys	Thr 85		Lys	Leu	Glu	Asn 90	Pro	Ser	Lys	Glu	Asn 95	Thr
Leu	Phe	Gly	Asn 100	Thr	Ser	Val	Glu	Asn 105	Thr	Met	Glu	Ser	Ile 110	Glu	Asp
Trp	Ile	Val 115		Asp	Asn	Cys	Gln 120		Leu	Thr	Ile	Thr 125	Gly	Glu	Glu
Val	Cys 130	Glu	Lys	Tyr	Ala	Val 135		Arg	Tyr	Tyr	Phe 140	Pro	Ser	Val	Thr
Ser 145	Ile	Gly	Trp	Phe	Leu 150		Ala	Leu	Ala	Phe 155		Leu	Ile	Ile	Asn 160
Ser	Thr	Gly	Phe	Leu 165		Phe	Glu	His	Tyr 170		Phe	Asn	Gln	Leu 175	Glm

Asp Tyr Leu Ser Gln Ser Phe Thr Leu His Thr Gly Gln Ala Ile Lys 180 185 190

Ile Arg Lys Glu Ile Val Asn Ser Thr Val Leu Leu Ser Ser Pro Asp 195 200 205

Ile Cys Val Glu Leu Asn Pro Pro Leu Leu Ile Lys Asn Gly Asp Lys 210 215 220

Asp Tyr Ile Arg Ile Phe Tyr Tyr Arg Cys Leu Tyr Asp Lys Lys Pro 225 230 235 240

Ile Phe Val Ser Lys Thr Ser Ile Ile Ser Lys Met Lys 245 250

<210> 4

<211> 186

<212> PRT

<213> Photorhabdus luminescens

<400> 4

Met Asn Val Leu Glu Gln Gly Lys Val Ala Ala Leu Tyr Ser Ala Tyr 1 5 10 15

Ser Glu Thr Glu Gly Ser Ser Trp Val Gly Asn Leu Cys Cys Phe Ser 20 25 30

Ser Asp Arg Glu His Leu Pro Ile Ile Val Asn Gly Arg Arg Phe Leu 35 40 45

Ile Glu Phe Val Ile Pro Asp His Leu Leu Asp Lys Thr Val Lys Pro 50 60

Arg Val Phe Asp Leu Asp Ile Asn Lys Gln Phe Leu Leu Arg Arg Asp 65 70 75 80

His Arg Glu Ile Asn Ile Tyr Leu Leu Gly Glu Gly Asn Phe Met Asp

Arg Thr Thr Asp Lys Asn Leu Phe Glu Leu Asn Glu Asp Gly Ser 100 105 110

Leu Phe Ile Lys Thr Leu Arg His Ala Leu Gly Lys Tyr Val Ala Ile 115 120 125

Asn Pro Ser Thr Thr Gln Phe Ile Phe Phe Ala Gln Gly Lys Tyr Ser 130 135 140

Glu Phe Ile Met Asn Ala Leu Lys Thr Val Glu Asp Glu Leu Ser Lys 145 150 155 160

Arg Tyr Arg Val Arg Ile Ile Pro Glu Leu Gln Gly Pro Tyr Tyr Gly
165 170 175

Phe Glu Leu Asp Ile Leu Ser Ile Thr Ala 180 185

<210> 5

<211> 258


<212> PRT


<213> Photorhabdus luminescens


<400> 5 Met Glu Lys Lys Ile Thr Thr Phe Thr Ile Glu Lys Thr Asp Asp Asn Phe Tyr Ala Asn Gly Arg His Gln Cys Met Val Lys Ile Ser Val Leu Lys Gln Glu Tyr Arg Asn Gly Asp Trp Ile Lys Leu Ala Leu Ser Glu Ala Glu Lys Arg Ser Ile Gln Val Ala Ala Leu Ser Asp Ser 50 60 Leu Ile Tyr Asp Gln Leu Lys Met Pro Ser Gly Trp Thr Thr Thr Asp 65 70 75 Ala Arg Asn Lys Phe Asp Leu Gly Leu Leu Asn Gly Val Tyr His Ala Asp Ala Phe Ile Asp Glu Gln Val Thr Asp Arg Ala Gly Asp Cys Cys Thr Asn Glu Asn Tyr Gln Asn Ser Val Lys Ser Val Pro Glu Ile Ile Tyr Arg Tyr Val Ser Ser Asn Arg Thr Ser Thr Glu Tyr Leu Met Ala Lys Met Thr Phe Glu Asp Thr Asp Gly Lys Arg Thr Leu Thr Thr Asn Met Ser Val Gly Asp Glu Val Phe Asp Ser Lys Val Leu Leu Lys Ala 165 Ile Ala Pro Tyr Ala Ile Asn Thr Asn Gln Leu His Glu Asn Ile Asn Thr Leu Phe Asp Lys Thr Glu Glu Pro Thr Lys Ser Asp Thr His His 195 200 Gln Ile Ile Asn Leu Tyr Arg Trp Thr Leu Pro Tyr His Leu Arg Ile 215 Leu Glu Gly Asn Asp Ser Thr Val Asn Arg Ile Tyr Val Leu Gly Lys 230 Glu Pro Ser Asn Asp Arg Phe Leu Thr Arg Gly Arg Val Phe Lys Arg Gly Thr His Met 255 <210> 6 <211> 1584 <212> PRT


<212> PRT
<213> Photorhabdus luminescens
<400> 6
Met Lys Ala Thr Asp Ile Tyr Ser Asn Ala Phe Asn Phe Gly Ser Tyr
1 5 10 15

Ile Asn Thr Gly Val Asp Pro Arg Thr Gly Gln Tyr Ser Ala Asn Ile
20 25 30









Gly Glu Gln Ser Pro Ile Asp His Thr Gly Arg Val Leu Asn Gln Gln 1090 1095 1100

Ile Tyr His Tyr Asp Gln Trp Gly Asn Ile Lys Arg Leu Asp Asn Thr 105 1110 1115 1120

Tyr Arg Asp Gly Lys Glu Thr Val Asp Tyr His Phe Ser Gln Ala Asp 1125 1130 1135

Pro Thr Gln Leu Ile Arg Ile Thr Ser Asp Lys Gln Gln Ile Glu Leu 1140 1145 1150

Ser Tyr Asp Ala Asn Gly Asn Leu Thr Arg Asp Glu Lys Gly Gln Thr 1155 1160 1165

Leu Ile Tyr Asp Gln Asn Asn Arg Leu Val Gln Val Lys Asp Arg Leu 1170 1180

Gly Asn Leu Val Cys Ser Tyr Gln Tyr Asp Ala Leu Asn Lys Leu Thr 185 1190 1195 1200

Ala Gln Val Leu Ala Asn Gly Thr Val Asn Arg Gln His Tyr Ala Ser 1205 1210 1215

Gly Lys Val Thr Asn Ile Gln Leu Gly Asp Glu Ala Ile Thr Trp Leu 1220 1225 1230

Ser Ser Asp Lys Gln Arg Ile Gly His Gln Ser Ala Lys Asn Gly Gln 1235 1240 1245

Ser Val Tyr Tyr Gln Tyr Gly Ile Asp His Asn Ser Thr Val Ile Ala 1250 1255 1260

Ser Gln Asn Glu Asn Glu Leu Met Ala Leu Ser Tyr Thr Pro Tyr Gly 265 1270 1275 1280

Phe Arg Ser Leu Ile Ser Ser Leu Pro Gly Leu Asn Gly Ala Gln Val 1285 1290 1295

Asp Pro Val Thr Gly Trp Tyr Phe Leu Gly Asn Gly Tyr Arg Val Phe 1300 1305 1310

Asn Pro Val Leu Met Arg Phe His Ser Pro Asp Ser Trp Ser Pro Phe 1315 1320 1325

Gly Arg Gly Gly Ile Asn Pro Tyr Thr Tyr Cys Gln Gly Asp Pro Ile 1330 1340

Asn Arg Ile Asp Leu Asn Gly His Leu Ser Ala Gly Gly Ile Leu Gly 345 1350 1355 1360


Ile Val Leu Gly Ala Ile Gly Ile Ile Val Gly Ile Val Ser Leu Gly 1365 1370 1375

Ala Gly Ala Ala Ile Ser Ala Gly Leu Ile Ala Ala Gly Gly Ala Leu 1380 1385 1390

Gly Ala Ile Ala Ser Thr Ser Ala Leu Ala Val Thr Ala Thr Val Ile 1395 1400 1405

Gly Leu Ala Ala Asp Ser Ile Gly Ile Ala Ser Ala Ala Leu Ser Glu 1410 1415 1420


Lys A 425	sp Pi	ro L	ys	Thr	Ser 1430	Gly	Ile	Leu		Trp 1435	Ile	Ser	Ala		Leu 1440	
Gly V	al Le	eu S	er 1	Phe 445	Gly	Ile	Ser	Ala	Ile 1450	Thr	Phe	Thr		Ser 1455	Leu	
Val L	ys Se	er A 14	la . 60	Arg	Ser	Gly	Ser 1	Gln l465	Ala	Val	Ser		Gly 1470	Val	Ile	
Gly S	er Va 147	al P: 75	ro	Leu	Glu	Phe	Gly 1480	Glu	Val	Ala		Arg L485	Ser	Ser	Arg	
Arg T	rp As 90	sp I	le.	Ala	Leu 1	Ser 1495	Ser	Ile	Ser	Leu 1	Gly .500	Ala	Asn	Ala	Ala	
Ser La 505	eu Se	er T	hr (Gly 1	Ile .510	Ala	Ala	Ala	Ala 1	Val .515	Ala	Asp	Ser		Ala 1520	
Asn A	la Al	la A	sn 1	Ile 525	Leu	Gly	Trp	Val 1	Ser .530	Phe	Gly	Phe		Ala .535	Val	
Ser Ti	hr Th	nr Se 154	er (40	Gly	Ile	Ile	Glu 1	Leu 1545	Thr	Arg	Thr		Tyr 1550	Ala	Val	
Asn H	is Gl 155	n Ti 55	hr 1	Irp	Glu	Leu 1	Ser 560	Ser	Ser	Ala		Thr 565	Ser	Glu	Ģlu	
Val Ly 15	ys Pr 70	o I	le i	Arg	Cys 1	Leu .575	Val	Ser	His	Arg 1	Trp 580	Asn	Gln	Lys	Gln	
<210> <211> <212> <213>	18 DNA	.fici	ial	Seq	uenc	e								-		
<223>		ript	cior	of	Art	ific	ial	Sequ	ence	oli	gonu	clec	tide			
<400> acacag		tto	cgto	cag							÷				•	18
<210> <211> <212> <213>	18 DNA	fici	ial	Sea	uenc	e										
<220> <223>							ial	Section .	ence		~~~.	-1			-	
<400> ggcaga	8							ocqu	<u>uice</u>	.011	goria	CIGO	ciae			18
<210><211><211><212><213>	20 Dinta	fici	.al	Seqi	uence	e										
<220> <223>	Desci	ript	ion	o£	Art:	ific	ial :	Seque	ence	:olig	gonu	cleo	tide			
<400>	9											٠.				





115





¥ψ



agaattattc	ataatggact	tgtaggccga	caacgcaacc	aatgcaacct	gatgaagaaa	6780
tacggtcagc	ttggtgataa	atttattatt	tatactactc	taggtattaa	ccccaataat	6840
ttgtcgaata	aaaaattcat	ttaccctgtt	tatcagtata	gtgggaacac	taccaataat	6900
gagaaaggac	gtctgctgtt	ttatcgagaa	agtactacta	actttgtaag	agcctggttc	6960
cctaaccttc	cctctggctc	tcaagaaatg	tccacaacca	ctggcggtga	cattagtggt	7020
aactatggtt	atattgataa	caaacatagt	gacgatgttc	catttaaaca	atatttctat	7080
atggatgacc	acggtggtat	tgacactgat	gtttcaggga	tattatctat	taatacgaac	7140
attaatcatt	caaaagttaa	agtaatagtg	aaagccgaag	gtatcacaga	gcaaactttt	7200
gtagcgagcg	aaaacagtaa	tgtccccacc	aatccgtccc	gcttcgaaga	aatgaattat	7260
cagtttaaag	agcttgaaat	agatatetee	acactgacat	ttcataataa	tgaagcaagt	7320
attgatatca	cctttatcgc	atttgctgag	aaatttgacg	ataatagtaa	tgatcgtaac	7380
ttaggcgaag	aacatttcag	tattcgtatt	atcaaaaaag	cggaaactga	taatgccctg	7440
accctgcacc	ataatgcaaa	cggggcgcaa	tatatgcagt	ggggaaactc	ttgtattcgc	7500
cttaatacgc	tatttgcccg	tcaattaatt	agccgagcca	acgcggggat	agatactatt	7560
ttgagcatgg	acactcagaa	tattcaggaa	cctaaattag	gagaagattc	tcctgatgct	7620
atggaaccaa	tggacttcaa	cggcgccaac	agcctctatt	tctgggaact	gttctactac	7680
accccgatgc	tgattgctca	acgtttgctg	cacgaacaaa	acttcgatga	ggctaaccgt	7740
tggctgaaat	atgtctggaa	cccatccggt	tatattgtca	atggtcaaat	gcaacattac	7800
cgctggaatg	ttcgcccatt	acaagaagac	actagttgga	acgatgatco	gttggattca	7860
tttgatcctg	ataccatage	tcaacatgat	ccaatgcact	acaaagtcgc	cacctttatg	7920
cgcaccctag	atctgttgat	cgaacgggga	gattacgcct	atcgccaatt	ggagcgggac	7980
acactcgctg	aagccaaaat	gtggtatatg	caggcactgc	atctattggg	tgataaacct	8040
catctaccac	tcagttcagc	atggaatgat	ccagagctag	aagaggccgc	agctcttgaa	8100
aaacaacagg	cacatgccaa	agaaatagca	gatttacgac	aaggacttco	tacatccaca	8160
gggtctaaag	atgaaatcaa	aacagatctt	. ttcctgccgc	aagtcaacga	agtgatgctg	8220
agctactggc	: agaaactaga	acaacggttg	tataacctgc	gccataacct	ctctattgat	8280
ggtcaacctt	tacatttgcc	tattttcgca	acaccagcag	atccaaaago	gctgctcage	8340
gccgctgtcg	ccagttcaca	aggtggaagt	aatcttccat	. cagaatttat	atcagtgtgg	8400
cgtttccctc	atatgctgga	aaacgcccgt	agtatggtca	gtcagctaac	ccaattcggc	8460
tccacattgo	aaaatattat	. cgaacgtcaa	gatgcggagg	cattaaacac	gctgttgcaa	8520
aatcaggcgg	g cagaactgat	attgaccaat	ctcagcatac	aggacaaaa	catecaagag	8580
ctggatgctg	g aaaaaactgt	gctagaaaaa	aaccgcgccc	gaacccagto	gcgttttgat	8640
agctacagca	a aattctacga	tgaagacato	: aacgcgggtç	g aaaaacaggo	aatggcgttg	8700




4.7

*

Ø



atgaaattac	tctccatcca	caggccgccg	cgcaacgtta	tctacacaca	gtgtattacg	10680
gcaaccggac	agccagcaaa	acgttacccg	gtctggatgg	cagcgcccca	ccacaagcag	10740
actggttatt	ctatctggta	tttgattacg	gcgaacgcag	taacaacctg	agaacgccgc	10800
cagcattttc	gactacaggt	agctggcttt	gtcgccagga	ccgtttttcc	cgttatgaat	10860
atggttttga	gattcgtacc	cgccgcttat	gccgtcaggt	attgatgtat	caccacctgc	10920
aagctctgga	tagcgagata	aaagaacaca	acggaccaac	gctggtttca	cgcctgatac	10980
tcaattatga	cgaaagcgca	atcgccagca	cgctggtatt	cgttcgtcga	gtaggccacg	11040
agcaagacgg	tactgccgtc	accctgccgc	cattagaatt	ggcgtatcag	gatttttcac	11100
cgcaacataa	cgctcgctgg	caatcgatga	atgtgctggc	aaacttcaat	gccattcagc	11160
gctggcaact	agttgatcta	aaaggcgaag	gattccccgg	tctgctatat	caagataaag	11220
gcgcctggtg	gtaccgctcc	gcacaacgtt	ttggcaaaat	tggctcagat	gccgtcactt	11280
gggaaaaaat	gcaacctttg	tcggttatcc	cttccttgca	aagtaatgcc	tcgctggtgg	11340
atatcaatgg	agacggccaa	cttgactggg	ttatcaccgg	accgggatta	cggggatatc	11400
atagtcagca	tccagatggc	agttggacac	gttttacccc	gctcaacgct	ctgccagtgg	11460
aatatactca	tccacgcgcg	caactcgccg	atttaatggg	agctggactt	tctgatttag	11520
tactgatcgg	ccctaagagt	gtacgtttat	atgccaatac	ccgcgacggc	tttgccaaag	11580
gaaaagatgt	agtgcaatcc	ggtgatatca	cactgccagt	accgggcgcc	gatccgtgta	11640
agttggtggc	atttagtgat	gtattgggtt	ccggtcaggc	acatctggtt	gaagtgagcg	11700
cgactaaagt	cacctgctgg	cctaatctgg	ggcacggacg	ttttggtcaa	ccaattactc	11760
ttccgggatt	tagccaacca	gaagegaegt	ttaatcctgc	tcaagtttat	ctggccgatc	11820
tagatggcag	cggcccgact	gatctgattt	atgttcacac	agatcgtctg	gatatcttcc	11880
tgaataaaag	cggcaacggc	ttcgccgcac	cagtaactct	ccccttccca	gccggagtgc	11940
gttttgatca	tacctgtcag	ttacaagtgg	ccgatgtaca	agggttaggc	gtcgccagcc	12000
tgatattaag	tgtgccgcat	atgactcccc	atcactggcg	ttgcgatctg	accaacacaa	12060
aaccgtggtt	actcagtgaa	atgaacaaca	atatgggggc	tcatcacacc	ctgcgttacc	12120
gtagttccgc	ccagttctgg	ctggatgaaa	aagccacggc	actggatgcc	ggacaaatac	12180
cagtttgtta	tctacccttc	ccggtacaca	ccctatggca	aacggaaata	gaggatgaaa	12240
tcagcggcaa	caaattagtc	acaatactac	gttatgcaca	tggcgcctgg	gatggacgtg	12300
agcgagaatt	tegeggattt	ggttatgttg	aacagaaaga	cagccatcaa	ctggcccaag	12360
gcagtgcgcc	agaatgcaca	ccacctgcac	tgacccaagg	caacgcgcct	gaactcacat	12420
cacccgcgct	gacccaaggc	aacgctccag	aactcacacc	acctgcgatg	acccaaagca	12480
acgcgcctga	actcacatca	cccgcgctga	cccaaggcaa	cgcgccagaa	ttcacatcac	12540
cegegetgge	ccaaggcaat	gcgccagaac	tcacaccacc	tgcgatgacc	aaaaactggt	12600



ccttgtt	cac t	cctt	ggtt	t ac	tgtc	aatg	aaç	gatga	aaa	tgac	acaç	jct a	actga	ıggtga	14580
aggtaaa	gaa g	gaaag	gaato	jt aa	agaa	iggta	aac	gaago	rtaa	agat	gtaa	att 1	tgato	aatcc	14640
cgcccgg	ttg a	aaggg	geggg	ga aa	cata	acat	aat	atag	gagg	tgaa	acgt	gt (catto	ataat	14700
gccgtca	gat a	actca	actt	a tç	agtt	ggtt	gat	catt	ggt	ttta	ttga	gg (cctgg	ggcgg	14760
attagta	agg (acct	catt	g at	atac	aaaa	caa	acaa	itgt	aaat	.ggaa	att (ggato	aacgt	14820
actctgt	caa o	ctcat	tato	t co	tgtt	ttac	: cgg	rtata	ttg	ggag	gact	.gc	tgagt	tttga	14880
aagcggc	ggc a	agcco	ctat	a to	actt	ttgc	gat	tgcc	ggg	ctat	ttgg	gca (ccacc	rggaa g	14940
ttctgga	ttg a	acto	gato	et gg	cgto	gcct	ttt	tato	gcat	tato	gcga	atg a	atgga	ıggaaa	15000
gcaataa	.ggc a	attco	cact	g co	gcaa	aaac	: cat	ctgt	ctc	cggc	agtt	taa a	accgg	gaaat	15060
tacctac	tac a	aacta	attgt	a aç	jaaaa	ecgaa	ı tat	atag	jaaa	aact	aaca	atg (cagat	aaaaa	15120
ctgcgat	tgc a	agaac	cagat	g ac	acac	caacg	ccc	ccaac	caac	gagg	rtaaa		atg a Met I 1		15176
aac ato Asn Ile	gat Asp 5	cct Pro	aaa Lys	ctt Leu	tat Tyr	caa Gln 10	aag Lys	acc Thr	cct Pro	gtc Val	gtc Val 15	aac Asn	atc Ile	tac Tyr	15224
gat aad Asp Asr 20	1 Arg	ggt Gly	cta Leu	acg Thr	atc Ile 25	cgt Arg	aac Asn	atc Ile	gac Asp	ttt Phe 30	cac His	cgt Arg	acc Thr	acc Thr	15272
gca aac Ala Asr 35	: ggc	gat Asp	acc Thr	gat Asp 40	atc Ile	cgt Arg	att Ile	act Thr	cgc Arg 45	cat His	caa Gln	tat Tyr	gac Asp	tcc Ser 50	15320
ctt ggg Leu Gly	cac His	cta Leu	agc Ser 55	caa Gln	agc Ser	acc Thr	gat Asp	ccg Pro 60	cgt Arg	cta Leu	tat Tyr	gaa Glu	gcc Ala 65	aaa Lys	15368
caa aaa Gln Lys	tct Ser	aac Asn 70	ttt Phe	ctc Leu	tgg Trp	cag Gln	tat Tyr 75	gat Asp	ttg Leu	acc Thr	ggt Gly	aat Asn 80	Ile	ttg L e u	15416
tgt aca Cys Thr	gaa Glu 85	agc Ser	gtc Val	gat Asp	gct Ala	ggt Gly 90	cgc Arg	act Thr	gtc Val	acc Thr	ttg Leu 95	Asn	gat Asp	att Ile	15464
gaa ggc Glu Gly 100	' Arg	ccg Pro	cta Leu	ctg Leu	aca Thr 105	gta Val	act Thr	gca Ala	aca Thr	ggt Gly 110	gtc Val	ata Ile	caa Gln	acc Thr	15512
cga caa Arg Glr 115	tat Tyr	gaa Glu	acg Thr	tct Ser 120	tcc Ser	cta Leu	ccc Pro	ggt Gly	cgt Arg 125	ctg Leu	ttg Leu	tct Ser	gtt Val	acc Thr 130	15560
gaa caa Glu Glr	ata Ile	cca Pro	gaa Glu 135	aaa Lys	aca Thr	tcc Ser	cgt Arg	atc Ile 140	acc Thr	gaa Glu	cgc Arg	ctg Leu	att Ile 145	tgg Trp	15608
gct ggc Ala Gly	aat Asn	agc Ser 150	gaa Glu	gca Ala	gag Glu	aaa Lys	aac Asn 155	cat His	aat Asn	ctt Leu	gcc Ala	agc Ser 160	Gln	tgc Cys	15656
gtg cgc	cac	tat	gac	acg	gcg	gga	gtc	acc	cga	tta	gag	agt	ttg	tca	15704

Va.	l Ár	g H.	is T	yr A	SP Th	nr Al	a Gl 17	y Va '0	l Th	r Ar	g Le	eu Gl 17		≘r L	eu S	Ser	
cto Lei	g aco u Thi 180	- 01	jt ad y Ti	et gi nr Va	at to	a to eu Se 18	T GI	a to n Se	c ag r Se	c ca r Gl	a ct n Le 19	u Le	gag au Se	gc ga er Ag	ac a Figa	ect Thr	15752
195	5	~ · ·	u 50	-1 11	20		y AS	p As	n GI	20	r Va 5	ıl Tr	p Gl	n As	sn M	let 210	15800
			P	21	.5	ic ac Th	L 111	r re	220	r Ala	a Ph	e As	p Al	a Th 22	ır. G 25	ly	15848
			23	10	71 11	c ga ir Asj	р. Alta	235 235	2 3 GTZ	/ Asi	n Il	e Gli	n Ar 24	g Le O	u T	hr	15896
•		24	5		<i>y</i> 01	g cta n Lei	250)	/ Ser	: 117	Lei	u Thi 259	r Le 5	u Ly	s A	sp	15944
	260)				t ato e Ile 265	, HTC) Ser	Let	i Thr	270	r Sei O	c Al	a Al	a G	ly	15992
caa Gln 275	aaa Lys	Lei	acg 1Ar	c ga g Gl	g gaz u Gli 280	a cac u His O	ggc Gly	aat Asn	ggt Gly	gtt Val 285	. Ile	acc Thr	gaz Gli	a ta ı Ty:	r Se	gt er 90	16040
-				29!	5	a cag n Gln	Leu	ı ıre	300	inr	. TÀS	Thr	His	30!	g Pi 5	0	16088
	•		31)		g caa ı Gln	. Asp	315	Arg	туr	GLu	ı Tyr	320) Pro	o Va	al .	16136
		325			. 110	cgt Arg	330	ASD	Ата	GIU	Ala	335	Arg	Phe	Tr	q.	16184
cac His	aat Asn 340	cag Gln	aaa Lys	a gtç Val	gcg Ala	ccg Pro 345	gaa Glu	aac Asn	act Thr	tat Tyr	acc Thr 350	Tyr	gac Asp	tco Ser	tt Le	gu	16232
355					360		GLY	Arg	GIU	365	Ala	Asn	Ile	Gly	G1 37	n 0	16280
caa Gln	agt Ser	aac Asn		ctt Leu 375	ccc Pro	tcc Ser	ctc Leu	acc Thr	cta Leu 380	cct Pro	tct Ser	gat Asp	aac Asn	aac Asn 385	Th	c r	16328
tac : Tyr '	acc Thr	aac Asn	tat Tyr 390	acc Thr	cgt Arg	act Thr	tat Tyr	act Thr 395	tat Tyr	gac Asp	cgt Arg	ggc Gly	ggc Gly 400	aat Asn	tt: Lei	n a	16376
act a Thr I	_	atc Ile 405	cag Gln	cac His	agt Ser	~~	ccg Pro 410	gcg Ala	acg Thr	caa Gln	aac Asn	aac Asn 415	tac Tyr	acc Thr	aca Thi	a c	16424
aac a Asn 1	atc . [le '	acg Thr	gtt Val	tct Ser	aac Asn	cgg Arg	agc Ser	aat Asn	cgc Arg	gca Ala	gta Val	ctc Leu	agc Ser	act Thr	cto	J 1	16472



	420					4 25					430					
								gct Ala								16520
								aac Asn								16568
								aaa Lys 475								16616
								agt Ser								16664
								aac Asn								16712
								cta Leu								16760
acc Thr	gaa Glu	gat Asp	ttg Leu	caa Gln 535	gtt Val	atc Ile	aca Thr	gta Val	gga Gly 540	gaa Glu	gcg Ala	ggt Gly	cgg Arg	gca Ala 545	cag Gln	16808
gta Val	cga Arg	gta Val	tta Leu 550	cat His	tgg Trp	gat Asp	agc Ser	ggt Gly 555	caa Gln	ccg Pro	gaa Glu	gat Asp	atc Ile 560	gac Asp	aat Asn	16856
aat Asn	cag Gln	cta Leu 565	cgt Arg	tat Tyr	agc Ser	tac Tyr	gat Asp 570	aat Asn	ctt Leu	atc Ile	ggt Gly	tcc Ser 575	agt Ser	caa Gln	ctt Leu	16904
gaa Glu	tta Leu 580	gac Asp	agc Ser	aaa Lys	gga Gly	gaa Glu 585	att Ile	att Ile	agt Ser	gag Glu	gaa Glu 590	gag Glu	tac Tyr	tat Tyr	ccc Pro	16952
tat Tyr 595	ggc ggc	ggc Gly	acg Thr	gca Ala	tta Leu 600	tgg Trp	gca Ala	aca Thr	agg Arg	aag Lys 605	cgg Arg	aca Thr	gaa Glu	gcc Ala	agt Ser 610	17000
tat Tyr	aaa Lys	acc Thr	atc Ile	cgt Arg 615	tat Tyr	tca Ser	ggt Gly	aaa Lys	gag Glu 620	cgg Arg	gat Asp	gcc Ala	acc Thr	gga Gly 625	cta Leu	17048
tat Tyr	tat Tyr	tac Tyr	ggt Gly 630	tac Tyr	cga Arg	tat Tyr	tat Tyr	cag Gln 635	cct Pro	tgg Trp	gta Val	gga Gly	cga Arg 640	tgg Trp	tta Leu	17096
agt Ser	gcc Ala	gat Asp 645	Pro	gca Ala	gga Gly	aca Thr	gta Val 650	gat Asp	ggg Gly	ttg Leu	aat Asn	tta Leu 655	tat Tyr	cgg Arg	atg Met	17144
gta Val	agg Arg 660	Asn	aat Asn	ccg Pro	gtt Val	act Thr 665	Leu	ctt Leu	gat Asp	cct Pro	gat Asp 670	gga Gly	tta Leu	atg Met	cca Pro	17192
aca Thr 675	Ile	gca Ala	gaa Glu	cgc Arg	ata Ile 680	Ala	gca Ala	ctg Leu	caa Gln	aaa Lys 685	Asn	aaa Lys	gta Val	gca Ala	gat Asp 690	17240

tca Ser	gcg Ala	cct Pro	tcg Ser	cca Pro 695	Thr	aat Asn	gcc Ala	aca Thr	aac Asn 700	Val	gcg Ala	ata Ile	aac Asr	ato Ile 705	cgc Arg	17288
PLO	PIO	vai	710		. rija	Pro	Thr	715	Pro	Lys	Ala	Ser	720	Ser	Ser	17336
caa Gln	tca Ser	act Thr 725	TIIL	tac Tyr	ccc Pro	atc Ile	aaa Lys 730	Ser	gca Ala	agc Ser	ata Ile	aaa Lys 735	Pro	acg Thr	acg Thr	17384
tcg Ser	gga Gly 740	tca Ser	tcc Ser	att Ile	act Thr	gct Ala 745	cca Pro	ctg Leu	agt Ser	cca Pro	gta Val 750	gga Gly	aat Asn	aaa Lys	tct Ser	17432
act Thr 755	cct Pro	gaa Glu	ata Ile	tct Ser	ctt Leu 760	Pro	gaa Glu	agc Ser	act Thr	caa Gln 765	agc Ser	aat Asn	tct Ser	tca Ser	agc Ser 770	17480
gct Ala	att Ile	tca Ser	aca Thr	aat Asn 775	cta Leu	cag Gln	aaa Lys	aag Lys	tca Ser 780	ttt Phe	act Thr	tta Leu	tat Tyr	aga Arg 785	gcg Ala	17528
gat Asp	aat Asn	aga Arg	tcc Ser 790	ttt Phe	gaa Glu	gac Asp	atg Met	cag Gln 795	Ser	aaa Lys	ttc Phe	cct Pro	gaa Glu 800	gga Gly	ttt Phe	17576
aaa Lys	gcc Ala	tgg Trp 805	act Thr	cct Pro	cta Leu	gat Asp	act Thr 810	aag Lys	atg Met	gca Ala	agg Arg	cag Gln 815	ttt Phe	gct Ala	agt Ser	17624
gtc Val	ttt Phe 820	att Ile	ggt Gly	cag Gln	aaa Lys	gat Asp 825	act Thr	tct Ser	aat Asn	tta Leu	cct Pro 830	aaa Lys	gaa Glu	aca Thr	gtc Val	17672
aag Lys 835	aat Asn	ata Ile	aac Asn	aca Thr	tgg Trp 840	gga Gly	aca Thr	aaa Lys	Pro	aaa Lys 845	tta Leu	aat Asn	gat Asp	ctc Leu	tca Ser 850	17720
act Thr	tac Tyr	ata Ile	aaa Lys	tat Tyr 855	acc Thr	aag Lys	gac Asp	aaa Lys	tct Ser 860	aca Thr	gta Val	tgg Trp	gtc Val	tct Ser 865	act Thr	17768
gca Ala	att Ile	aat Asn	act Thr 870	gaa Glu	gca Ala	ggt Gly	gga Gly	caa Gln 875	agt Ser	tca Ser	ggg ggg	gct Ala	cca Pro 880	ctc Leu	cat His	17816
gaa	att	aat	ato	gat:	ctt	tat	aaa	+++			~-~					

CCQ	CCC	· ota	~~-													
Pro	Pro	Val	Ala 710	Pro	a aaa Diys	cct Pro	acc Thr	Leu 715	Pro	aaa Lys	a gca s Ala	a tca a Ser	acq Thi 720	Ser	agc Ser	17336
caa Gln	tca Ser	act Thr 725	1111	tac Tyr	ccc Pro	ato Ile	aaa Lys 730	Ser	gca Ala	ago Ser	ata Ile	aaa Lys 735	Pro	a acg	acg Thr	17384
tcg Ser	gga Gly 740	Ser	tcc Ser	att Ile	act Thr	gct Ala 745	Pro	ctg Leu	agt Ser	cca Pro	gta Val 750	. Gly	aat Asr	aaa Lys	tct Ser	. 17432
act Thr 755	ETO	gaa Glu	ata Ile	tct Ser	ctt Leu 760	Pro	gaa Glu	agc Ser	act Thr	caa Gln 765	Ser	aat Asn	tct Ser	tca Ser	agc Ser 770	17480
gct Ala	att Ile	tca Ser	aca Thr	aat Asn 775	Leu	cag Gln	aaa Lys	aag Lys	tca Ser 780	ttt Phe	act Thr	tta Leu	tat Tyr	aga Arg 785	gcg Ala	17528
gat Asp	aat Asn	aga Arg	tcc Ser 790	Fue	gaa Glu	gac Asp	atg Met	cag Gln 795	agt Ser	aaa Lys	ttc Phe	cct Pro	gaa Glu 800	Gly	ttt Phe	17576
aaa Lys	gcc Ala	tgg Trp 805	act Thr	cct Pro	cta Leu	gat Asp	act Thr 810	aag Lys	atg Met	gca Ala	agg Arg	cag Gln 815	ttt Phe	gct Ala	agt Ser	17624
gtc Val	ttt Phe 820	att Ile	ggt Gly	cag Gln	aaa Lys	gat Asp 825	act Thr	tct Ser	aat Asn	tta Leu	cct Pro 830	aaa Lys	gaa Glu	aca Thr	gtc Val	17672
aag Lys 835	aat Asn	ata Ile	aac Asn	aca Thr	tgg Trp 840	gga Gly	aca Thr	aaa Lys	Pro	aaa Lys 845	tta Leu	aat Asn	gat Asp	ctc Leu	tca Ser 850	17720
act Thr	tac Tyr	ata Ile	aaa Lys	tat Tyr 855	acc Thr	aag Lys	gac Asp	aaa Lys	tct Ser 860	aca Thr	gta Val	tgg Trp	gtc Val	tct Ser 865	act Thr	17768
gca Ala	att Ile	aat Asn	act Thr 870	gaa Glu	gca Ala	ggt Gly	gga Gly	caa Gln 875	agt Ser	tca Ser	Gly ggg	gct Ala	cca Pro 880	ctc Leu	cat His	17816
gaa Glu	att Ile	aat Asn 885	atg Met	gat Asp	ctt Leu	tat Tyr	gag Glu 890	ttt Phe	acc Thr	att Ile	gac Asp	gga Gly 895	caa Gln	aag Lys	cta Leu	17864
aat Asn	cca Pro 900	cta Leu	cca Pro	agg Arg	gga Gly	aga Arg 905	tct Ser	aaa Lys	gac Asp	agg Arg	gtg Val 910	cct Pro	tca Ser	cta Leu	tta Leu	17912
ctt Leu 915	gac Asp	aca Thr	cca Pro	gaa Glu	ata Ile 920	gaa Glu	aca Thr	gca Ala	tcc Ser	ata Ile 925	att Ile	gca Ala	ctt Leu	aat Asn	cat His 930	17960
gga Gly	ccg Pro	gta Val	aat Asn	gat Asp 935	gca Ala	gaa Glu	gtt Val	Ser	ttc Phe 940	cta Leu	aca Thr	aca Thr	att Ile	ccg Pro 945	ctt Leu	18008



aaa aat gta aaa cct tat aag aga taa cgaaaaatta atattcttta Lys Asn Val Lys Pro Tyr Lys Arg 950 955	18055
totactttta atagcoctot tgaacttaca otcaaggggg ggaaaccaaa taagaaacca	18115
totttaataa caagooatga aagaatattt atttoatggo ttgattactt ttaacattoa	18175
atattaaata attaaaacaa tatctaacca attaaaataa caatacctta tttatcatat	18235
taaaatatca aatcagaaat taatgaattt aagggttett tatatttatt tetgagagea	18295
taggcacaat accttaccga tggcgctgga cgtgattcaa aatccagaaa tgctatattt	18355
tcatcaatat gggcagaata gcgcatttca ttgggagtca ttaaacttat cgcgacaccc	18415
gettttaeca gatecaatet attagtaaaa teagggaceg teaataaege taaattttgg	18475
tattcaggga gataattcaa tggcataaaa ttattgcatt gttttaaaaa agcactatta	18535
tgctgaacaa aaggaaaact agatattatt tcatcagcgt gactttctgg ttctaaaata	18595
tcatgggata cagcaagaga cagcatttga taagcaccat ctatcctgat gatatcatca	18655
ttatctggat aacattcagt cgtcacataa actgttatat cccctttcat taaggaagaa	18715
aataccgcat cttgccttat taaatcatca attagaaaat tgttgattat acaaatatcg	18775
cgataatgat aacgttgcac cgctcttttt acgaccgtag atattttatt aacatattct	18835
ccacttgtgc caataaccag tttgtctctg tttgataatt tataatttct acgacaattc	18895
caattattet caactttcag gatcetttca taacaeggea geaactettg atatagtgee	18955
ttteeetett etgtgagett ggttttteee ggtagteget caaacaattg acacccaca	19015
cgctgttcca gttgatatac gagcctgcta agtggagaag gggtaataca aagcgtatcc	19075
geogetaacg tgaatgacte tttettaget gatteeataa aataetttag ttgetttgaa	19135
caaaatatca tcacataccc tcttgttttc attccagaaa tagaatatta accatagaac	19195
atgacaacga tgtttctact ttgcattctt ttacattagg acatgcgtta atggacattg	19255
aatttcacta catcaattgt taatatttat ttaatacttg cacaataatt ataaaataaa	19315
tataacttag ttaattattt cttgatattg atcatggtaa gttttcctca atacctacag	19375
aagtagatat tattttatet teeagtaate tategtttgg egaeggaggt egattettee	19435
attgggatat tcaacccatt cgccgccttt cttattaatt acagtgattt ttggcatttt	19495
ggtttcatcc aacttaggtt tataggtgat tttccattta gcacccggtg ttaacttcaa	19555
cctaaaggga tacataccaa cttcaccttg taagaatatt ctgtttggtc taccttcaac	19615
gactttcaaa atggggtaaa taaccgggct aaaatcaatc gtatccaatg catcaatttc	19675
gctgatattt gtccgggctg catcattgat aaatgcgatt aaatcggttg ctgaatacgg	19735
aatagcatet tteactagat gaeggaeate ggtataaete aetgaeacaa aggeteggte	19795
aatettecae ttacategae egecaceatt aaaaggtagt tttgeetgaa agtaaeeggt	19855
ttteggatea gettttaeat eeagaegtaa teegttataa gttggtaeet taaaaggega	19915



- 35 -



catattggaa tetaaaegat atttaaggea atettttgag atatacacag eggatacatg 19975
eggetgtgtg tatttaggtg egaeteette taeagtaate eactgattet etttgggagg 20035
agagagegge teatttgggt eageacagee tgatattaaa atcaeggata agacagataa 20095
gtatttettg atatttatea tggtaagttt teeteaaete etaeagegtt atetgeatgt 20155
gtgtccaatt ccagatette etgtttatet atttagaaat aaataageta egetgatage 20215
attacttcat atttccatac atgaatcgaa aatcgacttc ttgagtgccg ttatcaattt 20275
tgeegeeegg atatteaace caetegeege etttettatt agteacegtg aeettegeea 20335
ttttggttte atecagetta ggettaaaaa taatttteea tttageteet ggagttaaeg 20395
tgagttgaaa aggacgcatt tttaatactt caccttgtaa gaatattetg ttegggegae 20455
cttcaacgac tttcaaaaca gggtaaataa ccgggctaaa atcaatcgta ttcaatgtcg 20515
agattttget aatatteate tggaetatge eattgataga tgegattaaa eeggttgetg 20575
aatacggaat agcatctttc accagatggc tgacatcagt ataactcacc gatacaaagg 20635
cccggttaat tttccattta catcgtcccc ctccattaaa aggtagtttt gcttgaaaat 20695
aaceggtttg tggateggee tteaetttea gaegaageee attataggte ggeaetttaa 20755
aaggcgacat attggaatcc agacgatact caaggcaatc ctttgatatg tattctgcgg 20815
atacatgtgg ttcggtatat ttcggcgcta ccccttctac cgtgatccat tgattttctt 20875
taggagggga aageggetea tttgggteag caeageetga tattaaaate aetgacaaga 20935
caaataagta ttttttaaca tttatcatgg taagttttcc tcaattccta cagcattatc 20995
cgcataaata teetgteaag aatagegtte attgattteg teaceaaaga aacaagatag 21055
taaaaateet attaecacag ataaaaaaca eegettatge egtgagtaat agtgagttga 21115
gcgacaggga tacagcagtg catececate aattagteee tttgaataaa gggaacagaa 21175
tttgaaattt ccgtcatacc gtccatatta cggaacttag attatgatta ttaaatcacc 21235
accaaatggc aagaaaaatt ttcatttttt aatttacgaa gaatgaattt gtaagaaagt 21295
gttacaaact taatagaaat taatttactg ttaatctaat gaaggatgaa attataaaaa 21355
taacccattt ctcagggaca acaatccaca atatatagaa ccactggtcc tcacttaatt 21415
teetgteagg agtagaaata teetgatgae teagtegatg acatacagea atgteattgg 21475
tattgagact accgactgtt taataaattt cttttgtctt taatggcgag atacaagtga 21535
ttcactattt aagcactatc gataaataag attccaaaat agcgccatat cttacaccac 21595
tcataattet atgtataaca attggttaaa taggateatg tgtaacagga ttatgaaacg 21655
ttatttatat caaatctatc aattatttta tatatagttt cacagtcaca ctcgctatct 21715
ggtacettea taaccaactg ecetecetge getacettet gataacaaca getacactaa 21775
ctataccege geetataatt atgacegtgt gaaaatteag egtagtteae eggeeaegea 21835

-





Met Ile Leu Lys Gly Ile Asn Met Asn Ser Pro Val Lys 960 965


gag ata cct gat gta tta aaa atc cag tgt ggt ttt cag tgt ctg aca Glu Ile Pro Asp Val Leu Lys Ile Gln Cys Gly Phe Gln Cys Leu Thr 970 975 980	23854
gat att age cac age tet titt aac gaa tit cac cag caa gia tee gaa Asp Ile Ser His Ser Ser Phe Asn Glu Phe His Gln Gln Val Ser Glu 985 990 995 1000	23902
cac ctc tcc tgg tcc gaa gca cac gac tta tat cat gat gca caa cag His Leu Ser Trp Ser Glu Ala His Asp Leu Tyr His Asp Ala Gln Gln 1005 1010 1015	23950
gcc caa aag gat aat cgg ctg tat gaa gcg cgt att ctt aaa cgc acg Ala Gln Lys Asp Asn Arg Leu Tyr Glu Ala Arg Ile Leu Lys Arg Thr 1020 1025 1030	23998
aat oot caa tta caa aat got gta cat ott goo ato gta gog oot aat Asn Pro Gln Leu Gln Asn Ala Val His Leu Ala Ile Val Ala Pro Asn 1035 1040 1045	24046
gct gaa ctg ata ggc tat aac aac caa ttt agc ggc agg gcc agt caa Ala Glu Leu Ile Gly Tyr Asn Asn Gln Phe Ser Gly Arg Ala Ser Gln 1050 1055 1060	24094
tat gtc gcg ccg ggt acc gtt tcc tcc atg ttc tcc ccc gcc gct tat Tyr Val Ala Pro Gly Thr Val Ser Ser Met Phe Ser Pro Ala Ala Tyr 1065 1070 1075 1080	24142
ttg act gag ctt tat cgt gaa gca cgc aat tta cac gcc agc gat tcc Leu Thr Glu Leu Tyr Arg Glu Ala Arg Asn Leu His Ala Ser Asp Ser 1085 1090 1095	24190
gtt tat cgc ctg gat act cgc cgc cca gat ctc aaa tca atg gcg ctc Val Tyr Arg Leu Asp Thr Arg Arg Pro Asp Leu Lys Ser Met Ala Leu 1100 1105 1110	24238
agt caa caa aat atg gat acg gaa ctt too act ctc tct tta too aat Ser Gln Gln Asn Met Asp Thr Glu Leu Ser Thr Leu Ser Leu Ser Asn 1115 1120 1125	24286
gag cta tta ttg gaa agc att aaa act gag tct aag ctg gat aat tat Glu Leu Leu Glu Ser Ile Lys Thr Glu Ser Lys Leu Asp Asn Tyr 1130 1140	24334
act caa gtg atg gaa atg ctc tcc gct ttc cgt cct tcc ggc gcg acg Thr Gln Val Met Glu Met Leu Ser Ala Phe Arg Pro Ser Gly Ala Thr 1145 1150 1155 1160	24382
cct tat cac gat gct tac gaa aat gtg cgt aaa gtt atc cag cta caa Pro Tyr His Asp Ala Tyr Glu Asn Val Arg Lys Val Ile Gln Leu Gln 1165 1170 1175	24430
gat cot ggg ott gag caa tta aat got toa coa ggg att gan to	24478
atg cat caa get tee eta tta get att aag get bes at	24526
ttg ttt aat att ctg acg gag gag att act gaa ggt aat gat	24574

٠											00					
	1210				1	1215			•	1	L220					
L	tt tat eu Tyr 225	aag Lys	aaa Lys	Asn	ttt	ggt	aat Asn	atc Ile	Glu	ccg	gct	tca Ser	ctg Leu	Ala	atg Met 1240	24622
C F	cg gaa ro Glu	tac Tyr	Leu	aga Arg 1245	cgt Arg	tat Tyr	tac Tyr	Asn	tta Leu 1250	agt Ser	gat Asp	gaa Glu	Glu	ctc Leu 1255	agc Ser	24670
C	ag ttt ln Phe	Ile	ggt Gly 1260	aaa Lys	gcc Ala	agc Ser	Asn	ttc Phe 1265	ggc Gly	caa Gln	caa Gln	Glu	tat Tyr 1270	agt Ser	aat Asn	24718
A	ac caa sn Gln	ctc Leu 1275	att Ile	act Thr	ccg Pro	Ile	gtc Val 1280	aac Asn	agc Ser	aat Asn	Asp	ggc Gly L285	aca Thr	gtc Val	aag Lys	24766
9 V	ta tat al Tyr 1290	cga Arg	att Ile	acc Thr	Arg	gaa Glu 1295	tat Tyr	aca Thr	aca Thr	Asn	gcc Ala 1300	aat Asn	caa Gln	gta Val	gac Asp	24814
V	tg gag al Glu 305	ctg Leu	ttt Phe	Pro	tac Tyr 1310	ggt Gly	gga Gly	gaa Glu	Asn	tat Tyr 1315	cag Gln	tta Leu	aat Asn	Tyr	aaa Lys 1320	24862
E	tc aaa he Lys	gat Asp	Ser	cgt Arg 1325	cag Gln	gat Asp	gtc Val	Ser	tat Tyr 1330	tta Leu	tcc Ser	atc Ile	Lys	tta Leu 1335	aat Asn	24910
Ą	ac aaa sp Lys	Arg	gaa Glu 1340	ctt Leu	atc Ile	cga Arg	Ile	gaa Glu 1345	gga Gly	gcg Ala	cct Pro	Gln	gtc Val 1350	aac Asn	atc Ile	24958
9	aa tat Slu Tyr	tca Ser 1355	gaa Glu	cat His	atc Ile	Thr	tta Leu 1360	agt Ser	aca Thr	act Thr	Asp	atc Ile 1365	agt Ser	caa Gln	cct Pro	25006
Ę	tt gaa he Glu 1370	atc Ile	ggc	cta Leu	Thr	cga Arg 1375	gta Val	tat Tyr	cct Pro	Ser	agt Ser 1380	tct Ser	tgg Trp	gca Ala	tat Tyr	25054
P	jca gcc la Ala .385	gca Ala	aaa Lys	Phe	acc Thr 1390	att Ile	gag Glu	gaa Glu	Tyr	aac Asn 1395	caa Gln	tac Tyr	tct Ser	Phe	ctg Leu 1400	25102
I	ta aaa eu Lys	ctc Leu	Asn	aaa Lys 1405	gct Ala	att Ile	cgt Arg	Leu	tct Ser 1410	cgt Arg	gcg Ala	aca Thr	Glu	tta Leu 1415	tca Ser	25150
F	cc acc Pro Thr	Ile	ctg Leu 1420	gaa Glu	agt Ser	att	Val	cgt Arg 1425	agt Ser	gtt Val	aat Asn	Gln	caa Gln 1430	ctg Leu	gat Asp	25198
î	itc aac le Asn	gca Ala 1435	gaa Glu	gta Val	tta Leu	Gly	aaa Lys 1440	gtt Val	ttt Phe	ctg Leu	Thr	aaa Lys 1445	tat Tyr	tat Tyr	atg Met	25246
C	aa cgt In Arg 1450	Tyr	gct Ala	att Ile	Asn	gct Ala 1455	gaa Glu	act Thr	gcc Ala	Leu	ata Ile 1460	cta Leu	tgc Cys	aat Asn	gca Ala	25294
I	ett att eu Ile .465	tca Ser	caa Gln	Arg	tca Ser 1470	Tyr	gat Asp	aat Asn	Gln	cct Pro 1475	agc Ser	caa Gln	ttt Phe	Asp	cgc Arg 1480	25342




Leu Phe Asn Thr Pro Leu Leu Asn Gly Gln Tyr Phe Ser Thr Gly Asp 1485 1490 1495	
gaa gag att gat tta aat cca ggt agt act ggc gat tgg cgt aaa tcc Glu Glu Ile Asp Leu Asn Pro Gly Ser Thr Gly Asp Trp Arg Lys Ser 1500 1505 1510	25438
gtg ctt aaa cgt gca ttt aat atc gat gat att tcc ctc tac cgc ctg Val Leu Lys Arg Ala Phe Asn Ile Asp Asp Ile Ser Leu Tyr Arg Leu 1515 1520 1525	25486
ctt aaa att acc aac cat aat aat caa gat gga aag att aaa aat aac Leu Lys Ile Thr Asn His Asn Asn Gln Asp Gly Lys Ile Lys Asn Asn 1530 1540	25534
tta aat aat ctt tct gat tta tat att ggg aaa tta ctg gca gaa att Leu Asn Asn Leu Ser Asp Leu Tyr Ile Gly Lys Leu Leu Ala Glu Ile 1545 1550 1560	25582
1565 1570 1575	25630
1580 1585 And Leu Ala Ala 1580 1590	25678
1595 1600 1605	25726
1610 1615 1620 The Val Met Thr Ser Thr Ser Tyr Asn Lys	25774
1625 1630 1640 1640 1625 1640	25822
1645 Lys Ala Ash Leu Leu His Val Met Ala 1655	25870
1660 1665 Ser Glu Asn Val Ala His	25918
tct gtg ctg ctt tgg gca gac aag tta aag ccc ggc gac ggc gca atg 2 Ser Val Leu Leu Trp Ala Asp Lys Leu Lys Pro Gly Asp Gly Ala Met 1675 1680 1685	5966
aca gcc gaa aaa ttc tgg gac tgg ttg aat act caa tat acg cca gat 20 Thr Ala Glu Lys Phe Trp Asp Trp Leu Asn Thr Gln Tyr Thr Pro Asp 1690 1695 1700	6014
1705 1710 1715 1716 Val Gln Tyr Cys Gln 1710 1720	6062
gcg ttg gcg caa tta gaa atg gtt tac cat tcc acc ggt atc aat gaa 26 Ala Leu Ala Gln Leu Glu Met Val Tyr His Ser Thr Gly Ile Asn Glu 1725 1730 1735	5110

		Phe					aca Thr 1					Phe				26158
act Thr	Glu	gca Ala .755	gta Val	cct Pro	gcg Ala	His	gat Asp 760	gca Ala	ctt Leu	tca Ser	Leu	atc Ile .765	atg Met	ctg Leu	acg Thr	26206
Arg	ttt Phe 770	gca Ala	gat Asp	tgg Trp	Val	aat Asn .775	gcg Ala	tta Leu	ggc Gly	Glu	aaa Lys .780	gcc Ala	tct Ser	tcc Ser	gta Val	26254
cta Leu 1785	Ala	gca Ala	ttt Phe	Glu	gct Ala 1790	aac Asn	agt Ser	tta Leu	Thr	gca Ala .795	gaa Glu	caa Gln	ttg Le u	Ala	gat Asp 1800	26302
gcc Ala	atg Met	aat Asn	Leu	gat Asp .805	gct Ala	aat Asn	ttg Leu	Leu	ttg Leu .810	caa Gln	gcc Ala	agt Ser	Thr	caa Gln 1815	gca Ala	26350
caa Gln	aac Asn	His	caa Gln .820	cat His	ctt Leu	ccc Pro	cca Pro	gtg Val 1825	acg Thr	caa Gln	aaa Lys	Asn	gct Ala 1830	ttc Phe	tcc Ser	26398
tgt Cys	Trp	aca Thr 1835	tct Ser	atc Ile	gac Asp	Thr	atc Ile 1840	ctg Leu	caa Gln	tgg Trp	Val	aat Asn L845	gtt Val	gca Ala	caa Gln	26446
Gln					Pro		gga Gly			Ala						26494
tat Tyr 186	Ile	caa Gln	tta Leu	Asn	caa Gln 1870	aaa Lys	atc Ile	ccc Pro	Thr	tat Tyr 1875	gcc Ala	cag Gln	tgg Trp	Glu	agt Ser 1880	26542
gct Ala	ggg Gly	gaa Glu	Ile	ttg Leu 1885	act Thr	gcc Ala	gga Gly	Leu	aat Asn 1890	tca Ser	caa Gln	cag Gln	Ala	gat Asp 1895	ata Ile	26590
tta Leu	cac His	Ala	ttt Phe 1900	ttg Leu	gac Asp	gaa Glu	tct Ser	cgc Arg 1905	agt Ser	gcc Ala	gca Ala	Leu	agc Ser 1910	acc Thr	tac Tyr	26638
tat Tyr	Ile	cgt Arg 1915	Gln	Val	Ala	Lys	cca Pro 1920	Ala	gca Ala	Ala	Ile	Lys	Ser	cgt Arg	gat Asp	26686
Asp	. ttg Leu 1930	tac Tyr	caa Gln	tac Tyr	Leu	cta Leu 1935	att Ile	gat Asp	aat Asn	Gln	gtt Val 1940	tcc Ser	gct Ala	gca Ala	atc Ile	26734
aaa Lys 194	Thr	acc Thr	cgg Arg	Ile	gcc Ala 1950	gaa Glu	gcc Ala	att Ile	Ala	agc Ser 1955	att Ile	caa Gln	ctg Leu	Tyr	gtc Val 1960	26782
aac Asn	cgc Arg	acg Thr	Leu	gaa Glu 1965	aat Asn	gta Val	gaa Glu	Glu	aat Asn 1970	gcc Ala	cat His	tca Ser	Gly	gtt Val 1975	atc Ile	26830
agc Ser	cgt Arg	Gln	Phe	ttt Phe	atc Ile	gac Asp	tgg Trp	Asp	Lys	tat Tyr	aac Asn	Lys	Arg	tac Tyr	agc Ser	26878
			1980					1985					1990			



2250	2255	2260	
		tat gaa att ccc tca tcg gta aat Tyr Glu Ile Pro Ser Ser Val Asn 2275 2280	27742
Ser Arg Lys Gly		gat tat tat ctc agt atg gta tat Asp Tyr Tyr Leu Ser Met Val Tyr 2290 2295	27790
	Pro Thr Ile Ser	tac aaa gcc aca tca agt gat tta Tyr Lys Ala Thr Ser Ser Asp Leu 2305 2310	27838
		aga att att cat aat gga tat gaa Arg Ile Ile His Asn Gly Tyr Glu 2325	27886
		cta atg aat aaa tat ggc aaa cta Leu Met Asn Lys Tyr Gly Lys Leu 2340	27934
		agc ttg gga gtt aat cca aat aat Ser Leu Gly Val Asn Pro Asn Asn 2355 2360	27982
Ser Ser Asn Lys		ccc gtt tat caa tat aac gga aat Pro Val Tyr Gln Tyr Asn Gly Asn 2370 2375	28030
		tta cta ttc cac cgt gac acc aat Leu Leu Phe His Arg Asp Thr Asn 2385 2390	28078
		g att cct gga gca gga cgt tct cta o Ile Pro Gly Ala Gly Arg Ser Leu 2405	
		gat gat tat gct aca gac tcg tta Asp Asp Tyr Ala Thr Asp Ser Leu 2420	
		a tac gtc tat atg act gac agt aaa n Tyr Val Tyr Met Thr Asp Ser Lys 2435 2440	
Gly Thr Ala Thr	gat gtc tca gga Asp Val Ser Gly 2445	a cca gta gat atc aat act gca att / Pro Val Asp Ile Asn Thr Ala Ile 2450 2455	28270
tcc ccg gca aaa Ser Pro Ala Lys 2460	Val Gln Val Thr	a gta aaa gcc ggt agc aaa gaa caa CVal Lys Ala Gly Ser Lys Glu Gln 2465 2470	28318
acg ttt acc gcg Thr Phe Thr Ala 2475	gat aaa aat gto Asp Lys Asn Val 2480	c tcc att cag cca tcc cct agc ttt l Ser Ile Gln Pro Ser Pro Ser Phe 0 2485	28366
		t gct ctc gaa ata gat ggc tca agt n Ala Leu Glu Ile Asp Gly Ser Ser 2500	
		c agt att gat att acc ttt acc gca a Ser Ile Asp Ile Thr Phe Thr Ala 2515 2520	ı



S. 23



tat caa tgg aac gtc cgc ccg tta ttg gaa gat acc agt tgg aac agt Tyr Gln Trp Asn Val Arg Pro Leu Leu Glu Asp Thr Ser Trp Asn Ser 2780 2785 2790	29278
gat cct ttg gat tcc gtc gat cct gac gcg gta gcg cag cac gat ccg Asp Pro Leu Asp Ser Val Asp Pro Asp Ala Val Ala Gln His Asp Pro 2795 2800 2805	29326
atg cac tat aaa gtt tca acc ttt atg cgc acc ctt gat ctg ttg atc Met His Tyr Lys Val Ser Thr Phe Met Arg Thr Leu Asp Leu Leu Ile 2810 2815 2820	29374
gcg cgc ggc gac cat gct tac cgc caa ttg gag cgc gat acg ctt aac Ala Arg Gly Asp His Ala Tyr Arg Gln Leu Glu Arg Asp Thr Leu Asn 2825 2830 2835 2840	29422
gaa gcg aag atg tgg tat atg caa gcg ctg cat ctg tta ggc gat aaa Glu Ala Lys Met Trp Tyr Met Gln Ala Leu His Leu Leu Gly Asp Lys 2845 2850 2855	29470
cct tat ctg ccg ctg agt acc aca tgg aat gat cca cga ctg gac aaa Pro Tyr Leu Pro Leu Ser Thr Thr Trp Asn Asp Pro Arg Leu Asp Lys 2860 2865 2870	29518
gcc gcg gat att act acc caa agt gct cat tcc agc tca ata gtc gct Ala Ala Asp Ile Thr Thr Gln Ser Ala His Ser Ser Ser Ile Val Ala 2875 2880 2885	29566
ttg cgg cag agt aca ccg gcg ctt tta tca ttg cgc agc gcc aat acc Leu Arg Gln Ser Thr Pro Ala Leu Leu Ser Leu Arg Ser Ala Asn Thr 2890 2895 2900	29614
ctg acc gat ctc ttc ctg ccg caa atc aat gaa gtg atg atg aat tac Leu Thr Asp Leu Phe Leu Pro Gln Ile Asn Glu Val Met Met Asn Tyr 2905 2910 2915 2920	29662
tgg caa aca tta gct cag aga gta tac aac ctg cgc cac aac ctc tct Trp Gln Thr Leu Ala Gln Arg Val Tyr Asn Leu Arg His Asn Leu Ser 2925 2930 2935	29710
atc gac ggt cag ccg tta tat ctg cca atc tat gcc aca ccg gcg gac Ile Asp Gly Gln Pro Leu Tyr Leu Pro Ile Tyr Ala Thr Pro Ala Asp 2940 2945 2950	29758
ccg aaa gcg tta ctc agc gcc gct gtt gcc act tct caa ggt gga ggc Pro Lys Ala Leu Leu Ser Ala Ala Val Ala Thr Ser Gln Gly Gly 2955 2960 2965	29806
aag ctg ccg gag tca ttt atg tcc ctg tgg cgt ttc ccg cac atg ctg Lys Leu Pro Glu Ser Phe Met Ser Leu Trp Arg Phe Pro His Met Leu 2970 2975 2980	29854
gaa aat gct cgc agc atg gtt agc cag ctc acc caa ttc ggc tcc acg Glu Asn Ala Arg Ser Met Val Ser Gln Leu Thr Gln Phe Gly Ser Thr 2985 2990 2995 3000	29902
tta caa aat att atc gaa cgt cag gac gca gaa gcg ctc aat gcg tta Leu Gln Asn Ile Ile Glu Arg Gln Asp Ala Glu Ala Leu Asn Ala Leu 3005 3010 3015	29950
tta caa aat cag gcc gca gag ctg ata ttg act aac ctg agt att caa Leu Gln Asn Gln Ala Ala Glu Leu Ile Leu Thr Asn Leu Ser Ile Gln 3020 3025 3030	29998
gac aaa acc att gaa gaa ctg gat gcc gag aaa acc gtg ctg gaa aaa	30046

Asp Lys Thr Ile Glu Glu Leu Asp Ala Glu Lys Thr Val Leu Glu Lys 3035 3040 3045	
tcc aaa gcg gga gca caa tcg cgc ttt gat agc tat agc aaa ctg cat Ser Lys Ala Gly Ala Gln Ser Arg Phe Asp Ser Tyr Ser Lys Leu His 3050 3055 3060	30094
gat gaa aac atc aac gcc ggt gaa aac caa gct atg acg cta cga gcg Asp Glu Asn Ile Asn Ala Gly Glu Asn Gln Ala Met Thr Leu Arg Ala 3065 3070 3080	30142
tcc gca gcc ggg ctt acc acg gcg gtt cag gca tcc cgt ctg gcc ggc Ser Ala Ala Gly Leu Thr Thr Ala Val Gln Ala Ser Arg Leu Ala Gly 3085 3090 3095	30190
gca gcg gct gat ctg gtg cct aac atc ttc ggc ttc gcc ggt ggt ggt Ala Ala Ala Asp Leu Val Pro Asn Ile Phe Gly Phe Ala Gly Gly 3100 3105 3110	30238
age egt tgg ggg get ate get gag geg ace gge tat gta atg gaa ttt Ser Arg Trp Gly Ala Ile Ala Glu Ala Thr Gly Tyr Val Met Glu Phe 3115 3120 3125	30286
tcc gct aat gtt atg aat acc gaa gcg gat aaa att agc caa tct gaa Ser Ala Asn Val Met Asn Thr Glu Ala Asp Lys Ile Ser Gln Ser Glu 3130 3135 3140	30334
acc tac cgt cgt cgc cgt cag gag tgg gaa att cag cgt aat aat gcc Thr Tyr Arg Arg Arg Gln Glu Trp Glu Ile Gln Arg Asn Asn Ala 3145 3150 3150 3160	30382
gaa gcg gag ctg aaa caa ctc gat gcc caa ctt aaa tcg ctg gca gta Glu Ala Glu Leu Lys Gln Leu Asp Ala Gln Leu Lys Ser Leu Ala Val 3165 3170 3175	30430
cgc cgt gaa gcc gcc gta ttg caa aaa acc agc ctg aaa acc caa caa Arg Arg Glu Ala Ala Val Leu Gln Lys Thr Ser Leu Lys Thr Gln Gln. 3180 3185 3190	30478
gag cag acc caa gcc caa ttg gcc ttc ctg caa cgt aag ttc agc aat Glu Gln Thr Gln Ala Gln Leu Ala Phe Leu Gln Arg Lys Phe Ser Asn 3195 3200 3205	30526
caa gcg ttg tac aac tgg cta cgt ggc cga ctg gca gca att tac ttc Gln Ala Leu Tyr Asn Trp Leu Arg Gly Arg Leu Ala Ala Ile Tyr Phe 3210 3215 3220	30574
caa ttc tac gac ttg gct atc gcg cgt tgt tta atg gca gag cag gct Gln Phe Tyr Asp Leu Ala Ile Ala Arg Cys Leu Met Ala Glu Gln Ala 3235 3230 3240	30622
3245 3250 Ala Arg Phe Ile Lys Pro Gly	30670
gcc tgg caa gga acc tat gca ggt ctg ctg gca ggt gaa acc ttg atg Ala Trp Gln Gly Thr Tyr Ala Gly Leu Leu Ala Gly Glu Thr Leu Met 3260 3265 3270	30718
cta agt ttg gca caa atg gaa gac gcc cat tta aga cgc gat aaa cgc Leu Ser Leu Ala Gln Met Glu Asp Ala His Leu Arg Arg Asp Lys Arg 3275 3280 3285	30766
gca tta gag gtc gaa cgt aca gta tcg ctg gcc gaa att tat gct ggt Ala Leu Glu Val Glu Arg Thr Val Ser Leu Ala Glu Ile Tyr Ala Gly	30814

3290	3295		3300	
tta ccg caa gat Leu Pro Gln Asp 3305	aaa ggc cca t Lys Gly Pro P 3310	tte tee etg aeg Phe Ser Leu Thr 3315	g caa gaa atc gag aag Gln Glu Ile Glu Lys 3320	30862
Leu Val Asn Ala			ggt aat aat aat ttg Gly Asn Asn Asn Leu 3335	30910
gca ttt ggc gcc Ala Phe Gly Ala 3340	Gly Thr Asp T	act aaa act tot Thr Lys Thr Ser 3345	ttg cag gca tcc att Leu Gln Ala Ser Ile 3350	30958
tca tta gct gat Ser Leu Ala Asp 3355	Leu Lys Ile A	ogt gag gat tac Arg Glu Asp Tyr 360	c ccg gaa tct att ggc r Pro Glu Ser Ile Gly 3365	31006
aaa atc cga cgc Lys Ile Arg Arg 3370	atc aaa cag a Ile Lys Gln I 3375	atc agc gtt acc Ile Ser Val Thr	c ctg ccg gcg cta ttg r Leu Pro Ala Leu Leu 3380	31054
gga cct tat cag Gly Pro Tyr Gln 3385	gat gtg cag g Asp Val Gln A 3390	gca ata tta tct Ala Ile L <i>e</i> u Ser 3395	tac ggc gat aaa gcc Tyr Gly Asp Lys Ala 3400	31102
gga tta gcg aac Gly Leu Ala Asn	ggc tgt gca g Gly Cys Ala A 3405	geg etg gee gtt Ala Leu Ala Val 3410	tee cae ggt aeg aat l Ser His Gly Thr Asn 3415	31150
gac agc ggt caa Asp Ser Gly Glr 3420	Phe Gln Leu A	gat ttc aac gat Asp Phe Asn Asp 3425	t ggc aaa ttc ctg ccg p Gly Lys Phe Leu Pro 3430	31198
ttt gaa ggt ato Phe Glu Gly Ile 3435	: Ala Ile Asp (caa ggt acg cta Gln Gly Thr Lew 440	a aca ctg agt ttt cct u Thr Leu Ser Phe Pro 3445	31246
aat gca tca acc Asn Ala Ser Thr 3450	cca gcc aaa q Pro Ala Lys (3455	ggt aaa caa gco Gly Lys Gln Ala	c act atg tta aaa acc a Thr Met Leu Lys Thr 3460	31294
ctg aac gat atc Leu Asn Asp Ile 3465	e att ttg cat a e Ile Leu His 1 3470	att cgc tac acc Ile Arg Tyr Th 347	r Ile Lys	31336
ccatcccaac acag	gaactaa gacaggo	ccc gaatcgggg	t ctggtaagga gtttct ato Me	
cag aat tca cag Gln Asn Ser Glr 3480	g aca ttc agc a n Thr Phe Ser n 3485	atg acc gag ct Met Thr Glu Le 349	g tca tta cct aag ggc u Ser Leu Pro Lys Gly 0 3495	31443 .
ggc ggc gcc att Gly Gly Ala Ile	acc ggt atg g Thr Gly Met (3500	ggt gaa gca tt. Gly Glu Ala Le 3505	a acg ccg gcc ggg ccg u Thr Pro Ala Cly Pro 3510	31491
gat ggt atg gca Asp Gly Met Ala 3515	a Ala Leu Ser I	ctg cca ttg cc Leu Pro Leu Pro 3520	c att tot goo gga ogt o Ile Ser Ala Gly Arg 3525	31539
ggt tat gcc ccc Gly Tyr Ala Pro 3530	Ser Leu Thr 1	ctg aac tac aa Leu Asn Tyr As 535	c age gga ace ggt aac n Ser Gly Thr Gly Asn 3540	31587



age eeg tte ggt ete ggt tgg gae tgt aac gte atg aca att egt egt Ser Pro Phe Gly Leu Gly Trp Asp Cys Asn Val Met Thr Ile Arg Arg 3545 3550 3555	31635
cgc acc agt acc ggc gtg ccg aat tat gat gaa acc gat act ttt ctg Arg Thr Ser Thr Gly Val Pro Asn Tyr Asp Glu Thr Asp Thr Phe Leu 3560 3565 3570 3575	31683
ggg ccg gaa ggt gaa gtg ttg gtc gta gca tta aat gag gca ggt caa Gly Pro Glu Gly Glu Val Leu Val Val Ala Leu Asn Glu Ala Gly Gln 3580 3585 3590	31731
gct gat atc cgc agt gaa tcc tca tta cag ggc atc aat ttg ggg atg Ala Asp Ile Arg Ser Glu Ser Ser Leu Gln Gly Ile Asn Leu Gly Met 3595 3600 3605	31779
acc ttc acc gtt acc ggt tat cgc tcc cgt ttg gaa agc cac ttt agc Thr Phe Thr Val Thr Gly Tyr Arg Ser Arg Leu Glu Ser His Phe Ser 3610 3615 3620	31827
cgg ttg gaa tac tgg caa ccc caa aca aca ggc gca acc gat ttc tgg Arg Leu Glu Tyr Trp Gln Pro Gln Thr Thr Gly Ala Thr Asp Phe Trp 3625 3630 3635	31875
ctg ata tac age eec gac gga caa gee eat tta etg gge aaa aat eet Leu Ile Tyr Ser Pro Asp Gly Gln Ala His Leu Leu Gly Lys Asn Pro 3640 3645 3650 3655	31923
caa gca cgc atc agc aat cca cta aat gtt aac caa aca gcg caa tgg Gln Ala Arg Ile Ser Asn Pro Leu Asn Val Asn Gln Thr Ala Gln Trp 3660 3665 3670	31971
cta ttg gaa gcc tcg gta tca tcc cac ggc gag cag att tat tat cag Leu Leu Glu Ala Ser Val Ser Ser His Gly Glu Gln Ile Tyr Tyr Gln 3675 3680 3685	32019
tat cga gcc gaa gat gaa act gat tgc gaa act gac gaa ctc aca gcc Tyr Arg Ala Glu Asp Glu Thr Asp Cys Glu Thr Asp Glu Leu Thr Ala 3690 3695 3700	32067
cac ccg aac aca acc gtc cag cgc tac ctg caa gta gta cat tac ggt His Pro Asn Thr Thr Val Gln Arg Tyr Leu Gln Val Val His Tyr Gly 3705 3710 3715	32115
aat cta acc gcc agc gaa gta ttt ccc acg cta aat gga gat gat cca Asn Leu Thr Ala Ser Glu Val Phe Pro Thr Leu Asn Gly Asp Pro 3720 3735 3730 3735	32163
ctc aaa tct ggc tgg ttg ttc tgt tta gta ttt gat tac ggt gag cgc Leu Lys Ser Gly Trp Leu Phe Cys Leu Val Phe Asp Tyr Gly Glu Arg 3740 3745 3750	32211
aaa aac agc tta tct gaa atg ccg cca ttt aaa gcc aca agt aac tgg Lys Asn Ser Leu Ser Glu Met Pro Pro Phe Lys Ala Thr Ser Asn Trp 3765 3760 3765	32259
ctt tgc cgc aaa gac cgt ttt tcc cgt tat gaa tac ggt ttt gca ttg Leu Cys Arg Lys Asp Arg Phe Ser Arg Tyr Glu Tyr Gly Phe Ala Leu 3770 3780	32307
cgc acc cgg cgc tta tgt cgc caa ata ctg atg ttt cac cgt ctg caa Arg Thr Arg Arg Leu Cys Arg Gln Ile Leu Met Phe His Arg Leu Gln 3785 3790 3795	32355
acc ctg tet ggt cag gca aaa gge gae gat gaa eee gea tta gtt tea	32403

Thr Leu Ser Gly Gln Ala Lys Gly Asp Asp Glu Pro Ala Leu Val Ser 3800 3805 3810 3815	
cgt ctg ata ctg gat tat gac gaa aac gcg gtg gtc agt acg ctc gtt Arg Leu Ile Leu Asp Tyr Asp Glu Asn Ala Val Val Ser Thr Leu Val 3820 3825 3830	32451
tet gte ege ega gtg gga eat gag eaa gat gge aca aeg geg gte gee Ser Val Arg Arg Val Gly His Glu Gln Asp Gly Thr Thr Ala Val Ala 3835 3840 3845	32499
ctg ccg cca ttg gaa ctg gct tat cag cct ttt gaa cca gaa caa aaa Leu Pro Pro Leu Glu Leu Ala Tyr Gln Pro Phe Glu Pro Glu Gln Lys 3850 3855 3860	32547
gca ctc tgg cga cca atg gat gta ctg gcg aat ttc aac acc atc caa Ala Leu Trp Arg Pro Met Asp Val Leu Ala Asn Phe Asn Thr Ile Gln 3865 3870 3875	32595
cgc tgg caa ctg ctt gat ctg caa ggc gaa ggc gta ccc ggt att ctg Arg Trp Gln Leu Leu Asp Leu Gln Gly Glu Gly Val Pro Gly Ile Leu 3880 3885 3890 3895	32643
tat cag gat aaa aat ggc tgg tgg tat cga tct gct caa cgt cag aca Tyr Gln Asp Lys Asn Gly Trp Trp Tyr Arg Ser Ala Gln Arg Gln Thr 3900 3905 3910	32691
ggg gaa gag atg aat gcg gtc acc tgg ggc aaa atg caa ctc ctt cct Gly Glu Glu Met Asn Ala Val Thr Trp Gly Lys Met Gln Leu Leu Pro 3915 3920 3925	32739
atc acg ccc gct att cag gat aac gcc tca ctg atg gat att aat ggt Ile Thr Pro Ala Ile Gln Asp Asn Ala Ser Leu Met Asp Ile Asn Gly 3930 3935 3940	32787
gat ggg caa ctg gat tgg gtt atc acc ggt ccg ggg cta agg ggt tat Asp Gly Gln Leu Asp Trp Val Ile Thr Gly Pro Gly Leu Arg Gly Tyr 3945 3950 3955	32835
cac agc cag cat cca gat ggc agt tgg aca cgt ttt acg ccg ttg cac His Ser Gln His Pro Asp Gly Ser Trp Thr Arg Phe Thr Pro Leu His 3960 3965 3970 3975	32883
gcc tta ccg ata gaa tat acc cat ccc cgc gcc caa ctt gcg gat tta Ala Leu Pro Ile Glu Tyr Thr His Pro Arg Ala Gln Leu Ala Asp Leu 3980 3985 3990	32931
atg ggg gcc ggg ctg tcc gat tta gtg ctg att ggt ccc aaa agc gtg Met Gly Ala Gly Leu Ser Asp Leu Val Leu Ile Gly Pro Lys Ser Val 3995 4000 4005	32979
Met Gly Ala Gly Leu Ser Asp Leu Val Leu Ile Gly Pro Lys Ser Val	32 97 9 33027
Met Gly Ala Gly Leu Ser Asp Leu Val Leu Ile Gly Pro Lys Ser Val 3995 4000 4005 cgt ttg tat gcc aat aac cgt gat ggt ttt acc gaa gga cgg gat gtg Arg Leu Tyr Ala Asn Asn Arg Asp Gly Phe Thr Glu Gly Arg Asp Val	
Met Gly Ala Gly Leu Ser Asp Leu Val Leu Ile Gly Pro Lys Ser Val 3995 4000 4005 cgt ttg tat gcc aat aac cgt gat ggt ttt acc gaa gga cgg gat gtg Arg Leu Tyr Ala Asn Asn Arg Asp Gly Phe Thr Glu Gly Arg Asp Val 4010 4015 4020 gtg caa tcc ggt ggt atc acc ctg ccg tta ccg ggc gcc gat gcg cgt Val Gln Ser Gly Gly Ile Thr Leu Pro Leu Pro Gly Ala Asp Ala Arg	33027

•				
406	50	4065	4070	
4075	ar rro rre	aca ttg ccg gga ttt Thr Leu Pro Gly Phe 4080	Ser Gln Ser Ala 4085	33219
4090	د نهام مرد د 4		Leu Asp Gly Ser 100	33267
4105	4110	gtt cat gct gac cat Val His Ala Asp His 4115	Leu Asp Ile Phe	33315
4120	4125	ttt gca caa cca ttc Phe Ala Gln Pro Phe 4130	Thr Leu Arg Phe 4135	33363
4140)	gat act tgc cag cta Asp Thr Cys Gln Leu 4145	Gin Val Ala Asp 4150	33411
4155	vai vai .	agc ctg atc ctg agc of Ser Leu Ile Leu Ser v 4160	Val Pro His Met 4165	33459
4170	41		Lys Pro Trp Leu 180	33507
4185	4190	atg gga gcc cat cac a Met Gly Ala His His 7 4195	Thr Leu His Tyr	33555
4200	4205	etg gat gaa aaa goo g eu Asp Glu Lys Ala A 4210	ula Ala Leu Ala 4215	33603
4220	· var cys r	ac ctg ccc ttc ccg g yr Leu Pro Phe Pro V 4225	al His Thr Leu 4230	33651
4235	914 12p G	aa atc agc ggc aat a lu Ile Ser Gly Asn L 4240	ys Leu Val Thr 4245	33699
4250	42	42	lu Arg Glu Phe 60	33747
4265	4270	ag aca gac agc cat c ln Thr Asp Ser His G 4275	In Leu Ala Gln	33795
	1285	4290	ys Asn Trp Tyr 4295	33843
gcc acc gga atc cct Ala Thr Gly Ile Pro 4300	ord var A	4305	la Gly Tyr Trp 4310	33891
cgc ggt gat acg cag Arg Gly Asp Thr Gln 4315	gct ttc ac Ala Phe Th	et ggt ttt acg cca ca nr Gly Phe Thr Pro Hi 4320	nc ttt act ctc .s Phe Thr Leu 4325	33939
			•	

tgg aaa Trp Ly:	a gag s Glu 4330	Gly	aaa Lys	gat Asp	Val	cca Pro 335	ctg Leu	aca Thr	ccg Pro	Glu	gat Asp 340	gac Asp	cac His	aat Asn	33987
ctg tad Leu Ty: 434	r Trp			Arg					Gln						34035
ctc ta Leu Ty 4360	c ggg r Gly	cta Leu	Asp	ggc Gly 1365	agc Ser	gca Ala	cag Gln	Gln	aag Lys 1370	atc Ile	ccc Pro	tat Tyr	Thr	gtg Val 375	34083
act ga Thr Gl		Arg					Gln					Thr			34131
tcc cc Ser Pr				-		Val		_		_	Ser				34179
gaa cg Glu Ar		e Ile	_	_	Pro		_			Āsp			_		34227
agt ga Ser As 442	p Lev			Gln					Val						34275
cgc cg Arg Ar 4440			Pro					Tyr					Pro		34323
act ct Thr Le	-	_	_	_		_	Asp		Gln			Leu			34371
acc ta Thr Ty			Ser			His					Asn		Leu		34419
gtg ti Val Le		y Leu			Gly		Arg			Ala		Thr			34467
gct aa Ala Ly 450	/s Hi			Val		Gly	Leu	Asr		Glu	·Ala				34515
gaa a Glu A 4520					Asp					Glu					34563
caa c Gln A				Thr					Asp					Thr	34611
cca c Pro L			c Pro					Le					Glu		34659
gcg g Ala V		u Thi					ı Ser					/ Gly			34707

cca gat gaa tta ccc ggc ctt ctg aca caa gca gga tac caa caa gaa Pro Asp Glu Leu Pro Gly Leu Leu Thr Gln Ala Gly Tyr Gln Gln Glu 4585 4590 4595	•
cct tat ctg ttc cca ctc agt ggc gaa aac caa gtc tgg gta gca cgc Pro Tyr Leu Phe Pro Leu Ser Gly Glu Asn Gln Val Trp Val Ala Arg 4600 4605 4610 4615	
aaa ggc tat acc gat tac gga act gag gta caa ttt tgg cgt cct gtc Lys Gly Tyr Thr Asp Tyr Gly Thr Glu Val Gln Phe Trp Arg Pro Val 4620 4630	34851
gca caa cgt aac acc cag tta acc ggg aaa acg act cta aaa tgg gat Ala Gln Arg Asn Thr Gln Leu Thr Gly Lys Thr Thr Leu Lys Trp Asp 4635 4640 4645	34899
acc cac tac tgt gtc atc act caa acc caa gac gcg gct ggt ttg act Thr His Tyr Cys Val Ile Thr Gln Thr Gln Asp Ala Ala Gly Leu Thr 4650 4660	34947
gtc tca gcc aat tat gac tgg cgt ttt ctc aca cct atg caa ctg act Val Ser Ala Asn Tyr Asp Trp Arg Phe Leu Thr Pro Met Gln Leu Thr 4665 4670 4675	34995
gat atc aac gat aat gtg cat atc ata acc ttg gat gcg cta gga cgc Asp Ile Asn Asp Asn Val His Ile Ile Thr Leu Asp Ala Leu Gly Arg 4680 4685 4690 4695	35043
cct gtc act caa cgt ttc tgg gga atc gaa aat ggt gtg gca aca ggt Pro Val Thr Gln Arg Phe Trp Gly Ile Glu Asn Gly Val Ala Thr Gly 4700 4705 4710	35091
tac tot toa coa gaa goa aaa coa tto act coa coa gto gat gto aat Tyr Ser Ser Pro Glu Ala Lys Pro Phe Thr Pro Pro Val Asp Val Asn 4715 4720 4725	35139
gct gcc att gct ctg acc gga cca ctc cct gtc gcg cag tgt ctg gtc Ala Ala Ile Ala Leu Thr Gly Pro Leu Pro Val Ala Gln Cys Leu Val 4730 4735 4740	35187
tat gcg ccg gac agt tgg atg ccg cta ttc ggt cag gaa acc ttc aac Tyr Ala Pro Asp Ser Trp Met Pro Leu Phe Gly Gln Glu Thr Phe Asn 4745 4750 4755	35235
aca tta acg cag gaa gag caa aag aca ctg cgt gat tta cgg att atc Thr Leu Thr Gln Glu Glu Gln Lys Thr Leu Arg Asp Leu Arg Ile Ile 4760 4765 4770 4775	35283
aca gaa gat tgg cgt att tgc gca ctg gct cgc cgc cgt tgg cta caa Thr Glu Asp Trp Arg Ile Cys Ala Leu Ala Arg Arg Arg Trp Leu Gln 4780 4785 4790	35331
agt caa aaa gcc ggc aca cca ttg gtt aag ctg tta acc aac agc atc Ser Gln Lys Ala Gly Thr Pro Leu Val Lys Leu Leu Thr Asn Ser Ile 4795 4800 4805	35379
ggt tta cct ccc cac aac ctc atg ctg gct acg gac cgt tat gac cgt Gly Leu Pro Pro His Asn Leu Met Leu Ala Thr Asp Arg Tyr Asp Arg 4810 4820	35427
gat tot gaa cag caa att ogt caa caa gto goa tto agt gat ggt ttt Asp Ser Glu Gln Gln Ile Arg Gln Gln Val Ala Phe Ser Asp Gly Phe 4825 4830 4835	35475
gge egt ttg ttg caa geg get gtg egg eat gag gea gge gaa gee tgg	35523

caa cgt aac caa gac ggt tct ctg gtg aca aaa atg gaa gat acc aaa Gln Arg Asn Gln Asp Gly Ser Leu Val Thr Lys Met Glu Asp Thr Lys 4860 4865 4870	35571
acg cgc tgg gcg att acg gga cgc act gaa tat gac aat aag ggg cag Thr Arg Trp Ala Ile Thr Gly Arg Thr Glu Tyr Asp Asn Lys Gly Gln 4875 4880 4885	35619
gcg ata cga act tat cag ccc tat ttc ctc aat gac tgg cga tat gtg Ala Ile Arg Thr Tyr Gln Pro Tyr Phe Leu Asn Asp Trp Arg Tyr Val 4890 4895 4900	35667
agt gat gac agc gcc aga aaa gag gcc tat gcc gat act cat atc tat Ser Asp Asp Ser Ala Arg Lys Glu Ala Tyr Ala Asp Thr His Ile Tyr 4905 4910 4915	35715
gat ccg att ggg cgg gaa atc caa gtt atc acg gca aaa ggc tgg ctg Asp Pro Ile Gly Arg Glu Ile Gln Val Ile Thr Ala Lys Gly Trp Leu 4920 4925 4930 4935	35763
cgg cag aac caa tat ttc ccg tgg ttt acc gtg agt gaa gat gaa aat Arg Gln Asn Gln Tyr Phe Pro Trp Phe Thr Val Ser Glu Asp Glu Asn 4940 . 4945 4950	35811
gat ttg tcc gct gac gcg ctc gtg taa ttgaatcaag attcgctcgt Asp Leu Ser Ala Asp Ala Leu Val 4955 4960	35858
ttaatgttaa cgagcgaata taatatacct aatagatttc gagttgcagc gcggcggcaa	35918
gtgaacgaat ccccaggagc atagataact atgtgactgg ggtgagtgaa agcagccaac	35978
aaagcagcag cttgaaagat gaagggtata aataagaaac tgcattgtga gttctaaata	36038
gagtagcagc atattttatt gccttttatt tcataggtaa taaaattcaa ttgctgtaaa	36098
aatctgtcat catgagaact aaaaataaca actttctctt ctgcaagaga aatcaataat	36158
tcaattaaaa atgttataga atctgaatca agaccatttg ttggctcatc aaaaatataa	36218
acateegeat eggtaataaa agetgatgte aatagaaatt tettittat eeeaagtgae	36278
atatgtccat actcaatacc agaataatta gatataccaa aaccatttaa atagtaatct	36338
aattgatatt ttaaattact tttcctataa cgctgactta aattaatcac atccattccc	36398
	36458
gtgatgaaat tataaaagtt aacattatcc gatagataaa aaccatgctg ttgcaaatta	
gtgatgaaat tataaaagtt aacattatcc gatagataaa aaccatgctg ttgcaaatta aatcggctct tttctccctt ttttataaaa ttaaccattc cttttttaac cttatttaca	
	36518
aatcggctct tttctccctt ttttataaaa ttaaccattc cttttttaac cttatttaca	36518 36578
aatcggctct tttctccctt ttttataaaa ttaaccattc cttttttaac cttatttaca ccagcaatac ttgaaagaaa agtcgtttta cccgccccat taactcccgc aatacggttt	36518 36578 36638
aateggetet titeteeett tittataaaa titaaeeatte etititaae etiatitaea eeggetet titeteeet tittataaa titaaeeatte etititaae etiatitaea eeggetet taaeteegge aataeggtit aateeaaeee gaaaateaea atigaeteet gaaaaaatag tettaeeatt aataaeaaee	36518 36578 36638 36698
aateggetet titeteeett tittataaaa titaaeeatte etititaae etiatitaea eeggetet eeggeaatae tigaaagaaa agtegtitta eeegeeeeat taaeteeege aataeggtit aateeaaeee gaaaateaea atigaeteet gaaaaaatag tettaeeatt aataaeaee tetaaeeeaa taaetteaag eataaataae eeetaaaaat aaegtaaaaa agaaaataae	36518 36578 36638 36698 36758



<210> 12

<211> 954

<212> PRT

<213> Photorhabdus luminescens

<400> 12

Met Lys Asn Ile Asp Pro Lys Leu Tyr Gln Lys Thr Pro Val Val Asn 1 5 10 15

Ile Tyr Asp Asn Arg Gly Leu Thr Ile Arg Asn Ile Asp Phe His Arg 20 25 30

Thr Thr Ala Asn Gly Asp Thr Asp Ile Arg Ile Thr Arg His Gln Tyr 35 40 45

Asp Ser Leu Gly His Leu Ser Gln Ser Thr Asp Pro Arg Leu Tyr Glu
50 55 60


Ala Lys Gln Lys Ser Asn Phe Leu Trp Gln Tyr Asp Leu Thr Gly Asn 65 70 75 80

Ile Leu Cys Thr Glu Ser Val Asp Ala Gly Arg Thr Val Thr Leu Asn 85 90 95

Asp Ile Glu Gly Arg Pro Leu Leu Thr Val Thr Ala Thr Gly Val Ile
100 105 110

Cln Thr Arg Gln Tyr Glu Thr Ser Ser Leu Pro Gly Arg Leu Leu Ser

		115					120	i				125			
Val	Thr 130	Glu	Gln	Ile	Pro	Glu 135	Lys	Thr	Ser	Arg	Ile 140	Thr	Glu	Arg	Leu
Ile 145	Trp	Ala	Gly	Asn ,	Ser 150	Glu	Ala	Glu	Lys	Asn 155	His	Asn	Leu	Ala	Ser 160
Gln	Cys	Val	Arg	His 165	Tyr	Asp	Thr	Ala	Gly 170	Val	Thr	Arg	Leu	Glu 175	Ser
Leu	Ser	Leu	Thr 180	Gly	Thr	Val	Leu	Ser 185	Gln	Ser	Ser	Gln	Leu 190	Leu	Ser
Asp	Thr	Gln 195	Glu	Ala	Ser	Trp	Thr 200	Gly	Asp	Asn	Glu	Thr 205	Val	Trp	Gln
Asn	Met 210	Leu	Ala	Asp	Asp	Ile 215	Tyr	Thr	Thr	Leu	Ser 220	Ala	Phe	Asp	Ala
Thr 225	Gly	Ala	Leu	Leu	Thr 230	Gln	Thr	Asp	Ala	Lys 235	Gly	Asn	Ile	Gln	Arg 240
Leu	Thr	Tyr	Asp	Val 245	Ala	Gly	Gln	Leu	Asn 250	Gly	Ser	Trp	Leu	Thr 255	Leu
Lys	Asp	Gln	Pro 260	Glu	Gln	Val	Ile	Ile 265	Arg	Ser	Leu	Thr	Tyr 270	Ser	Ala
Ala	Gly	Gln 275	Lys	Leu	Arg	Glu	Glu 280	His	Gly	Asn	Gly	Val 285	Ile	Thr	Glu
Tyr	Ser 290	Tyr	Glu	Pro	Glu	Thr 295	Gln	Gln	Leu	Ile	Gly 300	Thr	Lys	Thr	His
Arg 305	Pro	Ser	Asp	Ala	Lys 310	Val	Leu	Gln	Asp	Leu 315	Arg	Tyr	Glu	Tyr	Asp 320
Pro	Val	Gly	Asn	Val 325	Ile	Ser	Ile	Arg	Asn 330	Asp	Ala	Glu	Ala	Thr 335	Arg
Phe	Trp	His	Asn 340		Lys	Val	Ala	Pro 345		Asn	Thr	Tyr	Thr 350	_	Asp
Ser	Leu	Tyr 355		. Leu	Ile	Ser	Ala 360		Gly	Arg	Glu	Met 365	Ala	Asn	Ile '
Gly	Gln 370		Ser	Asn	Gln	Leu 375		Ser	Leu	Thr	Leu 380		Ser	Asp	Asn
Asn 385		Tyr	Thr	Asn	Tyr 390		Arg	Thr	Tyr	Thr 395		Asp	Arg	Gly	Gly 400
Asn	Leu	Thr	Lys	1le 405		His	Ser	Ser	Pro 410		Thr	Gln	Asn	Asn 415	Tyr
Thr	Thr	Asn	11∈ 420		· Val	Ser	Asn	425		Asn	Arg	Ala	Val 430		Ser
Thr	· Leu	Thr 435		ı Asp	Pro	Ala	Glr 440		. Asp	Ala	Leu	Phe 445		Ala	Gly
Gly	450		Asr	ı Thr	Leu	11e 455		Gly	/ Glr	a Asn	1 Leu 460		Trp) Asr	Thr



<212> PRT

<213> Photorhabdus luminescens

<400> 13

Met Ile Leu Lys Gly Ile Asn Met Asn Ser Pro Val Lys Glu Ile Pro

1 10 15

Asp Val Leu Lys Ile Gln Cys Gly Phe Gln Cys Leu Thr Asp Ile Ser 20 25 30

His Ser Ser Phe Asn Glu Phe His Gln Gln Val Ser Glu His Leu Ser 35 40

Trp Ser Glu Ala His Asp Leu Tyr His Asp Ala Gln Gln Ala Gln Lys 50 55 60

Asp Asn Arg Leu Tyr Glu Ala Arg Ile Leu Lys Arg Thr Asn Pro Gln 65 70 75 80


Leu Gln Asn Ala Val His Leu Ala Ile Val Ala Pro Asn Ala Glu Leu 85 90 95


Ile Gly Tyr Asn Asn Gln Phe Ser Gly Arg Ala Ser Gln Tyr Val Ala 100 105 110

Pro Gly Thr Val Ser Ser Met Phe Ser Pro Ala Ala Tyr Leu Thr Glu 115 120 125

Leu Tyr Arg Glu Ala Arg Asn Leu His Ala Ser Asp Ser Val Tyr Arg 130 135 140


Leu Asp Thr Arg Arg Pro Asp Leu Lys Ser Met Ala Leu Ser Gln Gln 145 150 155 160








850			855			860			
Gln His 865	Leu Pro	Pro Val 870	I Thr G	ln Lys	Asn A	Ala Phe 375	Ser Cy	s Trp	Thr 880
Ser Ile	Asp Thr	Ile Leu 885	ı Gln Tr	np Val	Asn (890	/al Ala	Gln Gl	n Leu 895	Asn
Val Ala	Pro Glr. 900	ı Gly Val	Ser Al	.a Leu 905	Val C	Sly Leu	Asp Ty 91	r Ile	Gln
Leu Asn	Gln Lys 915	Ile Pro	Thr Ty 92	r Ala 0	Gln I	rp Glu	Ser Ala 925	a Gly	Glu
Ile Leu 930	Thr Ala	Gly Leu	Asn Se 935	r Gln	Gln A	la Asp 940	Ile Le	ı His	Ala
Phe Leu 2 945	Asp Glu	Ser Arg 950	Ser Al	a Ala	Leu S	er Thr 55	Tyr Tyr		Arg 960
Gln Val A	Ala Lys	Pro Ala 965	Ala Al	a Ile	Lys S 970	er Arg	Asp Asp	Leu 975	Tyr
Gln Tyr I	Leu Leu 980	Ile Asp	Asn Gli	n Val : 985	Ser A	la Ala	Ile Lys 990	Thr	Thr
Arg Ile A	lla Glu 995	Ala Ile	Ala Se 1000	r Ile (Gln L	eu Tyr 1	Val Asn 005	Arg '	Thr
Leu Glu <i>A</i> 1010	usn Val	Glu Glu	Asn Ala 1015	a His S	Ser G	ly Val 1020	Ile Ser	Arg (Gln
Phe Phe I 025		2000			103	55		10	040
Gly Val S				τι.	JOU			1055	
Met Arg I				1002			1070		
Ser Gln S		:	1000			10)85		
Tyr Leu T 1090		_	000			1100			
Tyr His A: 105					111	5		11	20
Leu Ser G	•			11.	30		1	135	
Ser Lys Ph				1147			1150		
His Lys Il 115			1100			11	65		
Val Met Ty 1170			. , ,			1180			
Ile Thr Ly 185	s Gln 1	hr Gly A 1190	sn Ser	Lys As	sp Gly 1195	/ Tyr G	In Thr	Glu Th 120	



- Trp Asn Thr Pro Ile Thr Phe Asp Val Asn Glu Lys Ile Ser Lys Leu 1220 1225 1230
- Glu Leu Ala Lys Asn Lys Ala Pro Gly Leu Tyr Cys Ala Gly Tyr Gln 1235 1240 1245
- Gly Glu Asp Thr Leu Leu Val Met Phe Tyr Asn Gln Gln Asp Thr Leu 1250 1255 1260
- Asp Ser Tyr Lys Thr Ala Ser Met Gln Gly Leu Tyr Ile Phe Ala Asp 265 1270 1275 1280
- Met Glu Tyr Lys Asp Met Thr Asp Gly Gln Tyr Lys Ser Tyr Arg Asp 1285 1290 1295
- Asn Ser Tyr Lys Gln Phe Asp Thr Asn Ser Val Arg Arg Val Asn Asn 1300 1305 1310
- Arg Tyr Ala Glu Asp Tyr Glu Ile Pro Ser Ser Val Asn Ser Arg Lys 1315 1320 1325
- Gly Tyr Asp Trp Gly Asp Tyr Tyr Leu Ser Met Val Tyr Asn Gly Asp 1330 1335 1340
- Ile Pro Thr Ile Ser Tyr Lys Ala Thr Ser Ser Asp Leu Lys Ile Tyr 345 1350 1355 1360
- Ile Ser Pro Lys Leu Arg Ile Ile His Asn Gly Tyr Glu Gly Gln Gln 1365 1370 1375
- Arg Asn Gln Cys Asn Leu Met Asn Lys Tyr Gly Lys Leu Gly Asp Lys 1380 1385 1390
- Phe Ile Val Tyr Thr Ser Leu Gly Val Asn Pro Asn Asn Ser Ser Asn 1395 1400 1405
- Lys Leu Met Phe Tyr Pro Val Tyr Gl
n Tyr Asn Gly Asn Val Ser Gly 1410 1415 1420
- Leu Ser Gln Gly Arg Leu Leu Phe His Arg Asp Thr Asn Tyr Ser Ser 425 1430 1435 1440
- Lys Val Glu Ala Trp Ile Pro Gly Ala Gly Arg Ser Leu Thr Asn Pro 1445 1450 1455
- Asn Ala Ala Ile Gly Asp Asp Tyr Ala Thr Asp Ser Leu Asn Lys Pro 1460 1465 1470
- Asn Asp Leu Lys Gln Tyr Val Tyr Met Thr Asp Ser Lys Gly Thr Ala 1475 1480 1485
- Thr Asp Val Ser Gly Pro Val Asp Ile Asn Thr Ala Ile Ser Pro Ala 1490 1495 1500
- Lys Val Gln Val Thr Val Lys Ala Gly Ser Lys Glu Gln Thr Phe Thr 505 1510 1515 1520
- Ala Asp Lys Asn Val Ser Ile Gln Pro Ser Pro Ser Phe Asp Glu Met 1525 1530 1535
- Asn Tyr Gln Phe Asn Ala Leu Glu Ile Asp Gly Ser Ser Leu Asn Phe 1540 1545 1550



Lys Val Ser Thr Asp Asn Ser Leu Thr Leu Arg His Asn Glu Asn Gly 1590 1595

Ala Gln Tyr Met Gln Trp Gly Val Tyr Arg Ile Arg Leu Asn Thr Leu

Phe Ala Arg Gln Leu Val Ala Arg Ala Thr Thr Gly Ile Asp Thr Ile 1625

Leu Ser Met Glu Thr Gln Asn Ile Gln Glu Pro Gln Leu Gly Lys Gly 1640

Phe Tyr Ala Thr Phe Val Ile Pro Pro Tyr Asn Pro Ser Thr His Gly 1655

Asp Glu Arg Trp Phe Lys Leu Tyr Ile Lys His Val Val Asp Asn Asn 1670 1675

Ser His Ile Ile Tyr Ser Gly Gln Leu Lys Asp Thr Asn Ile Ser Thr 1690

Thr Leu Phe Ile Pro Leu Asp Asp Val Pro Leu Asn Gln Asp Tyr Ser 1705 1710

Ala Lys Val Tyr Met Thr Phe Lys Lys Ser Pro Ser Asp Gly Thr Trp 1720

Trp Gly Pro His Phe Val Arg Asp Asp Lys Gly Ile Val Thr Ile Asn 1735

Pro Lys Ser Ile Leu Thr His Phe Glu Ser Val Asn Val Leu Asn Asn 1750 1755

Ile Ser Ser Glu Pro Met Asp Phe Ser Gly Ala Asn Ser Leu Tyr Phe 1770

Trp Glu Leu Phe Tyr Tyr Thr Pro Met Leu Val Ala Gln Arg Leu Leu 1785

His Glu Gln Asn Phe Asp Glu Ala Asn Arg Trp Leu Lys Tyr Val Trp 1800 1805

Ser Pro Ser Gly Tyr Ile Val His Gly Gln Ile Gln Asn Tyr Gln Trp 1815

Asn Val Arg Pro Leu Leu Glu Asp Thr Ser Trp Asn Ser Asp Pro Leu 1830 1835

Asp Ser Val Asp Pro Asp Ala Val Ala Gln His Asp Pro Met His Tyr 1845

Lys Val Ser Thr Phe Met Arg Thr Leu Asp Leu Leu Ile Ala Arg Gly 1865

Asp His Ala Tyr Arg Gln Leu Glu Arg Asp Thr Leu Asn Glu Ala Lys 1880

Met Trp Tyr Met Gln Ala Leu His Leu Leu Gly Asp Lys Pro Tyr Leu

 \dot{z}


1890 1895 1900 Pro Leu Ser Thr Thr Trp Asn Asp Pro Arg Leu Asp Lys Ala Ala Asp 1910 1915 Ile Thr Thr Gln Ser Ala His Ser Ser Ser Ile Val Ala Leu Arg Gln 1930 Ser Thr Pro Ala Leu Leu Ser Leu Arg Ser Ala Asn Thr Leu Thr Asp 1945 Leu Phe Leu Pro Gln Ile Asn Glu Val Met Met Asn Tyr Trp Gln Thr 1960 Leu Ala Gln Arg Val Tyr Asn Leu Arg His Asn Leu Ser Ile Asp Gly 1975 Gln Pro Leu Tyr Leu Pro Ile Tyr Ala Thr Pro Ala Asp Pro Lys Ala 1990 1995 Leu Leu Ser Ala Ala Val Ala Thr Ser Gln Gly Gly Lys Leu Pro 2010 Glu Ser Phe Met Ser Leu Trp Arg Phe Pro His Met Leu Glu Asn Ala 2025 Arg Ser Met Val Ser Gin Leu Thr Gln Phe Gly Ser Thr Leu Gln Asn 2040 Ile Ile Glu Arg Gln Asp Ala Glu Ala Leu Asn Ala Leu Leu Gln Asn 2055 Gln Ala Ala Glu Leu Ile Leu Thr Asn Leu Ser Ile Gln Asp Lys Thr 2075 Ile Glu Glu Leu Asp Ala Glu Lys Thr Val Leu Glu Lys Ser Lys Ala 2085 Gly Ala Gln Ser Arg Phe Asp Ser Tyr Ser Lys Leu His Asp Glu Asn 2105 Ile Asn Ala Gly Glu Asn Gln Ala Met Thr Leu Arg Ala Ser Ala Ala 2115 2120 Gly Leu Thr Thr Ala Val Gln Ala Ser Arg Leu Ala Gly Ala Ala Ala 2135 . Asp Leu Val Pro Asm Ile Phe Gly Phe Ala Gly Gly Ser Arg Trp 2155 Gly Ala Ile Ala Glu Ala Thr Gly Tyr Val Met Glu Phe Ser Ala Asn 2170 2175 Val Met Asn Thr Glu Ala Asp Lys Ile Ser Gln Ser Glu Thr Tyr Arg Arg Arg Arg Gln Glu Trp Glu Ile Gln Arg Asn Asn Ala Glu Ala Glu

2200

2215

Leu Lys Gln Leu Asp Ala Gln Leu Lys Ser Leu Ala Val Arg Arg Glu

Ala Ala Val Leu Gln Lys Thr Ser Leu Lys Thr Gln Gln Glu Gln Thr



Tyr Asn Trp Leu Arg Gly Arg Leu Ala Ala Ile Tyr Phe Gln Phe Tyr 2260 2265 2270

Asp Leu Ala Ile Ala Arg Cys Leu Met Ala Glu Gln Ala Tyr Arg Trp 2275 2280 2285

Glu Ile Ser Asp Asp Ser Ala Arg Phe Ile Lys Pro Gly Ala Trp Gln 2290 2295 2300

Gly Thr Tyr Ala Gly Leu Leu Ala Gly Glu Thr Leu Met Leu Ser Leu 305 2310 2315 2320

Ala Gln Met Glu Asp Ala His Leu Arg Arg Asp Lys Arg Ala Leu Glu 2325 2330 2335

Val Glu Arg Thr Val Ser Leu Ala Glu Ile Tyr Ala Gly Leu Pro Gln 2340 2345 2350

Asp Lys Gly Pro Phe Ser Leu Thr Gln Glu Ile Glu Lys Leu Val Asn 2355 2360 2365

Ala Gly Ser Gly Ser Ala Gly Ser Gly Asn Asn Asn Leu Ala Phe Gly 2370 2375 2380

Ala Gly Thr Asp Thr Lys Thr Ser Leu Gln Ala Ser Ile Ser Leu Ala 385 2390 2395 2400

Asp Leu Lys Ile Arg Glu Asp Tyr Pro Glu Ser Ile Gly Lys Ile Arg 2405 2410 2415

Arg Ile Lys Gln Ile Ser Val Thr Leu Pro Ala Leu Leu Gly Pro Tyr 2420 2425 2430

Gln Asp Val Gln Ala Ile Leu Ser Tyr Gly Asp Lys Ala Gly Leu Ala 2435 2440 2445

Asn Gly Cys Ala Ala Leu Ala Val Ser His Gly Thr Asn Asp Ser Gly 2450 2455 2460

Gln Phe Gln Leu Asp Phe Asn Asp Gly Lys Phe Leu Pro Phe Glu Gly 465 2470 2475 2480

Ile Ala Ile Asp Gln Gly Thr Leu Thr Leu Ser Phe Pro Asn Ala Ser 2485 2490 2495

Thr Pro Ala Lys Gly Lys Gln Ala Thr Met Leu Lys Thr Leu Asn Asp 2500 2505 2510

Ile Ile Leu His Ile Arg Tyr Thr Ile Lys 2515 2520

<210> 14

<211> 1481

<212> PRT

<213> Photorhabdus luminescens

<400> 14

Met Gln Asn Ser Gln Thr Phe Ser Met Thr Glu Leu Ser Leu Pro Lys

1 5 10 15

Gly Gly Gly Ala Ile Thr Gly Met Gly Glu Ala Leu Thr Pro Ala Gly



			20					25					30		
Pro	Asp	Gly 35	Met	Ala	Ala	Leu	Ser 40	Leu	Pro	Leu	Pro	Ile 45	Ser	Ala	Gly
Arg	Gly 50	Tyr	Ala	Pro	Ser	Leu 55	Thr	Leu	Asn	Tyr	Asn 60	Ser	Gly	Thr	Gly
Asn 65	Ser	Pro	Phe	Gly	Leu 70	Gly	Trp	Asp	Cys	Asn 75	Val	Met	Thr	Ile	Arg 80
Arg	Arg	Thr	Ser	Thr 85	Gly	Val	Pro	Asn	Тут 90	Asp	Glu	Thr	Asp	Thr 95	Phe
Leu	Gly	Pro	Glu 100	Gly	Glu	Val	Leu	Val 105	Val	Ala	Leu	Asn	Glu 110	Ala	Gly
Gln	Ala	Asp 115	Ile	Arg	Ser	Glu	Ser 120	Ser	Leu	Gln	Gly	Ile 125	Asn	Leu	Gly
Met	Thr 130	Phe	Thr	Val	Thr	Gly 135	Tyr	Arg	Ser	Arg	Leu 140	Glu	Ser	His	Phe
Ser 145	Arg	Leu	Glu	Tyr	Trp 150	Gln	Pro	Gln	Thr	Thr 155	Gly	Ala	Thr	Asp	Phe 160
Trp	Leu	Ile	Tyr	Ser 165	Pro	Asp	Gly	Gln	Ala 170	His	Ĺeu	Leu	Gly	Lys 175	Asr
Pro	Gln	Ala	Arg 180	Ile	Ser	Asn	Pro	Leu 185	Asn	Val	Asn	Gln	Thr 190	Ala	Glr
Trp	Leu	Leu 195	Glu	Ala	Ser	Val	Ser 200	Ser	His	Gly	Glu	Gln 205	Ile	Tyr	Тут
Gln	Туг 210	Arg	Ala	Glu	Asp	Glu 215	Thr	Asp	Cys	G l u	Thr 220	Asp	Glu	Leu	Thr
Ala 225	His	Pro	Asn	Thr	Thr 230	Val	Gln	Arg	Tyr	Leu 235	Gln	Val	Val	His	Тут 240
Gly	Asn	Leu	Thr	Ala 245	Ser	Glu	Val	Phe	Pro 250	Thr	Leu	Asn	Gly	Asp 255	Asp
Pro	Leu	Lys	Ser 260	Gly	Trp	Leu	Phe	Cys 265	Leu	Val	Phe	Asp	Tyr 270	Gly	Glu
Arg	Lys	Asn 275	Ser	Leu	Ser	Glu	Met 280	Pro	Pro	Phe	Lys	Ala 285	Thr	Ser	Asr
Trp	Leu 290	Cys	Arg	Lys	Asp	Arg 295	Phe	Ser	Arg	Tyr	Glu 300	Tyr	Gly	Phe	Ala
Leu 305	Arg	Thr	Arg	Arg	Leu 310	Cys	Arg	Gln	Ile	Leu 315	Met	Phe	His	Arg	Leu 320
Gln	Thr	Leu	Ser	Gly 325	Gln	Ala	Lys	Gly	Asp 330	Asp	Glu	Pro	Ala	Leu 335	Val
Ser	Arg	Leu	Ile 340	Leu	Asp	Tyr	Asp	Glu 345	Asn	Ala	Val	Val	Ser 350	Thr	Leu
Val	Ser	Val 355	Arg	Arg	Val	Gly	His 360	Glu	Gln	Asp	Gly	Thr 365	Thr	Ala	Val



- Ala Leu Pro Pro Leu Glu Leu Ala Tyr Gln Pro Phe Glu Pro Glu Gln 370 380
- Lys Ala Leu Trp Arg Pro Met Asp Val Leu Ala Asn Phe Asn Thr Ile 385 390 395 400
- Gln Arg Trp Gln Leu Leu Asp Leu Gln Gly Glu Gly Val Pro Gly Ile 405 410 415
- Leu Tyr Gln Asp Lys Asn Gly Trp Trp Tyr Arg Ser Ala Gln Arg Gln
 420 425 430
- Thr Gly Glu Glu Met Asn Ala Val Thr Trp Gly Lys Met Gln Leu Leu 435 440 445
- Pro Ile Thr Pro Ala Ile Gln Asp Asn Ala Ser Leu Met Asp Ile Asn 450 455 460
- Gly Asp Gly Gln Leu Asp Trp Val Ile Thr Gly Pro Gly Leu Arg Gly 465 470 475 480
- Tyr His Ser Gln His Pro Asp Gly Ser Trp Thr Arg Phe Thr Pro Leu 485 490 495
- His Ala Leu Pro Ile Glu Tyr Thr His Pro Arg Ala Gln Leu Ala Asp 500 505 510
- Leu Met Gly Ala Gly Leu Ser Asp Leu Val Leu Ile Gly Pro Lys Ser 515 520 525
- Val Arg Leu Tyr Ala Asn Asn Arg Asp Gly Phe Thr Glu Gly Arg Asp 530 540
- Val Val Gln Ser Gly Gly Ile Thr Leu Pro Leu Pro Gly Ala Asp Ala 545 550 555 560
- Arg Lys Leu Val Ala Phe Ser Asp Val Leu Gly Ser Gly Gln Ala His 565 570 575
- Leu Val Glu Val Ser Ala Thr Lys Val Thr Cys Trp Pro Asn Leu Gly 580 585 590
- His Gly Arg Phe Gly Gln Pro Ile Thr Leu Pro Gly Phe Ser Gln Ser 595 600 605
- Ala Ala Asn Phe Asn Pro Asp Arg Val His Leu Ala Asp Leu Asp Gly
 610 615 620
- Ser Gly Pro Ala Asp Leu Ile Tyr Val His Ala Asp His Leu Asp Ile 625 630 635 640
- Phe Ser Asn Glu Ser Gly Asn Gly Phe Ala Gln Pro Phe Thr Leu Arg
- Phe Pro Asp Gly Leu Arg Phe Asp Asp Thr Cys Gln Leu Gln Val Ala 660 665 670
- Asp Val Gln Gly Leu Gly Val Val Ser Leu Ile Leu Ser Val Pro His 675 680 685
- Met Ala Pro His His Trp Arg Cys Asp Leu Thr Asn Ala Lys Pro Trp 690 695 700
- Leu Leu Ser Glu Met Asn Asn Asn Met Gly Ala His His Thr Leu His 705 710 715 720



Tyr	Arg	Ser	Ser	Val 725	Gln	Phe	Trp	Leu	Asp 730	Glu	Lys	Ala	Ala	Ala 735	Leu
Ala	Thr	Gly	Gln 740	Thr	Pro	Val	Cys	Туг 745	Leu	Pro	Phe	Pro	Val 750	His	Thr
Leu	Trp	Gln 755	Thr	Glu	Thr	Glu	Asp 760	Glu	Ile	Ser	Gly	Asn 765	Lys	Leu	Val
Thr	Thr 770	Leu	Arg	Tyr	Ala	His 775	Gly	Ala	Trp	Asp	Gly 780	Arg	Glu	Arg	Glu
Phe 785	Arg	Gly	Phe	Gly	Туг 790	Val	Glu	Gln	Thr	Asp 795	Ser	His	Gln	Leu	Ala 800
Gln	Gly	Asn	Ala	Pro 805	Glu	Arg	Thr	Ser	Pro 810	Ala	Leu	Thr	Lys	Asn 815	Trp
Tyr	Ala	Thr	Gly 820	Ile	Pro	Glu	Val	Asp 825	Asn	Thr	Leu	Ser	Ala 830	Gly	Tyr
Trp	Arg	Gly 835		Thr	Gln	Ala	Phe 840	Thr	Gly	Phe	Thr	Pro 845	His	Phe	Thr
Leu	Trp 850	_	Glu	Gly	Lys	Asp 855	Val	Pro	Leu	Thr	Pro 860	Glu	Asp	Asp	His
Asn 865	Leu	Tyr	Trp	Leu	Asn 870	Arg	Ala	Leų	Lys	Gly 875	Gln	Pro	Leu	Arg	Ser 880
Glu	Leu	Tyr	Gly	Leu 885	Asp	Gly	Ser	Ala	Gln 890	Gln	Lys	Ile	Pro	Tyr 895	Thr
Val	Thr	Glu	Ser 900		Pro	Gln	Val	Arg 905	Gln	Leu	Gln	Asp	Asn 910	Thr	Thr
Leu	Ser	Pro 915		Leu	Trp	Ala	Ser 920	Val	Val	Glu	Ser	Arg 925	Ser	Tyr	His
Tyr	Glu 930		Ile	Ile	Ser	Asp 935		Gln	Cys	Asn	Gln 940		Ile	Thr	Leu
Ser 945		Asp	Leu	Phe	950		Pro	Leu	Lys	Gln 955	Val	Ser	Val	Gln	Tyr 960
Pro	Arg	Arg	Asn	Lys 965	Pro	Thr	Thr	Asn	970		Pro	Asp	Thr	Leu 975	Pro
Asp	Thr	Leu	980		Ser	Ser	Tyr	985) Asp	Gln	Gln	Gln	Leu 990		Arg
Leu	Thr	995		Gln	Ser	Ser	1000		His	Leu	Ile	Ala 1005		Glu	Leu
Arg	Val 1010		Gly	Leu	Pro	Asp 1015		Thr	Arg		Asp 1020		Phe	Thr	Туз
Asp 025		Lys	His	: Val	. Pro 1030		l Asp	Gly	/ Leu	1035		Glu	ı Ala	Leu	Cys 1040
Alā	Glu	ı Asr	ı Ser	Let 1045		e Ala	a Asp) Ast	Lys 1050		Arç	Glu	ı Tyr	Leu 1055	

Gln Gln Arg Thr Phe Tyr Thr Asp Gly Lys Thr Asp Gly Lys Asn Pro




1060

1065

- Thr Pro Leu Lys Thr Pro Thr Arg Gln Ala Leu Ile Ala Phe Thr Glu 1075 1080 1085
- Thr Ala Val Leu Thr Glu Ser Leu Leu Ser Ala Phe Asp Gly Gly Ile 1090 1095 1100
- Thr Pro Asp Glu Leu Pro Gly Leu Leu Thr Gln Ala Gly Tyr Gln Gln 105 1110 1115 1120
- Glu Pro Tyr Leu Phe Pro Leu Ser Gly Glu Asn Gln Val Trp Val Ala 1125 1130 1135
- Arg Lys Gly Tyr Thr Asp Tyr Gly Thr Glu Val Gln Phe Trp Arg Pro 1140 1145 1150
- Val Ala Gln Arg Asn Thr Gln Leu Thr Gly Lys Thr Thr Leu Lys Trp 1155 1160 1165
- Asp Thr His Tyr Cys Val Ile Thr Gln Thr Gln Asp Ala Ala Gly Leu 1170 1175 1180
- Thr Val Ser Ala Asn Tyr Asp Trp Arg Phe Leu Thr Pro Met Gln Leu 185 1190 1195 1200
- Thr Asp Ile Asn Asp Asn Val His Ile Ile Thr Leu Asp Ala Leu Gly
 1205 1210 1215
- Arg Pro Val Thr Gln Arg Phe Trp Gly Ile Glu Asn Gly Val Ala Thr 1220 1225 1230
- Gly Tyr Ser Ser Pro Glu Ala Lys Pro Phe Thr Pro Pro Val Asp Val 1235 1240 1245
- Asn Ala Ala Ile Ala Leu Thr Gly Pro Leu Pro Val Ala Gln Cys Leu 1250 1255 1260
- Val Tyr Ala Pro Asp Ser Trp Met Pro Leu Phe Gly Gln Glu Thr Phe 265 1270 1275 1280
- Asn Thr Leu Thr Gln Glu Glu Gln Lys Thr Leu Arg Asp Leu Arg Ile 1285 1290 1295
- Ile Thr Glu Asp Trp Arg Ile Cys Ala Leu Ala Arg Arg Arg Trp Leu 1300 1305 1310
- Gln Ser Gln Lys Ala Gly Thr Pro Leu Val Lys Leu Leu Thr Asn Ser 1315 1320 1325
- Ile Gly Leu Pro Pro His Asn Leu Met Leu Ala Thr Asp Arg Tyr Asp 1330 1335 1340
- Arg Asp Ser Glu Gln Gln Ile Arg Gln Gln Val Ala Phe Ser Asp Gly 345 1350 1355 1360
- Phe Gly Arg Leu Leu Gln Ala Ala Val Arg His Glu Ala Gly Glu Ala 1365 1370 1375
- Trp Gln Arg Asn Gln Asp Gly Ser Leu Val Thr Lys Met Glu Asp Thr 1380 1385 1390
- Lys Thr Arg Trp Ala Ile Thr Gly Arg Thr Glu Tyr Asp Asn Lys Gly 1395 1400 1405

26



<210> 19

gagcgagctc ttacttaatg gtgtag



<211> 28 <212> DNA <213> Artificial Sequence	
<220> <223> Description of Artificial Sequence:oligonucleotide	
<400> 19 cagcgagete catgeagaat teacagae	28
<210> 20 <211> 18 <212> INVA <213> Artificial Sequence	
<220> <223> Description of Artificial Sequence:oligonucleotide	
<400> 20 ggcaatggca gcgataag	18
<210> 21 <211> 18 <212> INTA <213> Artificial Sequence	
<220> <223> Description of Artificial Sequence:oligonucleotide	
<400> 21 cattaacgca ggaagagc	18
<210> 22 <211> 26 <212> DNA <213> Artificial Sequence	
<220> <223> Description of Artificial Sequence:oligonucleotide	
<400> 22 gacctcgagt tacacgagcg cgtcag	26

PCT





INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6:

C12N 15/31, 15/82, 15/10, 1/21, 5/10, A01H 5/00, C07K 14/24, A01N 63/02

(11) International Publication Number: **A3**

WO 99/42589

(43) International Publication Date:

26 August 1999 (26.08.99)

(21) International Application Number:

PCT/EP99/01015

(22) International Filing Date:

18 February 1999 (18.02.99)

(30) Priority Data:

09/027,080 60/116,439 20 February 1998 (20.02.98) US

20 January 1999 (20.01.99) US

(71) Applicant (for all designated States except AT US): NOVAR-TIS AG [CH/CH]; Schwarzwaldallee 215, D-4058 Basel

(71) Applicant (for AT only): NOVARTIS-ERFINDUNGEN VER-WALTUNGSGESELLSCHAFT MBH [AT/AT]; Brunner Strasse 59, A-1235 Vienna (AT).

(72) Inventors; and

(75) Inventors/Applicants (for US only): KRAMER, Vance, Cary [US/US]; 608 Dana Court, Hillsborough, NC 27278 (US). MORGAN, Michael, Kent [US/US]; 5805 Garrett Road, Durham, NC 27707 (US). ANDERSON, Ame, Robert [US/US]; 1005 Green-Pace Road, Zebulon, NC 27597 (US). HART, Hope, Prim [US/US]; 4106 Planters Glen Court, Fuquay-Varina, NC 26526 (US). Warren, Gregory, Wayne [US/US]; 324 Bond Lake Drive, Cary, NC 27513 (US). DUNN, Martha, M. [US/US]; 6201 Oakview Court,

Hillsborough, NC 27278 (US). CHEN, Jeng, Shong [-/US]; 302 Orchard Lane, Chapel Hill, NC 27514 (US).

(74) Agent: BECKER, Konrad; Novartis AG, Corporate Intellectual Property, Patent & Trademark Dept., CH-4002 Basel (CH).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(88) Date of publication of the international search report:

23 December 1999 (23.12.99)

(54) Title: INSECTICIDAL TOXINS FROM PHOTORHABDUS

(57) Abstract

Novel nucleic acid sequences isolated from Photorhabdus luminescens, whose expression results in novel insecticidal toxins, are disclosed herein. The invention also discloses compositions and formulations containing the insecticidal toxins that are capable of controlling insect pests. The invention is further drawn to methods of making the toxins and to methods of using the nucleotide sequences, for example in microorganisms to control insect pests or in transgenic plants to confer insect resistance.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

INTERNATIONAL SEARCH REPORT



99/01015 a. classification of subject matter IPC 6 C12N15/31 C12N15/82 C12N5/10 C12N15/10 C12N1/21 C07K14/24 A01N63/02 A01H5/00 According to International Patent Classification (IPC) or to both national classification and IPC **B. FIELDS SEARCHED** Minimum documentation searched (classification system followed by classification symbols) C12N A01H C07K A01N IPC 6 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practical, search terms used) C. DOCUMENTS CONSIDERED TO BE RELEVANT Relevant to claim No Citation of document, with indication, where appropriate, of the relevant passages 1-3,7-9,WO 97 17432 A (WISCONSIN ALUMNI RES FOUND) Х 11-24, 15 May 1997 (1997-05-15) 26-36 the whole document, particularly SEQ ID NOS 31,46,47,48,49,50,51,60 1-3,7-9,WO 98 08932 A (DOW AGROSCIENCES LLC P,X 11-24, :WISCONSIN ALUMNI RES FOUND (US)) 26-36 5 March 1998 (1998-03-05) see pages 209-210,215-224,231-237, and 243-245. Patent family members are listed in annex. Further documents are listed in the continuation of box C. Х Χ Special categories of cited documents : "I later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the "A" document defining the general state of the art which is not considered to be of particular relevance earlier document but published on or after the international "X" document of particular relevance; the claimed invention filing date cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the citation or other special reason (as specified) document is combined with one or more other such docu-ments, such combination being obvious to a person skilled in the art. "O" document referring to an oral disclosure, use, exhibition or document published prior to the international filing date but *&* document member of the same patent family later than the priority date claimed Date of mailing of the international search report Date of the actual completion of the international search 0 8 11 99 20 October 1999

Form PCT/ISA/210 (second sheet) (July 1992)

Name and mailing address of the ISA

NL - 2280 HV Rijswijk

Fax: (+31-70) 340-3016


European Patent Office, P.B. 5818 Patentiaan 2

Tel. (+31-70) 340-2040, Tx. 31 651 epo ni,

Authorized officer


Maddox, A

INTERNATIONAL SEARCH REPORT



C.(Continu	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	EP	99/01015	
Category °	Citation of document, with indication, where appropriate, of the relevant passages		Relevant to claim No.	
A .	DAVID JOSEPH BOWEN: "Characterization of a High Molecular Weight Insecticidal Protein Complex Produced by the Entomopathogenic Bacterium Photorhabdus		1-36	
	luminescens (Nematodes, Biological Control)" THESIS UNIVERSITY WISCONSIN, 1 May 1995 (1995-05-01), XP002076022			
	see chapter 3	•		
A	WO 95 00647 A (COMMW SCIENT IND RES ORG; SMIGIELSKI ADAM JOSEPH (AU); AKHURST RAY) 5 January 1995 (1995-01-05) the whole document		1-36	
A	SZITTNER, R., ET AL.: "Nucleotide sequence, expression, and properties of luciferase coded by the lux genes from a terrestrial bacterium"		2,11	
	JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 265, no. 27, 1990, pages 16581-16587, XP002119674 figure 5			
4	WO 93 07278 A (CIBA GEIGY AG) 15 April 1993 (1993-04-15) the whole document	j	12-19, 29-34	
P,A	WO 98 08388 A (MORGAN JAMES ALUN WYNNE; JARRETT PAUL (GB); ELLIS DEBORAH JUNE (GB) 5 March 1998 (1998-03-05) see SEQ ID NO:1		1-36	
			. **	
			·	
			ŀ	
			1	
		•		
	•		·	





Box I Observations wher certain claims were found unsearchable (Continuation of item 1 of first sheet)
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. X Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows:
see additional sheet
As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
· · · · · · · · · · · · · · · · · · ·
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark on Protest The additional search fees were accompanied by the applicant's protest.
No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 4,5,6,10,25 all completely, and 1-3,12-24, 27-36 all partially

Nucleic acid molecule comprising the claimed regions of sequence ID 1, chimeric genes and hosts containing said molecule, toxins expressed by said regions, and method for producing said toxins and controlling insects using said toxins, method for mutagenizing said nucleic acid molecules.

2. Claims: 7-9,11,26 all completely, and 1-3,12-24, 27-36 all partially

Nucleic acid molecule comprising the claimed regions of sequence ID 11, chimeric genes and hosts containing said molecule, toxins expressed by said regions, and method for producing said toxins and controlling insects using said toxins, method for mutagenizing said nucleic acid molecules.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box 3.

The reference to claim 44 in claim 30 is inconsistent with the numbering of the claims, since claim 44 has not been filed. For the purpose of defining the search, claim 30 has been considered to refer to the toxin of claim 20, and searched accordingly.

BN8DOCID: <WO___9942589A3_|>

INTER TIONAL SEARCH REPORT

EP 99/01015

			EP 99/01015				
Patent document cited in search repo	-	Publication date		ent family ember(s)	Publication date		
WO 9717432	A	15-05-1997	AU BR CA EP HU PL SK AU WO	1050997 A 9606889 A 2209659 A 0797659 A 9900768 A 321212 A 93197 A 2829997 A 9808932 A	29-05-1997 28-10-1997 15-05-1997 01-10-1997 28-06-1999 24-11-1997 06-05-1998 19-03-1998		
WO 9808932	A	05-03-1998	AU AU BR CA EP HU PL SK WO	1050997 A 2829997 A 9606889 A 2209659 A 0797659 A 9900768 A 321212 A 93197 A 9717432 A	29-05-1997 19-03-1998 28-10-1997 15-05-1997 01-10-1997 28-06-1999 24-11-1997 06-05-1998 15-05-1997		
WO 9500647	A	05-01-1995	AU AU EP JP	675335 B 6991694 A 0705340 A 9500264 T	30-01-1997 17-01-1995 10-04-1996 14-01-1997		
WO 9307278	Α	15-04-1993	US AU BG BR CA CZ EP HU JP RO SK US	5625136 A 2795292 A 98747 A 9206578 A 2120514 A 9400769 A 0618976 A 68261 A 7500012 T 110263 A 37894 A 5859336 A	29-04-1997 03-05-1993 28-02-1995 11-04-1995 15-04-1993 15-03-1995 12-10-1994 28-06-1995 05-01-1995 30-11-1995 05-10-1994 12-01-1997		
WO 9808388	Α	05-03-1998	AU EP	4024997 A 0923295 A	19-03-1998 23-06-1999		